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Controlled release systems for therapeutic drugs have received extensive 
attention in recent years, due to their great clinical potential. Biodegradable 
microspheres are well-recognized systems to control the release rate of a 
drug out of a pharmaceutical dosage form; they are able to protect these 
agents against rapid degradation and clearance and release them in the body 
with a desired controlled rate and amount. Particularly, biopolymer 
microspheres are attracting increasing attention as drug carriers for injectable 
controlled release formulations.  
Biopolymer microspheres for controlled drug delivery can be 
conventionally prepared by solvent evaporation/extraction of emulsions, but 
this technique shows many drawbacks (high temperature, long processing 
times, large polidispersity, high residual solvents, lower encapsulation 
efficiency). To overcome the limits of the traditional process, in recent years, 
Supercritical Emulsion Extraction (SEE) has been proposed for the 
production of drug/polymer microspheres with controlled size and 
distribution, starting from oil-in-water (o-w) and water-in-oil-in-water (w-o-
w) emulsions. This process uses supercritical carbon dioxide (SC-CO2) to 
extract the “oil” phase of emulsions, leading to near solvent-free 
microparticles. SEE offers the advantage of being a one-step process and is 
superior to other conventional techniques for the better particle size control, 
higher product purity and shorter processing times; but, as traditional 
processes, it shows problems related to batch-to-batch reproducibility and 
reduction of the process yield, due to the intrinsically discontinuous 
operation.  
In the present work, a novel SEE configuration is proposed in a 
continuous operation layout (Continuous Supercritical Emulsion Extraction, 
SEE-C) using a countercurrent packed tower, for the production of 
controlled-size biopolymer microparticles in a robust and reproducible 
mode. Particularly, the purpose of this thesis is the optimization and 
characterization of the SEE-C process to investigate its capabilities and 
performances in the production of poly-lactic-co-glycolic acid (PLGA) 
microparticles with an engineered size and distribution and charged with 
different active principles (APs).  
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Before to investigate the possibility to produce AP/PLGA microspheres, 
an optimization of the process has been performed. Indeed, the 
thermodynamics of the selected system (ethyl acetate+CO2) has been 
studied, together with the analysis of the process operating parameters. 
Moreover, a fluidodynamic characterization of the packed tower has been 
carried out to identify the best condition of operation, below the flooding 
point. The capacity limits for the packing material have been evaluated and, 
then, directly measured in terms of flooding point at different operating 
conditions.  
Afterwards, firstly blank (drug-free) PLGA microparticles have been 
successfully produced, starting from single and double emulsions. Secondly, 
anti-inflammatory drugs (such as Piroxicam and Diclofenac Sodium), 
corticosteroids (such as Hydrocortisone acetate) and proteins (such as 
Insulin) have been chosen as model compounds to be entrapped within 
PLGA microspheres.  
All the emulsions produced were stable with non-coalescing droplets. The 
corresponding microspheres obtained were spherical in shape and well-
defined with narrow size distributions, due to the short processing time that 
prevents aggregation phenomena typically occurring during conventional 
solvent evaporation process.  
The influence of some emulsion formulation parameters (such as polymer 
concentration and emulsion stirring rate) on particle size has been 
investigated, showing that the droplet formation step determines size and 
size distribution of the resulting microspheres; particularly, a significant 
increase in particle size with the increase of polymer concentration or the 
decrease of emulsion stirring rate has been observed. Moreover, the effect of 
kind and formulation of emulsion on the microsphere characteristics has also 
been investigated, demonstrating that the choice of the encapsulation 
approach and the emulsion composition have a considerable influence on the 
attainable drug encapsulation efficiency. 
The produced microspheres have been characterized by X-ray, DSC, 
HPLC and UV-vis analysis. DSC and X-ray analyses confirmed that the 
microspheres were formed by an AP/PLGA solid solution and the active 
principle was entrapped in an amorphous state into the polymeric matrix. 
HPLC analysis revealed that good encapsulation efficiencies have been 
obtained in the products obtained. Release studies showed uniform drug 
concentration profiles, confirming a good dispersion of the drug into the 
polymer particles. The obtained AP/PLGA microspheres can degrade and 
release the encapsulated active principle slowly with a specific release 
profile. Active principle loading, particle size and emulsion kind revealed to 
be the controlling parameters for drug release. A study of PLGA 
microparticles degradation has also been carried out to monitor any 




Moreover, a comparative study between the characteristics of the PLGA 
microspheres obtained by SEE-C and the ones produced by the 
corresponding batch operating mode process (SEE) and conventional 
evaporation technology (SE) has been performed. PLGA microparticles 
produced by SEE-C showed a mean particle size always smaller than that 
associated with particles produced by SEE and SE; physico-chemical 
properties showed no morphological and structural differences between the 
processes. Compared with conventional technologies for the preparation of 
drug delivery systems, e.g. solvent evaporation emulsion techniques, the 
novel process is environmentally superior and suitable for scaling up to 
industrial dimensions. Moreover, the higher degree of control, as indicated 
by the high reproducibility, makes validation of the process very simple.  
In conclusion, the SEE-C process has shown to be an attractive way of 
incorporating active principles into biodegradable microparticles for 
controlled release formulations. Greater product uniformity, higher 
throughput with smaller plant volumes and elimination of batch-to-batch 









In recent years, the pharmaceutical industry has focused considerable 
attention on the development and optimization of formulations that can 
release an active principle in the body with a desired controlled rate and 
amount. Biodegradable polymer microspheres are the most promising form 
for controlled release devices development, especially if produced with a 
narrow particle size distribution. They can also be used for site specific 
controlled delivery of small molecular weight drugs and proteins in a large 
variety of applications such as chemotherapy, cardiovascular disease, 
hormone therapy, therapeutic protein delivery and vaccine development 
(Burgess and Hickey, 1994; Cohen et al., 1991; Cao and Schoichet, 1999). 
The use of biodegradable polymers as drug carriers has long been of 
interest in controlled release technology due to the ability of these polymers 
to be reabsorbed by the body. The field of biodegradable polymers is 
progressing rapidly, so that researchers now have at their disposal a 
substantial number of degradable polymers with range of degradation rates 
(Vert et al., 1993). The most widely used and studied class of biodegradable 
polymers is the polyesters, including poly-lactic acid (PLA) and poly-lactic-
co-glycolic acid (PLGA). Microspheres formulated with these polymers 
have shown wide applicability for oral (Chacón et al., 1996), parenteral 
(Uchida et al., 1997a; Soriano et al., 1996), respiratory (Emami et al., 2009) 
and topical (Rolland et al., 1993) administration. 
Throughout the past few years, some products based on active principle-
loaded biodegradable microspheres have reached the pharmaceutical market 
place. Well-known examples are Lupron Depot
®
 (Abbott Laboratories), 
Trelstar
®





McNeil-Janssen Pharmaceuticals). These types of injectable depot 
formulations (intramuscular, IM, or subcutaneous, SC) can provide sustained 
and controlled delivery of the active substance over a period of weeks. Some 
of the advantages of these formulations include: decrease in the amount of 
residual active principle concentrations due to lower dose, targeting of active 
principles to the affected area in the body, preservation of the efficacy of 
unstable active principles, reduction of the need for patient follow-up care, 
and also increase of patient comfort and compliance (Langer, 1998; Bandi et 
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al., 2004). Therefore, from the perspective of the pharmaceutical companies, 
microsphere-based depot formulations of existing compounds offer an 
attractive tool in life cycle management, but most importantly, offer 
significant value to patients. Although microsphere-based drug delivery is 
attractive from both market and patient perspective, developers of 
microsphere formulations have to face many challenges in achieving the 
desired product performance and process efficiency. Many of these 
challenges are related to the lack of control over particle size and uniformity 
of conventional microsphere manufacturing methods. Indeed, conventional 
methods for producing microspheres, such as solvent evaporation/extraction 
of emulsions, do not allow for total control of microsphere size and 
uniformity. Typically, wide particle size distributions with standard 
deviations of the mean diameter over 50% are achieved. Moreover, 
conventional processes often show long processing times and toxic solvent 
residues may remain in the final formulation because the organic solvents 
used to dissolve polymers are difficult to remove. However, the international 
regulations for the use of solvents in pharmaceutical industries require 
controlled use of organic solvents and radical reduction of conventional 
solvents used in pharmaceutical processes. To obtain narrower size 
distributions, expensive classification steps with high losses of active 
compound in the unwanted size ranges are required, as well as further 
operations are necessary to reduce solvent residue values below safety limits.  
Given the fact that the current manufacturing processes have difficulties in 
predictably producing solvent-free microparticles with an engineered size 
and distribution, a technology that can offer complete control over size 
distribution and very reduced solvent residues within microspheres is of 
great industrial value. There are a number of techniques in development 
designed to overcome issues regarding toxicity, size and uniformity. Among 
them, a supercritical fluid (SCF) based technique can offer the best and most 
straightforward opportunity to overcome these challenges. The most 
common supercritical fluid used is the carbon dioxide (SC-CO2) because it is 
chemically stable, nonflammable, non toxic, inexpensive, available in high 
quantity and purity and with critical properties easy to be reached.  
SCFs exhibit gas-like (high diffusivity, low viscosity, no surface tension) 
and liquid-like (high density and high solvent strength) properties. Mild 
operating conditions and solventless or organic solvent reduced operations 
are relevant advantages. They also offer several degrees of freedom with 
respect to process setup and operating conditions, which may be exploited to 
tune size and shape of product particles (Fusaro et al., 2004; Muhrer et al., 
2006). Supercritical fluid technology allows to access domains of miscible as 
well as of immiscible conditions for the same solvent-SCF system, i.e. by 
simply changing the operating pressure and temperature. In addition, lower 
viscosity and higher diffusivity of SCF with respect to the liquid solvent can 
improve mass transfer, which is often a limiting factor for the extraction 
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processes. Due to these favorable properties, supercritical fluids are currently 
proposed in a wide range of extraction applications (Reverchon and De 
Marco, 2006), microparticle formation (Della Porta and Reverchon, 2008; 
Della Porta et al., 2006; Reverchon and Adami, 2006; Reverchon and 
Antonacci, 2007) and membrane drying technologies (Reverchon et al., 
2006). For example, in the last 10 years, different supercritical fluid 
technologies have been proposed in literature to produce microparticles of 
PLGA and also of drug-PLGA composites, such as the Rapid Expansion of 
Supercritical Solutions (RESS), the Solution-Enhanced Dispersion by 
Supercritical Fluids (SEDS) and the Supercritical AntiSolvent (SAS) 
(Debenedetti, 1993; Della Porta and Reverchon, 2008a). 
In RESS technology, SC-CO2 acts as solvent, solubilizing the compound to 
be treated and producing microparticles by a rapid decompression of the 
supercritical solution and the subsequent sovrasaturation of the solubilized 
biopolymer. SAS technique uses SC-CO2 as phase-separating anti-solvent to 
induce the biopolymer precipitation from its liquid solution. In the SEDS 
technology, the general principle is the same as for the SAS process: the 
precipitation of the polymer is due to the anti-solvent effect of SC-CO2. The 
main problem reported for RESS technology is the very low solubility of 
almost all PLGA co-polymers in SC-CO2 that will prevent affordable 
process yields or will require the use of co-solvent (Kongsombut  et al., 
2009). On the other hand, the solubility of SC-CO2 in the PLGA (even if 
very low) is again the main problem for SAS or SEDS technologies, because 
it causes strong microparticles agglomeration resulting in products with 
irregular shapes or recovered with a low yield due to the strong tendency to 
form a film (Kang et al., 2008; Ginty et al., 2005; Ghaderi et al., 2000). It is 
worth mentioning that other authors (Young and Johnston, 1999; Pini et al., 
2008) also reported a large CO2 uptake by sorption into PLGA co-polymers, 
during the supercritical CO2 antisolvent processing of PLGA, resulting in a 
significant decrease in PLGA glass transition temperature that will 
advantage the formation of strong intra-particle adhesion or continuous film 
structures. 
Recently, the use of SC-CO2 for PLGA microparticles manufacture has 
also been proposed starting from emulsions. Particularly, SC-CO2 has been 
proposed to extract the „„oily‟‟ phase of single oil-in-water (o-w) and double 
water-in-oil-in-water (w-o-w) emulsions, leading to near solvent-free 
microparticles (Chattopadhyay et al., 2006;  Della Porta and Reverchon, 
2008b; Kluge et al., 2009a). The process, named Supercritical Emulsion 
Extraction (SEE), produces an aqueous suspension of microparticles after 
the supercritical extraction of the organic solvent contained in the emulsion. 
It is described as faster and selective compared to the conventional 
techniques, and capable of affecting the size distribution of the produced 
microparticles, since the fast extraction rate results in a narrower particle 
size distribution because the droplets aggregation is minimized. One of the 
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major limitations of SEE technology, shared with traditional 
evaporation/extraction processes, is the intrinsically discontinuous operation. 
Indeed, emulsions must be treated batch-to-batch, with problems of batch-to-
batch variability and reduction of the process yield (Della Porta and 
Reverchon, 2008b; Kluge et al., 2009).  
For this reason, in the present work, Supercritical Emulsion Extraction 
process is proposed in a Continuous operating mode (SEE-C) (Reverchon 
and Della Porta, 2007) for the production of biopolymer microspheres with 
different size and distribution, in a robust and reproducible mode. 
Particularly, the aim of the PhD research project is to optimize and 
characterize the SEE-C process to investigate its capabilities and 
performances in the production of controlled-size active principle/PLGA 
microspheres for controlled release formulations, starting from single and 
double emulsion systems. Anti-inflammatory drugs, corticosteroids and 
proteins have been selected as model active compounds to be entrapped 
within microspheres. 
SEE-C process arrangement is obtained using a high pressure packed 
column operating in countercurrent flow. Countercurrent extraction is 
expected to achieve a multistage treatment that should reduce the amount of 
solvent necessary and increase throughput. This manufacturing technique 
should provide not only particles having predictable and controllable 
physical properties such as size distribution, composition and structure, but, 
it must also conform to the rigorous requirements of product consistency, 
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In this chapter, the concepts and the parameters involved in the 
microencapsulation of pharmaceutical agents for controlled release 
formulations are described. In addition, an in-depth discussion on the 
emulsions and on the conventional and innovative microencapsulation 
processes (solvent evaporation/extraction and supercritical extraction 
emulsions, respectively) for the preparation of microencapsulated drug 
formulations starting from emulsions is provided. 
I.1 Microencapsulation technology in controlled release 
formulations 
Microencapsulation describes a process of incorporation of micron-sized 
(very tiny) particles of solids or droplets of liquids or gasses in an inert 
polymer matrix, which in turn isolates and protects them from the external 
environment. The inertness is related to the reactivity of the polymer with 
the entrapped substance. Microencapsulation provides the possibility of 
combining the properties of different types of material (e.g., inorganic and 
organic), a process which is difficult to achieve using other techniques.  
Microencapsulation technology and its applications have advanced over 
the last several decades. This technology is used in pharmaceutical, 
biomedical, agricultural, food, textile, consumer products, cosmetic, 
veterinary, medicine, industrial chemicals, biotechnology, sensor industries 




















Figure I.1 Schematic representation of microencapsulation applications. 
 
The pharmaceutical industry has long used microencapsulation for the 
preparation of particles containing active principles. The reasons for 
microencapsulation in the pharmaceutical industries are countless. 
Microencapsulation is often used to provide a protection for a drug from the 
reactive surroundings and to prevent drug degradation from light or exposure 
to oxygen. Furthermore, microencapsulation can be used to improve the 
formulation characteristics such as taste, stability and wettability. 
Microencapsulated formulations can also be used to extend the dosage time 
from a repeated to single administration and to provide controlled release of 
drugs in a desired part of the body (Tandya et al., 2007). 
A large variety of bioactive compounds with different physical and 
chemical properties have been formulated into polymeric systems, including 
anti-cancer drugs (Boisdron-Celle et al., 1995), narcotic agents (Mason et al., 
1976), local anesthetics (Chung et al., 2001) as well as steroids (Cowsar et 
al., 1985), therapeutic peptides (Jeyanthi et al., 1997) and proteins (Meinel et 
al., 2001), DNA (Hsu et al., 1999), viruses (Sturesson et al., 1999) and 
bacteria-derived compounds (Ren et al., 2002).  
Microencapsulation has been widely used in the design of controlled 
release dosage forms for the past few decades, since it can readily be adapted 
for various administration methods. Indeed, there have been significant 
developments in controlled release administration in the last three decades, 
from primitive delayed-release dosage forms in the 1960s to highly 
sophisticated self-regulated delivery systems in the 1990s (Park, 1997). 
These advances have produced many clinically useful controlled release 
dosage forms and provided better shelf-life for many existing drugs.   
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Controlled release systems can be described as formulations intended to 
provide temporal or spatial control of drug release in the body. The term 
“control” includes phenomena such as protection and masking, reduced of 
dissolution rate, facilitation of handling and spatial targeting of the active 
principle to the affected area in the body. 
Conventional drug administration may provide an immediate release of drug 
concentration in the blood followed by a reduction of drug concentration, as 
shown in Figure I.2(a); whereas, controlled release formulations, illustrated 
in Figure I.2(b), can circumvent problems related to the conventional 
formulations by enhancing the durability and effectiveness of the drug in the 
body, because they provide a constant drug concentration in the body at 
some optimum level over the duration of therapy. As a consequence, these 
formulations have outstanding advantages compared to conventional 
pharmaceutical dosage forms: increased patient compliance and acceptance 
by reducing the frequency of administration; increased therapeutic benefit by 
minimizing the drug blood level fluctuations and potentially lowering the 
total administered amount of drug by reducing peaks and valleys; drug 
targeting to specific locations resulting in a higher efficiency; protection of 
labile compounds before and after administration and prior to appearance at 
the site of action  (Berkland et al., 2002; Freiberg et al., 2004; Hickey et al., 
2002a; Kim et al., 2002; King et al., 2000; Meinel et al., 2001). Although 
controlled release formulations are invariably more expensive than 
conventional formulations, the overall cost of treatment may be lower due to 
one or more therapeutic advantages, fewer side-effects and less time required 
of health care personnel to dispense and administer drugs and monitor 
patients. However, controlled release delivery systems may present some 
disadvantages, such as the loss of flexibility in adjusting the drug dose 
and/or dosage regimen and an increased risk of sudden and total drug release 















































Figure I.2(a-b) Comparison between (a) traditional dosing and (b)  
controlled delivery dosing (MEC = minimum effective concentration, MTC 
= minimum toxic concentration). 
 
Controlled release formulations are commonly prepared with the use of 
microparticles of drug-polymer composites, either as microspheres (or 
matrix system) or microcapsules (or core-and-shell system), both 
schematically illustrated in Figure I.3(a-b). The former are polymer 
microparticles in which the active agent is uniformly dispersed; the latter are 
structured microparticles composed by a core (the intrinsic part) of the active 
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substance surrounded by a polymer shell (the extrinsic part). Typically, the 











Figure I.3(a-b) Classification of controlled release systems: (a) microsphere 
and (b) microcapsule. 
 
Biopolymer microspheres are the best devices for locally injectable 
controlled release formulations, providing a number of advantages over 
conventional parenteral formulations. 
Investigations about drug incorporation and release are an important tool 
in the design and evaluation of a potential drug-carrier system (zur Mühlen  
et al., 1998). Biodegradable polymers have been successfully employed as 
drug carriers to design controlled drug delivery systems. In general, when 
biodegradable and bioerodible polymers are used in controlled release 
formulations, the polymers are degraded or eroded to non-toxic materials by 
body fluids over time. Thus, the removal of polymeric material from the 
body after the drug release is unnecessary. 
Controlled drug release from biodegradable matrices is obtained by 
different mechanisms: polymer swelling, diffusion of drug through the 
polymer matrix, polymer degradation or a combination of these mechanisms 
(Washington, 1996). The design of a controlled release system is a 
complicated process due to the interdependency of several factors: particle 
size and surface morphology, as well as, drug and polymer physical 
chemistry are key factors governing release kinetics. Particularly, sphere size 
and distribution will determine the surface area/volume ratio and, thereby, 
the amount of surface available for drug release. Monodisperse microspheres 
may exhibit the most uniform drug release (Berkland et al., 2002, 2003). It 
was also observed that there is an ideal sphere size which provides a desired 
release rate; but, since the rate of drug release from microspheres dictates 
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their therapeutic action, sphere size and therapeutic action are related. 
Spheres that are „„too small‟‟ exhibit poor sustained release efficiency, they 
also may migrate from the site of injection producing undesirable drug 
release; whereas, spheres that are „„too large‟‟ may not easily pass through a 
syringe needle. Thus, the typically polydisperse samples generated by 
conventional fabrication techniques must be filtered or sieved to isolate 
particles within the desired size range. Precise size distributions may also 
allow the preparation of advanced delivery systems formulation that are not 
possible using polydisperse microspheres; for example, uniform 
microspheres approximately of 1-5 µm in diameter would be ideal for 
passive targeting of specific antigen-presenting cells (APCs) such as 
macrophages and dendritic cells (Evora et al., 1998). Similarly, microspheres 
of 10-20 µm in diameter could be used to target the tortuous capillary bed of 
tumor tissues by chemo-embolization (Dass and Burton, 1999). 
I.2 Emulsions 
Emulsions are mixtures consisting of at least two completely o partially 
immiscible liquid phases, one of which (i.e. the dispersed phase, oil phase) is 
dispersed as droplets of microscopic or ultramicroscopic size in the other 
liquid phase (i.e., the continuous phase, aqueous phase). Depending upon the 
nature of the dispersed phase, there are different kinds of emulsions. For 
example, a solution of hydrophobic active principle and polymer in an 
organic solvent (oil phase) is emulsified in an aqueous solution containing an 
emulsifying agent (water phase) to produce single oil-in-water (o-w) 
emulsion. This method can be successfully employed to encapsulate poorly 
water soluble active principles, but it is not suitable for the encapsulation of 
high hydrophilic active principles. There are two main reasons: 1) the 
hydrophilic active principle may not be dissolved in the organic solvent; 2) 
the active principle will diffuse into the continuous phase during emulsion, 
leading to a high loss of active principle. Therefore, depending on the 
solubility of active principle in water and encapsulating polymer, the 
emulsion kind can be varied from water-in-oil-in-water (w-o-w for 
encapsulation of water-soluble drug in water-insoluble polymer) or water-in-
oil-in-oil (w-o-o for encapsulation of water-soluble drug in water-insoluble 
polymer) to water-in-oil (w-o for encapsulation of water-soluble drug in 
water-soluble polymer). Some examples of different kinds of emulsions are 
reported in a schematic representation in Figure I.4: 
 
 











Figure I.4 Schematic representation of oil-in-water (o-w), water-in-oil (w-o) 
and water-in-oil-in-water (w-o-w) emulsions. 
From a thermodynamic point of view, the emulsions are metastable 
systems which means they are prepared using an excess energy (mechanical 
in most cases, such as shaking, stirring, homogenizing or spraying). To 
achieve a thermodynamic equilibrium between the solvent in the emulsion 
droplets and the aqueous phase, the addition of an emulsifying agent, such as 
a surfactant, to the dispersed phase is required. 
Surfactants are amphiphilic molecules which consist of a hydrophilic 
“head” group and a hydrophobic “tail” (Figure I.5). This means one part of 
the molecule has more affinity to polar solutes, such as water (hydrophilic), 
and the other part has more affinity to non-polar solutes, such as 
hydrocarbons (hydrophobic). Therefore, a surfactant molecule contains both 
a water insoluble (or oil soluble) component and a water soluble component. 
Due to their amphiphilic nature, surfactant molecules have a high affinity 
towards surfaces and interfaces, thereby the term “surfactant” which is an 
abbreviation for “surface active agent”. 
 
hydrophilic head hydrophobic tail
 
Figure I.5 Schematization of surfactants. 
 
Surfactant molecules will diffuse in water and adsorb at the interface 
between oil and water. As shown in Figure I.6, the insoluble hydrophobic 
group may extend out of the bulk water phase, into the oil phase, while the 
water soluble head group remains in the water phase. This alignment of 
surfactant molecules at the surface modifies the surface properties of water 
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at the water/oil interface. Particularly, surfactants reduce the interfacial 
tension of the continuous phase and stabilize the droplets forming a film at 
the droplets surface that acts as protective layer and prevents droplets from 






Figure I.6 Schematization of the adsorption of surfactant at the interface 
between an aqueous phase and an oil phase. 
In aqueous solutions, the surfactants associate into aggregates called 
micelles, if the concentration is above the critical micelle concentration 
(CMC). If the concentration is increased even further or a polar additive is 
added, the surfactants self-assemble into liquid crystalline mesophases. 
I.2.1 The theory of emulsification 
Many theories have been proposed to account for the way by which the 
emulsion is stabilized by the emulsifier. At the present time no theory has 
been postulated that seems to apply universally to all emulsions. Probably, 
different factors play a role and the relative importance of each varies not 
only in different emulsions but in the same emulsion under different 
circumstances. The “Adsorbed film and interfacial tension theory” proposed 
by Bancroft (1913) is probably the most universally accepted for the 
formation of emulsions. It has been developed or rather extended from 
earlier theories. Particularly, Bancroft stated the underlying principles, 
basing them upon Donnan's early work of interfacial tension; but many 
others have extended the interpretations. 
The emulsifier may be adsorbed by the water or by the oil, but it is usually 
adsorbed more in one liquid than in the other and thus lowers the interfacial 
tension of one liquid to a greater extent than that of the other. If the tension 
of the water is lowered more than that of the oil, the water has less tendency 
to form drops, flows to form a film more readily and becomes the continuous 
phase. Thus the kind of emulsion formed depends upon the nature of the 
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emulsifying agent: if the emulsifying agent is more soluble in water than in 
oil, the water becomes the continuous phase; if the emulsifying agent is more 
soluble in oil than in the water, the oil phase becomes the continuous phase 
(Figure I.7). When the tension on each side of the film or the emulsifying 
agent is the same, no emulsion is formed. This may occur when opposing 
emulsifying agents are in the mixture and the effect of each counterbalances 
that of the other. 
w-o emulsion o-w emulsion
 
Figure I.7 Films of surfactants at the water/oil interface of w-o and o-w 
emulsions. 
1.2.2 Physical instability of emulsions 
Over the time (depending on the preparation method, the surfactant and 
the oil properties), emulsions eventually tend to revert to the stable state of 
the phases comprising the emulsion: a water plus surfactant phase and an 
organic phase; an example of this is observed in the separation of the oil and 
vinegar components of vinaigrette, an unstable emulsion that will quickly 
separate unless shaken continuously. There are different main types of 
physical instability in emulsions: creaming or sedimentation, flocculation, 
coalescence, phase inversion and Ostwald ripening (disproportionation). The 
physics of these instability processes is rather complex. They may occur 
simultaneously rather than consecutively. A schematic representation of 




Figure I.8 Schematic representation of the break-down processes in 
emulsions. 
Emulsions can undergo creaming or sedimentation under gravitational 
forces. Creaming refers to the migration of dispersed droplets to the top of 
the emulsion, under the influence of buoyancy, or under centripetal force 
when a centrifuge is used; whereas, sedimentation refers to  the migration of 
dispersed droplets to the bottom of the emulsion. Sedimentation or creaming 
occurs depending on the relative densities of the solvent and the droplets. 
Creaming happens when the droplets density is lower than the solvent 
density (oil-in-water system) and sedimentation happens in the opposite case 
(water-in-oil system). In most cases, creaming rather than sedimentation 
occurs, since most oils have densities lower than the continuous aqueous 
phase. Creaming or sedimentation can be prevented by homogenization to 
reduce the dimensions of the droplets. Also by reducing the difference in 
density or by increasing the viscosity of the dispersed phase, creaming or 
sedimentation may be prevented.  
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Flocculation describes clustering of individual dispersed droplets 
together, whereby the individual droplets do not lose their identity. This 
phenomenon may occur when the van der Waals attractive energy between 
the droplets exceeds the repulsive energy. Flocculation is thus the initial step 
leading to further aging of the emulsion: droplet coalescence and ultimate 
separation of the phases. In the coalescence, droplets bump into each other 
and combine to form progressively larger droplets, losing their original 
identity. Coalescence is induced by thinning and disruption of the liquid film 
between the droplets. The final result is the breaking of the emulsion and the 
phase separation, that is an irreversible process. To come back to the original 
stage (emulsion), energy has to be furnished to the system. The characteristic 
time of coalescence can vary tremendously, depending upon the systems. In 
given cases, this time can be extremely long and no coalescence happens for 
years, making this kind of emulsions kinetically "stable". The mechanical 
strength of the interfacial film is important to prevent coalescence. 
Phase inversion of an emulsion happens when the continuous phase 
becomes the dispersed phase and vice versa, i.e. the dispersed medium forms 
the droplets and the dispersed droplets form the continuous phase (e.g. an o-
w emulsion reverting to a w-o emulsion and vice versa). An emulsion may 
be inverted by adding an electrolyte that can react with the emulsifying agent 
changing its characteristics; for example, an o-w emulsion formed by sodium 
stearate as emulsifier can be inverted to w-o emulsion by addition of CaCl2. 
Ostwald ripening (disproportionation) is a physical phenomenon in which 
the large particles grow at the expense of smaller ones which eventually 
disappear. It is caused by the difference in solubility between the small and 
large droplets. Indeed, it may occur when the small droplets, which have 
higher solubility than the larger ones, tend to dissolve on storage and become 
deposited on the larger ones. 
Accelerated storage testing is needed for prediction of the long-term 
physical stability of the formulations as well as the change of consistency 
with time. Several procedures have been applied to predict such stability: (a) 
subjecting the formulation to temperature changes as well as temperature 
cycling; (b) application of high centrifugal forces to detect separation of the 
emulsion; (c) subjecting the emulsion to vibration and investigation of the 
resulting system by microscopy (Tadros, 2004).  
I.3 Microencapsulation techniques from emulsions 
A successful microencapsulation of drug should include the following 
requirements: 
 the stability and biological activity of the encapsulated drug should be 




 the yield of the microspheres having a good entrapment efficiency, a 
desired particle size and an effectively sustained release property should 
be high;  
 the microsphere quality and the drug release profile should be 
reproducible within specified limits; 
 the microspheres should not exhibit aggregation or coalescence. 
Moreover, technologies capable of producing larger amounts of 
microspheres in a safe, economic, robust and well-controlled manner are 
required.  
Different methods of microencapsulation have been developed over the 
years for the production of biopolymer microspheres starting from 
emulsions. The selection of a particular technique depends on the nature of 
the polymer and the drug to be incorporated, the intended use and the 
duration of the therapy. 
The following discussion is focused on the most investigated 
conventional technique of microencapsulation, and also provides a 
comprehensive description of a recently developed process based on the use 
of supercritical carbon dioxide.  
 
I.3.1 Conventional techniques of microencapsulation  
One of the earliest and most popular conventional methods used to 
produce biopolymer microspheres is the solvent evaporation/extraction of 
single or double emulsions. The technique of microencapsulation by solvent 
evaporation/extraction of emulsions is widely applied in pharmaceutical 
industries to obtain the controlled release of drug. 
 
Single emulsion solvent evaporation/extraction method. This method has 
been primarily used to encapsulate insoluble or poorly water-soluble active 
substances through oil-in-water (o-w) emulsification process. The polymer is 
first dissolved in a water immiscible, volatile organic solvent (the oil phase). 
The drug is either dissolved or dispersed in this solution. The resultant 
mixture is then emulsified with large quantities of an aqueous continuous 
phase, containing a suitable emulsifier, to form discrete droplets. The 
emulsion formed is stirred until most of the organic solvent is removed by 
either evaporation or extraction process, resulting in phase separation of the 
polymer and the drug to produce solid microparticles, suspended in an 
aqueous phase (Arshady, 1991). In the former case, the emulsion is 
maintained at reduced or atmospheric pressure, with a low stirring rate to 
enable the volatile solvent to evaporate. In the latter case, a further 
continuous phase and/or additional extraction agents are added to the 
emulsion at an amount sufficient to absorb the entire solvent leaching from 
the solidifying microspheres (Freitas et al., 2005). The solid microspheres 
obtained from evaporation/extraction method are, then, washed and collected 
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by centrifugation and filtration or sieving. They are dried under appropriate 
conditions or lyophilized. A schematic diagram of this technique is shown in 
Figure I.9: 
 
Figure I.9 Schematic diagram showing the preparation of microparticles by 
o-w single emulsion solvent evaporation/extraction method. 
Double emulsion solvent evaporation/extraction method. Sensitive 
water-soluble drugs such as proteins, peptides and vaccines can be 
incorporated into microspheres using the double emulsion solvent 
evaporation/extraction (Herrmann and Bodmeier, 1995; Cohen et al., 1991). 
Briefly, the water soluble drug is initially dissolved in a small aqueous 
aliquot (sometimes containing a viscosity enhancer and/or stabilizer), which 
is then emulsified with the organic polymer solution to form a w-o emulsion. 
In a second emulsification, this emulsion is gently added into an aqueous 
solution containing an emulsifier and a double w-o-w emulsion is the result. 
The organic solvent is then removed by either evaporation or extraction 
process to leave an aqueous suspension of microspheres containing the drug. 
The solid microspheres obtained are washed and collected by centrifugation 
and filtration or sieving. These are then dried under appropriate conditions or 
lyophilized to give the final free flowing microsphere product. A schematic 




Figure I.10 Schematic diagram showing the preparation of microparticles 
by the w-o-w double emulsion-solvent evaporation method. 
 
In solvent evaporation/extraction techniques, the solvent of the dispersed 
phase must be slightly soluble in the continuous phase, so that partitioning 
into the continuous phase can occur leading to precipitation of the polymer. 
In solvent evaporation, the capacity of the continuous phase is not sufficient 
to dissolve the entire volume of the dispersed phase solvent; therefore, the 
solvent has to evaporate from the surface of the dispersion (air-liquid 
interface) to yield sufficiently hardened microspheres. In solvent extraction, 
the amount and composition of the continuous phase are chosen so that the 
entire volume of the dispersed phase solvent can be dissolved.  
The rate of solvent removal by evaporation method strongly depends on 
the temperature, pressure and the solubility parameters of polymer, solvent 
and dispersion medium. Very rapid solvent evaporation may cause local 
explosion inside the droplets and lead to the formation of porous structures 
on the microsphere surface. The rate of solvent removal by extraction 
method depends on the temperature of the additional continuous phase or 
extraction agents, the ratio of emulsion volume to continuous phase/medium 
volume and the solubility characteristics of polymer, solvent and dispersion 
medium. The solvent removal by extraction method is faster than the 
evaporation process and, hence, the microspheres obtained by the solvent 
extraction method are more porous in comparison to those produced from 
the solvent evaporation method under similar conditions (Arshady, 1991). 
The solvent evaporation/extraction is widely used because it is easy to be 
implemented into a simple reactor/stirrer setup. However, solvent 
evaporation/extraction technology has several drawbacks. Solvent 
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evaporation requires relatively high temperatures because they facilitate the 
solvent evaporation from the continuous phase and thereby maintain a high 
concentration gradient for the solvent between the microspheres and the 
continuous phase. As an alternative to elevated temperature, reduced 
pressure is sometimes used to promote the evaporation of the solvent (Freitas 
et al., 2005); nevertheless, solvent evaporation, in several cases, can be 
inappropriate for producing large amounts of microspheres in a robust and 
well-controlled manner. Solvent extraction uses relatively large amounts of a 
second solvent and, consequently, involves expensive downstream processes 
to recover the solvents used. 
Common drawbacks are the low encapsulation efficiency and the extremely 
slow rate that requires quite long processing times (several hours) and, as a 
consequence, aggregation phenomena occur between the droplets producing 
microspheres with a larger polidispersity than the starting emulsion (Yang et 
al., 2000). Both processes are also intrinsically discontinuous and, therefore, 
problems of batch-to-batch reproducibility (Li et al., 2008) are expected, as 
well as difficulties for process scale up to industrial scale. High batches 
reproducibility is particularly relevant for biomedical and pharmaceutical 
applications because the approval of a manufacturing process by Food and 
Drug Administration (FDA) requires the demonstration that all batches give 
a product with identical characteristics. 
 
I.3.2 Supercritical Emulsion Extraction (SEE) 
The limitations of the conventional techniques has been the focus of 
studies towards the potential replacement of traditional organic solvents with 
more environmentally friendly materials, such as supercritical fluids (SCFs).  
The supercritical fluid is a substance above its critical temperature and 
critical pressure. Beyond the critical point, the liquid and gas phases become 
indistinguishable. SCFs are highly compressed gasses that possess several 
advantageous properties of both liquids and gases. The density of a SCF is 
generally closer to that of conventional liquids and several orders of 
magnitude higher than that of conventional gases, and accounts for the 
solvating capabilities of the SCFs. It is well known that near to the critical 
point, small changes in pressure or temperature can greatly modify the 
density and, hence, the solvating ability of the supercritical fluid. Thus the 
physicochemical properties of SFCs can be varied significantly without 
changing the molecular structure of the substance. This ability to change the 
properties of the supercritical fluid by changing the temperature and pressure 
in the vicinity of the critical point provides the equivalent of a series of 
different solvents, thus giving selective extraction properties. Like gases, 
SCFs possess high diffusivities (two orders of magnitude larger than those of 
liquids), improving the mass transfer which is often a limiting factor of 
conventional technologies.  
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Among all the possible SCFs, carbon dioxide (CO2) is the most widely 
used for its readily accessible critical points on the industrial scale (Tc = 
31.1°C; Pc = 73.8 bar), in addition to its nontoxic and nonflammable 
properties; it is also readily available, highly pure and cost-effective. Critical 
temperature is very near to the room temperature allowing the treatment of 
thermolabile compounds. The Pressure-Temperature diagram of pure CO2 is 
reported in Figure I.11: 
 
 
Figure I.11 Pressure-Temperature diagram of pure CO2. 
Due to the favorable properties, SCFs are currently proposed in a wide 
range of different processes for the production of biopolymer microparticles, 
since several processes can operate in the micronic domain depending on the 
operating conditions and on the process arrangement (Della Porta et al., 
2005, 2006; Yeo and Kiran, 2005; Tandya et al., 2007).  
As a major advantage, supercritical fluids processes lead to pure and solvent-
free products while working at mild operating conditions. For this reasons, 
supercritical fluid-processed products can be extended to pharmaceutical 
applications. The application to pharmaceutical compounds has been 
developed far, mainly with the view of exploring processes that could give 
new characteristics to the compound itself either in the formulation or the 
delivery systems. The increasing interest in advanced controlled release 
formulations and the combination of their characteristics provide the 
increasing potential of supercritical fluids technology in the pharmaceutical 
industry. The preparation of controlled release formulations using 
supercritical fluid-assisted techniques offers several unique features such as 
the ability to perform the process in a single stage without any exposure of 
the products to the external environment, the ease solvent removal, the use 
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of high-grade stainless steel equipment and the inherent sterilizing effects, 
low handling and disposal expenses (York, 1999). Furthermore, the 
supercritical fluid technology may facilitate the development of significant 
improvements in the efficiency of both currently marketed drugs and new 
therapeutic entities. 
Recently, Supercritical Emulsion Extraction (SEE) has been proposed in 
literature for the production of particles with controlled size and distribution, 
starting from oil-in-water (o-w) and water-in-oil-in-water (w-o-w) 
emulsions. In this process, SC-CO2 has been proposed for the selective 
extraction of the oily phase of emulsions, obtaining the polymer hardening 
and microspheres formation. 
The use of supercritical fluids as extraction media is a promising 
alternative for the formation of microparticles of active principles and 
pharmaceutical excipients. There are two main reasons for using this 
technique. Firstly, the selective solvating power of supercritical fluids makes 
it possible to extract the organic solvent from emulsions and produce 
microspheres. Secondly, the favorable mass transfer properties and high 
solubility of solvents in the supercritical fluid make the solvent removal 
rapid and efficient with low level of residual solvent as requested by the 
authorities. In a recent study, it was shown that SC-CO2 can be used for  
inactivation of a wide variety of bacterial organisms. This means that the 
final product (microparticles) obtained by supercritical carbon dioxide is 
sterilized (Dillow et al., 1999). 
The process layout of SEE has been first proposed by Chattopadhyay et 
al. (2004, 2006, 2007), obtaining particles of nanometric and micrometric 
size with narrow particle size distribution. Particularly, they used SC-CO2 to 
eliminate the organic solvent from o-w emulsions for the preparation of drug 
microparticles of megestrol acetate, griseofulvin and cholesterol acetate, or 
for the formation of biopolymer particles charged with ketoprofen and 
indometacin. It has been reported that the mean diameter of the particles 
ranged between 0.1 and 2 µm and the residual solvent was less than 50 ppm.  
A schematic representation of the apparatus used by Chattopadhyay et al. for 
the precipitation of particles is shown in Figure I.12. The extraction of the 
solvent from emulsions was carried out in an electrically heated stainless-
steel extraction column. The SCF fluid delivery system consisted of a liquid 
CO2 pump which provided SC-CO2 to the bottom of the extraction column 
through a frit. The emulsion was delivered from the top countercurrently, 
using an HPLC pump, and was injected through a capillary nozzle, which 
broke the emulsion into droplets, thereby increasing its surface area of 
contact with SC-CO2. After the contact with SC-CO2, an aqueous particles 
suspension was formed at the bottom of the column and removed through a 
needle valve. The effluent SC-CO2 was vented from the top of the column. 
The pressure inside the column was maintained constant using a 
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Figure I.12 Schematic representation of the SEE experimental system 
proposed by Chattopadhyay et al. 
 
A different process layout for the extraction of the emulsion organic 
phase using SC-CO2 was also proposed by Della Porta and Reverchon (Della 
Porta and Reverchon, 2008b; Della Porta et al., 2010). They gave some 
indications on the mechanism of solvent extraction by SC-CO2 of o-w and w-
o-w emulsions for the production of polymer (PLGA) microspheres loaded 
with different anti-inflammatory drugs (Piroxicam and Diclofenac Sodium), 
controlling their size, distribution and drug loading by varying both emulsion 
and SC-CO2 process conditions. PLGA microspheres with mean sizes 
ranging between 1 to 3 µm and solvent residue smaller than 40 ppm were 
successfully obtained at optimized operating conditions.  
A schematic representation of the apparatus proposed by Della Porta and 
Reverchon for the precipitation of particles in the supercritical fluid 
extraction, in batch mode, is reported in Figure I.13. The emulsion was 
placed into a cylindrical stainless steel vessel. SC-CO2, delivered using a 
high pressure diaphragm pump, was bubbled into the extraction vessel, 
through a cylindrical stainless steel porous dispenser located at the bottom of 
the extractor. The dispenser maximizes the contact between the two phases 
during the extraction. Temperature was controlled using an air-heated 
thermostated oven. The pressure inside the reactor was controlled by a 
micrometric valve located downstream the extractor. A separator located 
downstream the extractor was used to recover the liquid solvent extracted 
State of the art 
 19 
and the pressure in the separator was regulated by a backpressure valve. At 
the exit of the separator, a rotameter and a dry test meter were used to 
measure the CO2 flow rate and the total quantity of CO2 delivered, 
respectively. When the extraction process was complete, the microspheres 
suspension produced was removed from the bottom of the extractor vessel 









Figure I.13 Schematic representation of the SEE apparatus proposed by 
Della Porta and Reverchon. 
Mazzotti and co-workers (Kluge et al., 2009a, 2009b) also proposed the 
use of SC-CO2 for the production of particles of pure PLGA and PLGA 
loaded with lysozyme or ketoprofen through supercritical fluid extraction of 
emulsions. Particles with average sizes ranging between 0.1 µm and a few 
μm with very narrow size distributions were produced. A schematic 
representation of the experimental setup used by Mazzotti and co-workers 
for supercritical fluid extraction of emulsions is shown in Figure I.14. CO2 
was drawn from a dip tube cylinder and pre-cooled in a pressure module 
before being delivered to the reactor by a piston pump. The stream then 
passed a backpressure regulator above the desired reactor pressure, to reduce 
stream fluctuations generated by the piston pump. The emulsion was 
delivered to the reactor by an HPLC pump. Both streams were mixed at the 
inlet of the reactor in a two substance nozzle. The reactor was kept at the 
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operating temperature by a thermostat. The particles were formed by solvent 
extraction from the organic emulsion droplets and remained suspended in the 
continuous water phase throughout the whole process. The product 
suspension accumulated at the bottom of the reactor was withdrawn through 
an outlet at the bottom of the reactor. The off-gas stream left the reactor 
through an outlet at the top. The pressure inside the reactor was controlled 
by a backpressure regulator located downstream, through which the off-gas 
















Figure I.14 Schematic representation of the SEE setup proposed by Mazzotti 
and co-workers for solvent extraction experiments. 
It has been shown that the average size of particles is clearly related to 
the average size of droplets in the original emulsion. The size of the 
emulsion droplets mainly depends on the mixing rate or the degree of 
homogenization and the concentration of surfactant or polymer. Generally, a 
high degree of homogenization, higher concentrations of surfactant and 
lower concentrations of polymer tend to produce smaller droplets 
(Chattopadhyay et al., 2004; Della Porta and Reverchon, 2008b; Kluge et a., 
2009a). Therefore, precipitation of particles with different sizes can be 
accomplished by varying the emulsion formulations and by optimization of 
the solvent-surfactant system.  
Moreover, SC-CO2 is known to produce porous structures with plasticized 
amorphous polymers such as PLGA. This phenomenon is related to the 
expansion of CO2 bubbles within the polymer during decompression. The 
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number and the sizes of these pores are dependent upon the rate of 
decompression, the operating conditions such as pressure and temperature, 
and the size of polymer particles (Chattopadhyay et al., 2006). 
The SCF-based emulsion extraction is beneficial compared to the 
traditional emulsion evaporation/extraction. Indeed, SEE process combines 
the advantages of traditional emulsion based technology, namely control of 
particle size and surface properties, with the advantages of supercritical fluid 
extraction process, such as higher product purity and shorter processing 
times. Due to the enhanced mass transfer of SC-CO2, this process has a 
relatively faster extraction rate compared to other conventional techniques 
(processing in minutes instead of several hours) and, thus, adds to the 
formation of relatively smaller particles with narrow size distributions (Della 
Porta et al., 2010). In the SEE process, PLGA microparticles aggregation 
phenomena are not observed, due to the presence of the external water 
phase, immiscible with SC-CO2, which prevents their aggregation (Kluge et 
al., 2009a). High product purity and low content of residual solvents may be 
achieved at the same time, at moderate operating temperatures and with 
reasonable CO2 consumption. 
One of the major limitation of the SEE process is that the process remains 
intrinsically discontinuous, sharing this inconvenient with traditional solvent 
evaporation/extraction processes. Indeed, a batch of emulsion can be treated 
for each run with problems of repeatability of the batches and reduction of 
the process yield, due to the material lost (Della Porta and Reverchon, 
2008b). 
I.4 Factors influencing the properties of microspheres 
The formation of  microspheres is affected by a number of factors.  The 
main variables influencing the microencapsulation process and the final 
microsphere product are summarized in Figure I.15 (Li et al., 2008). 
Particularly, the characteristics of microspheres containing drug should be 
correlated with the required therapeutic action and are strongly dependent on 
the nature of materials and also on the parameters during the manufacturing 
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Figure I.15 Scheme of the factors influencing the properties of 
microspheres. 
 
The most important physico-chemical characteristics that may be 
controlled in microsphere manufacture are:  
 nature and solubility of the drug being encapsulated; 
 polymer concentration, composition and molecular weight; 
 drug/polymer ratio; 
 organic solvents used; 
 concentration and nature of the emulsifier used; 
 stirring/agitation rate of the emulsification process; 
 viscosities and volume ratio of the dispersed and continuous phases 
(Lewis, 1990). 
Each of these can be related to the manufacture and the rate of drug 
release from the system.  
 
I.4.1 Choice of materials  
I.4.1.1 Dispersed phase 
Polymer. The biodegradability or biocompatibility is an essential 
property for the polymer used for pharmaceutical applications. 
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„Biodegradability‟ means that the components are degraded into harmless 
by-products which are either metabolized or excreted, avoiding the removal 
of empty remnants upon drug exhaust. „Biocompatibility‟ means that the 
component should be physiologically tolerable and should not cause an 
adverse local or systemic response after administration.  
Polymers and copolymers of lactic and glycolic acids are the most 
commonly used to develop drug delivery systems due to their safe and FDA 
(Food and Drug Administration) approved applications in humans (Chulia e 
al., 1994; Langer, 2000). They can ultimately degrade by hydrolysis of their 
constituents, which are usual metabolic products. Other biodegradable 
polymers, such as bacterial storage polyesters, have been studied for 
pharmaceutical and medical applications (Amass et al., 1998). Poly-3-
hydroxybutyrate and its copolymers with hydroxyvalerate are members of 
this biopolymer group. They are produced biosynthetically by bacteria from 
natural raw materials and indeed can be readily broken down by 
microorganisms under different conditions. 
The choice of polymer used as drug carrier depends also on the desired 
drug release rate, which is essentially determined by the polymer‟s physical 
properties. If one polymer cannot offer a satisfying drug release, a single 
polymer, called co-polymer, can be synthesized from two different 
polymers. The properties of the co-polymer are improved since it has two 
segments on the chain. For example, a co-polymer (PEG/PLA) was 
synthesized from polyethylene glycol (PEG) and polylactic acid 
homopolymers (PLA) to increase the degradation rate (Huang et al., 1997). 
Hydrophilic PEG segments in the PLA copolymers enhance the diffusion of 
water or drug in the polymer carriers (Zhu et al., 1990). As a result, drug 
release is faster with PEG/PLA than with PLA. 
Solvent. A suitable solvent should meet the following criteria to be used 
in microencapsulation: 
 being able to dissolve the chosen polymer; 
 being poorly soluble in the continuous phase; 
 having a high volatility and a low boiling point; 
 having low toxicity. 
Although moderate conditions are used, potentially toxic solvents are 
indispensable to dissolve lipophilic polymers (Bitz and Doelker, 1996).  
Chloroform was frequently used before, but due to its toxicity and low 
vapor pressure, it was gradually replaced by methylene chloride.  
Methylene chloride is the most common solvent for the encapsulation 
using solvent evaporation technique because of its high volatility, low 
boiling point and high immiscibility with water. Its high saturated vapor 
pressure compared to other solvents promises a high solvent evaporation 
rate, which shortens the duration of fabrication of microspheres. 
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Furthermore, the use of methylene chloride may also impose a problem in 
obtaining product approval by regulatory agencies because this solvent is 
confirmed carcinogenic according to EPA (Environmental Protection 
Agency) data and may be retained in the microsphere as a residual organic 
volatile impurity (O‟Donnell and McGinity, 1997). As evidenced by Lupron 
Depot

, a small amount of methylene chloride remaining in a microsphere 
product is acceptable by the FDA, but only if the product‟s therapeutic 
benefits clearly outweigh a safety concern over the residual solvent. 
However, its use is not recommended for manufacturing process.  
In recognition of this issue, the researchers are making great efforts to 
find less toxic replacements. Among them, ethyl acetate is considered one of 
the most preferable solvents because it shows promising potential as a less 
toxic substitute of methylene chloride. But due to the partial miscibility of 
ethyl acetate in water (4.5 times higher than that of methylene chloride), 
microspheres cannot form if the dispersed phase is introduced directly into 
the continuous phase. The sudden extraction of a big quantity of ethyl 
acetate from the dispersed phase makes the polymer precipitate into fibre-
like agglomerates (Freytag et al., 2000). To resolve this problem created by 
the miscibility of solvent with water, the aqueous solution can be pre-
saturated with solvent (Bahl and Sah, 2000). However, according to 
Herrmann and Bodmeier (1995), the drug encapsulation efficiency reduces 
significantly compared to the microspheres made by methylene chloride. 
This behavior can be due to the higher solubility of ethyl acetate in water (83 
g/100 mL at room temperature), leading to the loss of drug, with respect to 
the more largely used methylene chloride that has a considerable lower 
solubility in water (1.32 g/100 mL at room temperature). Based on this 
assumption, Li et al. (2008) proposed a further explanation that is due to two 
main causes: (1) more drug is entrained into the continuous phase by the 
higher mass flux of solvent, which is driven by the diffusion from the 
dispersed phase into the continuous phase; (2) the large amount of solvent 
present in the continuous phase increases the solubility of drug in the 
continuous phase, facilitating its diffusion into the continuous phase. In 
addition, the reduced encapsulation efficiency is also affected by the 
increased porous nature of the microspheres produced using ethyl acetate 
instead of methylene chloride as organic solvent (O‟Donnell and McGinity, 
1997). 
Ethyl formate shows also interesting results. Sah (2000) observed that the 
solvent removal rate of ethyl formate in water was 2.1 times faster than that 
of methylene chloride although ethyl formate possesses a lower vapor 
pressure and a higher boiling point. This phenomenon is explained by the 
fact that more molecules of ethyl formate are exposed to the air-liquid 
interface because of its higher water solubility. His work proved that water 
immiscibility of a solvent is not an absolute prerequisite for making an 
emulsion. 
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Moreover, Matsumoto et al. (2008) tried to establish a new preparation 
method of microencapsulation using acetone as the solvent for the dispersed 
phase. Acetone presents a low toxic potential to humans. It is a water-
miscible solvent with a higher boiling point than methylene chloride, which 
allows its easy removal from formulations by washing. 
 
Alternatives components. In given cases, other constituents are added to 
the dispersed phase such as co-solvent and porosity generator.  
Co-solvent is used to dissolve the drug that is not totally soluble in the 
solvent of the dispersed phase (Luan et al., 2006). Organic solvents miscible 
with water, such as methanol or ethanol, are the common choices.  
Porosity generator, called also porosigen or porogen, is used to generate 
the pores inside the microspheres, which consequently increases the 
degradation rate of polymer and improves drug release rate. For example, 
Incorporating Sephadex (cross-linked dextran gel) into Insulin-PLA 
microspheres significantly increases microsphere porosity (Watts et al., 
1990). 
 
I.4.1.2 Continuous phase 
For the microencapsulation of an active principle it is favorable to have a 
continuous phase that is a non-solvent for the active principle. While for 
lipophilic compounds aqueous solutions may be comfortably chosen, the use 
of hydrophobic, organic liquids as continuous phase for the encapsulation of 
hydrophilic compounds (Viswanathan et al., 1999) is more delicate because 
hydrophobic extraction fluids may not be readily removed from the final 
product, potentially causing undesired residues. Therefore, aqueous solutions 
are usually used as continuous phase, even for the microencapsulation of 
hydrophilic compounds. 
 
Surfactants. A suitable surfactant should be able to give microspheres a 
regular size and a small size distribution, guaranteeing a more predictable 
and stable drug release. Surfactants must exhibit the following 
characteristics to be effective as emulsifiers: 
 good surface activity; 
 ability to form a condensed interfacial film; 
 diffusion rates to interface comparable to emulsion forming time. 
Before choosing the type of surfactant and its concentration, it is 
important to know the polarity of the two immiscible phases, the desired size 
of microspheres and the demand on the sphericity of microspheres. 
There are four different types of surfactant classified by the nature of the 
hydrophilic part of molecule: anionic, cationic, amphoteric and non-ionic.  
The anionic surfactants (sodium dodecyl sulphate, SDS) release a negative 
charge in the aqueous solution. They have a relatively high HLB 
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(hydrophile-lipophile balance) level because they have prone to be 
hydrophilic.  
The cationic surfactants (cetyltrimethyl ammonium bromide, CTAB) on the 
contrary release a positive charge in aqueous solution.  
The amphoteric surfactants behave as anionic in alkali pH and as cationic in 
acid pH. 
Non-ionic surfactants (partially hydrolyzed PVA (polyvinyl alcohol), 
methylcellulose, tween and span) have no charge. 
Among different surfactants, partially hydrolyzed PVA is mostly used 
because it gives the smallest microspheres. The addition of surfactant 
reduces the surface tension of the continuous phase and the diminution of the 
latter one decreases the size of microspheres (Carrio et al., 1995; Yang et al., 
2001). However, due to the critical micelle concentration (CMC), the surface 
tension cannot decrease infinitively. When surfactants concentration reaches 
a certain level, the solution surface is completely loaded. Any further 
additions of surfactant will arrange as micelles and the surface tension of the 
aqueous phase will not decrease any more (Li et al., 2008).    
        
Alternative components. Besides the surfactant, the antifoam is 
sometimes added into aqueous phase in the case of strong agitation because 
the foaming problem will disturb the formation of microspheres. When the 
stirring rate increase, more air is entrained and foam forms. So anti-foams of 
silicon and non-silicon constituents are used to increase the rate at which air 
bubbles are dissipated (Berchane et al., 2006). 
Recent studies showed that it is possible to prepare microspheres without 
surfactant by replacing it with an amphiphilic biodegradable polymer. The 
advantage is to avoid the potential harm of surfactant residual on the surface 
or inside the final microspheres (Carrio et al., 1995).  
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Biodegradable microspheres for controlled release formulations can be 
prepared by various conventional methods, but the most thoroughly 
investigated method is the emulsion solvent evaporation. However, several 
processes are currently being studied to design composite microparticles and 
SCF-based technologies are able to overcome many drawbacks present in 
conventional methods. Among these SCF processes, Supercritical Emulsion 
Extraction (SEE) appears to be fast and selective, allowing the production of 
composite microparticles with better particle size control and good 
encapsulation efficiencies; but it shows problems related to the intrinsically 
discontinuous operation. Therefore, the PhD thesis is focused on an 
innovative SEE process layout operating in continuous mode, named SEE-C 
(Continuous Supercritical Emulsion Extraction), for the production of 
controlled-size biopolymer microparticles intended for controlled release 
formulations. Particularly, the aim of this work is the optimization and 
characterization of the SEE-C process to investigate its capabilities and 
performances in the production of PLGA microparticles with engineered size 
and distribution and charged with different active principles.  
PLGA has been chosen as biopolymer, due to its safety in biomedical 
preparations and its approval for human use by the FDA. The extraction 
experiments have been performed using both single and double emulsions; 
different active principle/PLGA systems have been tested. Particularly, anti-
inflammatory drugs (such as Piroxicam and Diclofenac Sodium), 
corticosteroids (such as Hydrocortisone acetate) and proteins (such as 
Insulin) have been selected as active principles to be entrapped within 
microspheres. 
This work has been developed in the following steps: 
 process parameters optimization: 
 thermodynamic study of the selected system (ethyl acetate+CO2) 
over a temperature range from 295 to 340 K at pressures up to 32 
MPa; indeed, information on the volumetric properties of fluid 
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mixtures at high pressures is important for the operation of 
processes involving supercritical fluids. 
 analysis of SEE-C operating parameters to select the conditions 
for the maximum extraction of the oily dispersed phase of the 
emulsion. 
 fluidodynamic characterization of the packed tower. Indeed, the 
hydrodynamic behavior strongly depends on parameters such as, 
density difference of the phases, kind of the internal packing and 
the relative amounts of phases flowing in the tower. 
 investigation of the effect of emulsion formulation parameters (such 
as polymer concentration and emulsion stirring rate) and of different 
emulsion approaches on the droplets and, therefore, on the produced 
microspheres. 
 detailed characterization of the produced microspheres in terms of 
size distribution, morphology, encapsulation efficiency and physico-
chemical properties (solid state, solvent residue) of the different 
products obtained using the SEE-C technology. 
 comparison of SEE-C process performance with the one of the 
corresponding batch operating mode processes (supercritical and 
conventional evaporation) in terms of process yield, particle size 
distributions, morphology, encapsulation efficiency and physico-
chemical properties. 
 study of the PLGA microparticles degradation to monitor any 
morphological differences in time of the biodegradable devices 
produced by SEE-C. 
 study of the influence of active principle loading, particle size and 
emulsion kind on drug release profiles from microspheres produced 
by SEE-C technology, to obtain further information about the 
microspheres structure and their efficiency to achieve sustained 
release. 
Microparticles characterization and drug release analyses have required 
the use of several analytical methods such as laser scattering, scanning 
electron microscopy, HLPC analysis, UV-vis spectrophotometry, differential 
scanning calorimetry and X-Ray diffractometry.  
The most significative results have been reported in the next chapters, 
related to some examples of the materials tested and thought to be the most 
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III.1 SEE-C apparatus description 
Process equipment consists of a high pressure packed column where gas 
and liquid phases (SC-CO2 and emulsion) are contacted counter currently 
and mass transfer between the two phases is improved by the internal 
packing elements.  
The SEE-C apparatus mainly consists of a 1680 mm long column with an 
internal diameter of 13.11 mm. The column is packed with stainless steel 
packings 4 mm nominal size with 1889 m
-1
 specific surface and 0.94 voidage 
(0.16-inch Pro-Pak, Scientific Development Company, State College, PA, 
USA), and is formed by five AISI 316 cylindrical sections connected by 4-
port elements. The extraction stages are three. The apparatus is thermally 
insulated by ceramic cloths and its temperature is controlled by six 
controllers (Series 93, Watlow, Milan, Italy) inserted at different heights of 
the column. SC-CO2 is fed at the bottom of the column by a high-pressure 
diaphragm pump (mod. Milroyal B, Milton Roy, Pont Saint-Pierre, France) 
at a constant flow rate. The emulsion is taken from a reservoir and delivered 
from the top of the column, using a high pressure piston pump (mod. 305; 
Gilson, Villiers-le-Bel, France), at a constant flow rate. Particles formation 
in emulsion is achieved by removal of the internal organic oil phase from the 
emulsion droplets by extraction using SC-CO2. A separator located 
downstream the top of the column is used to recover the extracted “oily” 
solvent and the pressure in the separator is regulated by a backpressure valve 
(26-1700 Series, Tescom, Selmsdorf, Germany). At the exit of the separator, 
a rotameter (mod. N5-2500, ASA, Sesto San Giovanni, Italy) and a dry test 
meter (mod. LPN/S80AL class G2.5, Sacofgas, Milan, Italy) are used to 
measure the CO2 flow rate and the total amount of CO2 delivered, 
respectively. The microspheres suspension is continuously removed from the 
bottom of the extraction column by decompression, using a needle valve 
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(mod. SS-31RS4, Swagelok, Brescia, Italy). A detailed representation of the 
































Figure III.1 Continuous tower diagram: C, CO2 supply; E, emulsion supply; 
PG_1 and PG_2, pressure gauges; SC_P, diaphragm pump used for high 
pressure SC-CO2; L_P, piston pump used for the emulsion; TC1…TC8, 
thermocouples; S, separator; R, rotameter; E_1 and E_2, heat exchangers; 
V_1…V_8, valves. 
The start-up of the extraction process begins delivering SC-CO2 from the 
bottom of the column until the operating pressure is reached. Then, the 
emulsion delivery is started at the top of the column. At the end of each run, 
the column is washed with distilled water to eliminate any processing 
residue from the packing surface. 
After the SEE-C experiment, particles are recovered from the suspension 
and separated from the surfactant by centrifugation with a large volume of 
distilled water at a rotation speed of 4500 rpm for 45 min. Then, the 
supernatant is discharged and particles are re-suspended in pure water, 
recovered by membrane filtration and dried at air for further processing. 
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The laboratory apparatus used is located at the University of Salerno 
(Italy) and a picture is shown in Figure III.3: 
 
 
Figure III.3 Laboratory SEE-C apparatus located at the University of 
Salerno (Italy). 
 
III.2 SEE-C process description 
The continuous packed tower takes advantage from the similarities of this 
process with the classical absorption/stripping procedure, in which mass 
transfer between the liquid and the gaseous phase can be obtained in a 
continuous packed column. The major difference with the traditional 
“stripping” process is the progressive formation of a solid phase into the 
tower. The use of packed towers is commonly not recommended for 
processes involving the presence of a solid phase; indeed, it is expected that 
the solid precipitates from the liquid phase and deposits on the packing 
surface, producing a progressive reduction of the mass transfer and, 
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subsequently, the blockage of the process. However, in the SEE-C, this 
limitation is not observed. There are two good conditions to justify why this 
phenomenon does not significantly interfere with the continuous solvent 
elimination process. As the dimensions of the microspheres produced 
(related to droplet diameters) are always in the range 0.2-50 µm, they remain 
suspended in the falling liquid film (i.e., the emulsion external phase) inside 
the column (i.e., particles residence time in the column is expected to be 
shorter than their sedimentation time); moreover, the presence of the 
surfactant on the particle surfaces allows their easy slipping on the packing 
surfaces. The presence of surfactant around the microspheres suspension is 
also useful for their recovery at the bottom of the column, since it avoids any 
other particle collapsing or aggregation. Moreover, the Joule-Thomson effect 
that follows the CO2 lamination induces a strong cooling effect on the 
microparticles suspension (2-4°C are normally reached), improving 
drug/polymer particles stability during their recovery (Della Porta et al., 
2011). 
In the classical interpretation of a liquid extraction process, mass transfer 
is concentrated at the interface between the two films formed by liquid and 
gas phase (Richardson et al., 2002). This schematization can also be applied 
to SEE-C process, therefore, mass transfer between the liquid and the gas 
can be hypothesized to take place at the interface between the film of liquid 
moving downwards the surface of the packing and the film of SC-CO2 
moving upward in the column. During the continuous operation, due to the 
interactions between the two countercurrent flow rates, mass transfer 
between the two phases is activated, but, variations in the top and bottom 
product compositions can be observed until steady state conditions have 
been obtained. As a consequence, another relevant process parameter in the 
continuous operation is the time required to obtain steady state conditions in 
the column. In preliminary experiments performed, using an empty o-w 
emulsion (ratio 20:80), it was observed that after 30 min, the solvent residue 
in the water recovered at the bottom of the column became almost constant. 
Following these indications, the SEE-C experiments were always performed 
after the attainment of the steady state conditions using an empty emulsion. 
III.3 SEE-C process mechanism 
Precipitation of PLGA inside the droplets is induced by SC-CO2 
extraction of the organic solvent of the oily dispersed phase. Although the 
detailed behavior of this process has not yet been defined, a possible 
mechanism can be described as follows (Della Porta et al., 2011); when 
emulsion and SC-CO2 come in contact, the mass transfer of the organic 
solvent proceeds by two parallel pathways: (A) the diffusion of the organic 
solvent into water followed by subsequent extraction of the solvent from the 
aqueous phase into SC-CO2; (B) the direct extraction upon contact between 
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SC-CO2 and the organic phase inside the droplet (Figure III.4). The path (A) 
is the only one used to describe the conventional SE because, in that case, 
the quantity of solvent evaporated at the liquid air interface is compensated 
by the solvent diffusing into the continuous phase from the droplet (Li et al., 
1995). This path can be justified also in the supercritical emulsion extraction 
process by the fact that a thermodynamic equilibrium occurs into the 
solvent-rich and aqueous-rich phases. Moreover, at selected operating 
conditions, very large solubility of the oily phase is assured in SC-CO2; 
therefore, it may extract the solvent of the dispersed oily phase from the 
external water phase of the emulsion causing the subsequent diffusion of the 
solvent from the droplets to the continuous phase, to restore the 
thermodynamic equilibrium. This phenomenon may prevail, for example, in 
the case of ethyl acetate because its solubility in water is particularly great 
(8.7% w/w at ambient conditions (Meng et al,. 2004)). However, the co-
existence of the path (B) in the supercritical emulsion extraction process 
should be confirmed by the process of water-in-oil emulsion reactions 
assisted by SC-CO2 for the production of metal oxides (Chattopadhyay and 
Gupta, 2003; Reverchon et al., 2010). In that case, the CO2 was used not 
only as extracting agent of the organic external phase, but also as a reagent 
that, reacting with the solute in the internal water phase, forms metal oxides 
nanoparticles. In this particular application, the SC-CO2 diffusion into the 
droplet is necessary for the reaction evolution and the results reported in the 
literature indicated a very fast reaction rate after SC-CO2 diffusion into the 
droplets, through the surfactant shell. Mattea et al. (2010) also observed the 
behavior of a dichloromethane drop (covered by surfactant) in water after its 
contact with SC-CO2 at a given pressure, temperature and CO2 molar 
fraction and reported possible swelling of the drops, after SC-CO2 diffusion 
in it (that may suggest the direct extraction of the solvent), suddenly 
overcame by a rapidly drop shrinking, probably due to the dichloromethane 
diffusion out of the drop into the external water phase (that may also suggest 
the indirect solvent extraction). Both mass transfer paths, namely „„direct 
solvent extraction‟‟ and „„indirect solvent extraction‟‟ from the external 
phase, may concur in generating the drug/polymer supersaturation inside the 
droplet and its fast precipitation. An hypothesis about the possible prevailing 
mechanism in the SEE-C process cannot be attempted at the moment due to 
lack of experimental data in the literature.  
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Figure III.4 Schematic representation of the possible mass transfer 
pathways of the oily phase during the SEE process. Two parallel pathways: 
(A) diffusion of the organic solvent into water followed by subsequent 
supercritical extraction of the solvent from the aqueous phase; (B) direct 
supercritical extraction upon contact between SC-CO2 and the organic 
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IV.1.1 Biopolymer: Poly (lactic-co-glycolic acid) (PLGA) 
Poly (lactic-co-glycolic acid) (PLGA) is a Food and Drug Administration 
(FDA) approved copolymer, used for controlled release devices production 
(Jain, 2000; Mundargi et al., 2008), owing to its biodegradability and 
biocompatibility (Anderson and Shive, 1997). The list of some FDA 
approved controlled release products available in the market is given in 
Table IV.1: 
Table IV.1 PLGA-based microparticles available in the market. 
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PLGA is synthesized by means of random ring-opening co-
polymerization of two different monomers, the cyclic dimers (1,4-dioxane-
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2,5-diones) of glycolic acid and lactic acid. During polymerization, 
successive monomeric units (of glycolic or lactic acid) are linked together in 
PLGA by ester linkages, thus yielding a linear, aliphatic polyester as a 
product. 
PLGA has been successful as a biodegradable polymer because it 
degrades by non-enzymatic hydrolysis of its ester linkages into non-toxic 
and non-harmful by-products, lactic and glycolic acid, which are 
metabolized primarily via the Krebs cycle (Anderson and Shive, 1997).  
Depending on the ratio of lactide to glycolide (PLA/PGA) used for the 
polymerization, different forms of PLGA can be obtained; these are usually 
identified with respect to the monomers ratio used (e.g. PLGA 75:25 
identifies a copolymer whose composition is 75% lactic acid and 25% 
glycolic acid). The time required for degradation of PLGA within an 
organism is related to the monomers ratio, as shown in Figure IV.1 (Miller et 
al., 1977): the higher the content of glycolide units, the lower the time 
required for degradation. An exception to this rule is the copolymer with 
50:50 monomers ratio, which exhibits the faster biodegradation rate of the 
lactide/glycolide polymers (about 50-60 days). Other combinations, i.e. 























Figure IV.1 Half life of various lactic acid and glycolic acid as copolymers 
implanted in rat tissue. 
 
PLGA ([C3H4O2]m [C2H2O2]n) copolymers with different lactide/glycolide 
ratios have been used in this work. PLGA 75:25 with molecular weight in 
the range 66000-107000 was supplied by Sigma Aldrich (Milan, Italy) and it 
appears as light yellow granules, whereas PLGA 50:50 RESOMER
®
 RG 
504H with molecular weight ranging between 38,000-54,000 was received 
from Boehringer Ingelheim (Ingelheim, Germany) and it appears as white 
powder. All PLGAs are amorphous and show a glass transition temperature 
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in the range of 40-50°C. Unlike the homopolymers of lactic acid and 
glycolic acid which show poor solubilities, PLGA can be dissolved by a 
wide range of common solvents, including chlorinated solvents, 
tetrahydrofuran, acetone or ethyl acetate. The chemical structure of PLGA is 
shown in Figure IV.2: 
 
Figure IV.2 Chemical structure of PLGA. 
 
IV.1.2 Pharmaceutical compounds 
NSAIDs. Piroxicam and Diclofenac Sodium are nonsteroidal anti-
inflammatory drugs (NSAIDs), i.e. agents that possess analgesic and 
antipyretic (fever-reducing) effects and, in higher doses, anti-inflammatory 
effect. Indeed, Piroxicam and Diclofenac Sodium are widely used for the 
treatment of inflammatory disorders and painful conditions such as 
rheumatoid arthritis, gout, bursitis, painful menstruation and headache; but, 
they are also effective in the relief of pain and fever. Research continues into 
their potential for prevention of colorectal cancer and treatment of other 
conditions, such as cancer and cardiovascular disease.  
Piroxicam (PX, C15H13N3O4S, purity ≥ 98% (TLC)) with molecular 
weight of 331.348 g/mol, and Diclofenac Sodium (DS, C14H10Cl2NNaO2, 
purity 99% (TLC)) with molecular weight of 318.13 g/mol were supplied 
from Sigma-Aldrich (Milan, Italy). Both of them appear as a yellowish 
hygroscopic crystalline powder. The approximate solubility of Piroxicam in 
water is 23 mg/L at room temperature and the melting point is 198-200°C. 
The solubility of Diclofenac Sodium in water is approximately 50 mg/mL at 
room temperature; moreover, it is soluble in alcohols (PBS pH 7.2, in EtOH, 
DMF) and insoluble in chloroform and in dilute acid. The melting point is 
288-290°C. The chemical structure of Piroxicam and Diclofenac Sodium are 





Figure IV.3 Chemical structures of Piroxicam and Diclofenac Sodium. 
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Corticosteroids. Hydrocortisone Acetate is classified as a steroid 
hormone which is used primarily for its anti-inflammatory, anti-allergic and 
antipruriginisa action. It is more specifically a glucocorticoid, produced by 
the adrenal gland. Hydrocortisone Acetate stimulates gluconeogenesis (the 
breakdown of protein and fat to provide metabolites that can be converted to 
glucose in the liver) and activates anti-stress and anti-inflammatory 
pathways. It is used in oral administration, intravenous injection or topical 
application.  
Hydrocortisone Acetate (HA, C23H32O6, purity ≥ 98 (HPLC)) with a 
molecular weight of 404.5 g/mol was received from Sigma-Aldrich (Milan, 
Italy). Untreated Hydrocortisone Acetate is a white powder. It is stable, but 
may be light or moisture sensitive. The solubility in water is 1.08x10
-3
 M 




Figure IV.4 Chemical structure of Hydrocortisone Acetate. 
 
Proteins. Insulin is a hormone (and like many hormones, it is a protein), 
produced in vivo by β-cells from inside the pancreas, which is required to 
regulate carbohydrate and fat metabolism in the body. It is a peptide 
composed of 51 amino acids shared between two intramolecular chains, A 
and B, linked together by two disulfide bonds. In most species, the A chain 
consists of 21 amino acids and the B chain of 30 amino acids. 
Insulin is medically used to treat some forms of diabetes mellitus. Indeed, 
diabetes is a chronic disease which is characterized by high blood glucose 
(sugar) levels resulting from the body not producing Insulin or using it 
properly. Insulin must be injected into the fat under the skin in order for it to 
reach into the blood. There are many different types of Insulin for many 
different situations and lifestyles. Each Insulin differs in how it is made, how 
it works in the body, and in price. There are 4 types of Insulin mainly used: 
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 Rapid-acting Insulin – it begins to work immediately after injection 
and reaches the peak time in an hour. Its duration lasts for about 2-4 
hours.  
 Regular or Short-acting insulin – this type of Insulin reaches the 
bloodstream within 30 minutes after injection. It reaches the peak 
time anywhere from 2-3 hours after injection and stays effective for 
about 3-6 hours.  
 Intermediate Acting Insulin – this type of Insulin reaches the 
bloodstream within 2-4 hours after injection, hits peak time around 
4-12 hours after, and then stays effective for about 12-18 hours. 
 Long Acting Insulin – this type of Insulin reaches the bloodstream 
at a much slower rate, usually 6-10 hours after injection. Its duration 
is about 20-24 hours. 
Insulin from bovine pancreas (INS, C254H377N65O75S6, purity 99%) with a 
molecular weight of 5733.5 g/mol was obtained from Sigma-Aldrich (Milan, 
Italy). Untreated Insulin is a white powder. The isoelectric point for the 
native protein is pI=5.3. Insulin is sparingly soluble in water and insoluble in 
organic solvents. It has low solubility at neutral pH. It can be solubilized (1-
10 mg/ml) at 2 mg/mL in dilute acetic or dilute hydrochloric acid, pH 2-3. 
Typically, it is used as a medium supplement for cell culture. The 
concentration range is 1-10 mg/mL, depending on the cell type. The 
chemical structure of Insulin is shown in Figure IV.5: 
 
 
Figure IV.5 Chemical structure of Insulin. 
 
IV.1.3 Surfactant: Polyvinyl alcohol (PVA) 
Polyvinyl alcohol (PVA) has been used as surfactant to stabilize the 
emulsions. It is a synthetic polymer produced by hydrolysis of polyvinyl 
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acetate. The physical characteristics and its specific functional uses depend 
on the degree of polymerization and the degree of hydrolysis. Polyvinyl 
alcohol has excellent film forming, emulsifying and adhesive properties. It 
has high tensile strength and flexibility, as well as high oxygen and aroma 
barrier properties. PVA is fully degradable and dissolves quickly.  
PVA with an hydrolization grade of 98-99% and molecular weight of 
31000-50000 g/mol was supplied by Sigma-Aldrich (Milan, Italy). Untreated 
PVA is a white fine powder formed of irregular particles with size ranging 
from about 50 to 250 μm. Polyvinyl alcohol is soluble in water, slightly 
soluble in ethanol, but insoluble in other organic solvents. It has a melting 
point of 180-190°C and decomposes rapidly above 200°C. The chemical 
structure of the monomer is given in Figure IV.6: 
 
 
Figure IV.6 Chemical structure of PVA. 
 
IV.1.4 Liquid solvents 
Ethyl acetate (EA, purity 99.9%), supplied by Carlo Erba Reagents 
(Milan, Italy), was used as organic solvent in the preparation of the oily 
phase of emulsions. This solvent is classified by the International 
Conference on Harmonization (ICH) as Class 3 solvent with residual solvent 
limit in drug substances fixed at 5000 ppm (Federal Register, 1997). 
Dimethyl sulfoxide (DMSO, purity 99.9%, Carlo Erba Reagents, Milan, 
Italy), ethanol (EtOH, purity 99.9%, Carlo Erba Reagents, Milan, Italy) and 
distilled water were used as solvents of the internal water phase of w-o-w 
emulsions. 
Trifluoroacetic acid (TFA, purity 99%) (supplied by Sigma-Aldrich, 
Milan, Italy), HPLC grade Acetonitrile (ACN, purity 99.8%) (purchased 
from Carlo Erba Reagents, Milan, Italy) and Sodium hydroxide (NaOH) 0.25 
M (supplied by Sigma-Aldrich, Milan, Italy) were used in the analyses.  
 
IV.1.5 Other materials 
Carbon dioxide (CO2) purchased from SON (Napoli, Italy) was used in 
the SEE-C process for the extraction of the organic solvent from the 
emulsions in supercritical conditions. Sodium chloride (NaCl,  purity 99%), 
Dibasic sodium phosphate (Na2HPO4, purity 99%), Monobasic sodium 
phosphate dihydrate (NaH2PO4 · 2H2O, purity 99%), Tween-80 and Glycerol 
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(GLY, purity 99%) obtained by Sigma-Aldrich (Milan, Italy) were used in 
the analyses.  
IV.2 Methods 
IV.2.1 Emulsion Preparation 
For the encapsulation of the mentioned active principles into PLGA, 
different possible emulsion kinds (o-w, w-o-w and s-o-w) have been tested, 
generically described below. Empty emulsions have also been prepared.  
The emulsions have been produced varying the active principle or PLGA 
concentrations in the emulsion droplets or the emulsion stirring rate.  
o-w emulsion. Oily phase was prepared dissolving fixed amounts of AP 
and PLGA into an organic solvent. Water phase was prepared dissolving 
PVA into an aqueous solution. The oily phase was added into the water 
phase using a high-speed stirrer (model L4RT, Silverson Machines Ltd., 
Waterside, Chesham Bucks, United Kingdom). 
w1-o-w2 emulsion. A known amount of AP was pre-suspended or 
dissolved into a solution containing PVA and used as the inner water phase 
(w1); a known amount of PLGA was dissolved into an organic solvent, 
which was used as the oil phase (o). The water phase (w1) was emulsified 
with the oily phase (o) to form a primary w1-o emulsion upon sonication by a 
digital ultrasonic probe at 50% of amplitude (mod. S-450D, Branson 
Ultrasonics Corporation, Danbury, CT, USA) or an ultrasonic bath (mod. 
VCX130, Vibra Cell, Sonics & Materials, Inc., Newtown, CT, USA). 
Sonication, in particular, is an exothermic operation; this is why using an ice 
bath during the different steps can be beneficial. Then, the resulting primary 
emulsion was immediately poured into a known amount of an aqueous PVA 
solution, which was used as the outer water phase (w2), and homogenized to 
form the secondary emulsion by high-speed stirring. 
s-o-w suspension emulsion. A fixed amount of AP was mixed with a 
solution of a known amount of PLGA in an organic solvent to form a 
suspension, which was then added into a known amount of an aqueous PVA 
solution to form a s-o-w suspension emulsion by high-speed 
homogenization.  
Emulsions composition and conditions used in this work are described in 
details in Table IV.2: 
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Table IV.2 Emulsions composition and conditions used. 
AP Emulsions composition and conditions 
Drug free 
 
o-w emulsion (20:80 w/w).  
- oil phase: 5-10% w/w PLGA 50:50 (of the oil phase) into 
EA 
- water phase: EA-saturated aqueous solution with 0.8% w/w 
PVA 
Emulsion conditions: high-speed homogenization operating 
at 2800 rpm for 3 min. 
w-o-w emulsion (1:19:80 w/w/w).  
- inner water phase: water solution with 0.04% w/w PVA 
- oil phase: 10% w/w PLGA 50:50 (of the oil phase) into EA 
- outer water phase: EA-saturated aqueous solution with 
0.8% w/w PVA 
Primary emulsion conditions: 60-second sonication by 
digital ultrasonic probe at 50% of amplitude.  
Secondary emulsion conditions: high-speed stirring at 2800 
rpm for 6 min. 
PX  
o-w emulsion (20:80 w/w) 
- oil phase: 5-7.5% w/w PLGA 75:25 (of the oil phase) and 
10% w/w PX (of the PLGA) into EA 
- water phase: EA-saturated aqueous solution with 0.8% w/w 
PVA  
Emulsion conditions: high-speed homogenization operating 
at 2800 rpm for 3 min. 
DS 
w-o-w emulsion (2:18:80 w/w) 
- inner water phase: 10% w/w DS (of the polymer) in water 
solution with 0.04% w/w PVA 
- oil phase: 2.5-5% w/w PLGA 75:25 (of the oil phase) into 
EA 
- outer water phase: EA-saturated aqueous solution with 
0.8% w/w PVA 
Primary emulsion conditions: sonication by ultrasonic bath 
for 2 min. 
Secondary emulsion conditions: high-speed stirring at 2800 
rpm for 6 min.  
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AP Emulsions composition and conditions 
HA 
w1-o-w2 emulsion (1:19:80 w/w/w).  
- inner water phase: 2.3-9% w/w HA (of the polymer) in 
EtOH or DMSO with 0.04% w/w PVA 
- oil phase: 5-10% w/w PLGA 50:50 (of the oil phase) into 
EA 
- outer water phase: EA-saturated aqueous solution with 
0.8% w/w PVA 
Primary emulsion conditions: 60-second sonication by 
digital ultrasonic probe at 50% of amplitude. 
Secondary emulsion conditions: high-speed stirring at 2800 
rpm for 6 min.  
s-o-w suspension emulsion (20:80 w/w).  
- solid phase: 4.5-9% w/w HA (of the polymer) in EA 
- oil phase: 10% w/w PLGA 50:50 (of the oil phase) into EA 
- water phase: EA-saturated aqueous solution with 0.8% w/w 
PVA 
Emulsion conditions: high-speed homogenization operating 
at 2800 rpm for 3 min. 
INS 
w1-o-w2 emulsion (1:19:80 w/w)  
- inner water phase: 0.5-1% w/w INS (of the polymer) an 
aqueous/TFA GLY solution (250 µl of GLY and 750 µl of 
water with 0.1% TFA) with 0.04% w/w PVA 
- oil phase: 10% w/w PLGA 50:50 (of the oil phase) into EA 
- outer water phase: EA-saturated aqueous solution with 
0.8% w/w PVA 
Primary emulsion conditions: 90-second sonication by 
digital ultrasonic probe at 50% of amplitude. 
Secondary emulsion conditions: high-speed stirring at 
1000-2800 rpm and 10°C in an ice bath for 3 min.  
 
IV.2.2 Droplets and microspheres morphology 
The droplets formed in the emulsions were observed using an optical 
microscope (mod. BX 50 Olympus, Tokyo, Japan) equipped with a phase 
contrast condenser.  
Microspheres shape and morphology were analyzed by Field Emission-
Scanning Electron Microscope (FE-SEM mod. LEO 1525, Carl Zeiss SMT 
AG, Oberkochen, Germany). Powders were dispersed over an adhesive 
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carbon tab, previously stuck to an aluminum stub. Samples were coated with 
a thin gold film (layer thickness 250 Ǻ) using a sputter coater (mod.108 A, 
Agar Scientific, Stansted, United Kingdom).  
 
IV.2.3 Droplets and microspheres size and distribution 
Droplet Size Distributions (DSDs) and Particle Size Distributions (PSDs) 
were measured by dynamic light scattering (DLS, mod. Mastersizer S, 
Malvern Instruments Ltd., Worcherstershire, United Kingdom). The 
Mastersizer S software uses Mie theory to produce an optimal analysis of the 
light energy distribution and to obtain the size distribution of the particles. 
Analyses were performed immediately after the preparation of the emulsion 
and of the microspheres suspension, using several milligrams of sample 
appropriately diluted with distilled water. The distributions proposed are the 
mean of several DLS analysis. Droplets and particle size are expressed as 
volume mean diameter (in µm) ± SD of values collected. Droplet Size 
Distributions (DSDs) and Particle Size Distributions (PSDs) are also 
described through the values of D10, D50 and D90 of the volumetric 
distribution. 
 
IV.2.4 Solvent residue analysis 
Ethyl acetate content in the final suspensions was analyzed, to determine 
the efficiency of solvent removal from the emulsion during SC-CO2 
extraction. The solvent residue was evaluated using a head space sampler 
(mod. 50 Scan, Hewlett & Packard, Palo Alto, CA, USA) coupled to a gas 
chromatograph interfaced with a flame ionization detector (GC-FID, mod. 
6890 Agilent Series, Agilent Technologies Inc., Wilmington, DE). Ethyl 
acetate was separated using a fused-silica capillary column 30 m length, 0.25 
mm internal diameter, 0.25 µm film thickness (mod. DB-1, J&W, Folsom, 
CA, USA). GC conditions were: oven temperature at 40°C for 8 min. The 
injector was maintained at 180°C (split mode, ratio 1:1) and Helium was 
used as the carrier gas (7 mL/min). Head space conditions were: 
equilibration time 60 min at 100 °C, pressurization time 2 min, loop fill time 
1 min. Head space samples were prepared in 10 mL vials filled with 3 mL of 
suspension. Analyses were performed on each sample in three replicates. 
Calculation of the concentration of ethyl acetate in microsphere samples was 
based on the standard calibration curve obtained using different EA/water 
solutions at fixed concentration (8-80-800 ppm). 
 
IV.2.5 Solid state characterization 
Diffraction patterns (XRD) of precipitated powders were obtained using 
an X-ray diffractometer (mod. D8 Discover, Bruker AXS, Inc., Madison, 
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WI) with a Cu sealed tube source. Samples were placed in the holder and 
flattened with a glass slide to assure a good surface texture. The measuring 
conditions were as follows: Ni-filtered CuK radiation, λ=1.54 Å, 2θ angle 
ranging between 20° and 70° with a scan rate of 3 seconds/step and a step 
size of 0.2°. 
Thermograms of powder samples were obtained using a differential 
scanning calorimeter (DSC mod. TC11, Mettler Toledo, Inc., Columbus, 
OH). Fusion temperature and enthalpy were calibrated with an indium 
standard material (melting point 156.6°C). The samples (±5 mg) were 
accurately weighed, crimped in an aluminum pan and heated from to 25 to 
400°C at 10°C/min, under a nitrogen purge of 50 mL/min. 
X-ray and DSC analyses were performed in three replicates for each 
batch of material. 
 
IV.2.6 Active principle loading 
The amount of active principle loaded into the microspheres was 
determined by HPLC analyses (mod. 1200 series, Agilent Technologies Inc., 
Italy) or UV-vis spectrophotometry (mod. Cary 50, Varian, PA, CA, USA). 
The methods adopted for the determination of the AP loading are described 
in details below, for each AP charged into the microspheres. 
PX and DS loadings were measured by dissolving 2.5 mg of 
microspheres in 1 mL of 0.25 M sodium hydroxide. Samples were stirred for 
at least 24 h at 10 rpm to ensure the complete dissolution of the polymer. 
Pure PX and DS were treated identically to verify their stability in the 
polymer degradation medium; no drug degradation was observed. The 
concentration of drug in the resulting solution was determined by UV-Vis, 
measuring the absorbance at 276 nm (both for PX and DS) in a quartz 
cuvette and then subtracting absorbance values obtained for the blank 
microspheres treated identically.  
HA loading was determined by UV-Vis method at 254 nm, measuring the 
absorbance value obtained in the release medium at the end of the drug 
release performed, i.e. when all the HA was diffused from the microspheres 
to the outer water phase. 
The amount of INS loaded into the microspheres was measured using the 
procedure described by Bilati et al. (2005). Briefly, accurately weighed 10 
mg aliquots of dried microspheres were dissolved in 0.6 mL of acetonitrile in 
centrifuge tubes and sonicated until complete transparency. Then, 1.4 mL of 
water containing 0.1% TFA were added to the sonicated mixture to dissolve 
Insulin completely. The remaining undissolved PLGA was separated by 
centrifugation at 2000 rpm for 2 min. The clear supernatant was then 
withdrawn and the protein concentration in the resulting clear solution was 
directly analyzed at room temperature by HPLC equipped with a C18 
column (LiCrosphere 250x4.6 mm, particles size 5 µm, pore size 100 Å). 
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Elution was performed with a mobile phase of acetonitrile:water mixture 
(32:68 v/v) containing 0.1% v/v TFA. The flow rate was 0.9 mL/min, the 
injection volume was 20 µL and the detecting wavelength was 214 nm. Pure 
INS was also tested to verify its stability in water with 0.1% TFA; no protein 
degradation was observed.  
The measurements were performed in three replicates and a good 
reproducibility was observed. The amount of measured AP, calculated from 
a calibration curve, was then converted in the effective AP loaded into 
microspheres. The encapsulation efficiency (EE) is the ratio of the final 




EE  (IV.1) 
 
IV.2.7 Active principle release 
Active principles release rates were determined using the UV-Vis 
spectrophotometer or monitored by HPLC. The percentage of released AP is 
defined as the mass of released AP divided by the total mass of AP in the 
microspheres. The methods used for the determination of the AP released 
from the microspheres are described below. Each sample was assayed in 
triplicate and the proposed curves are the mean profiles obtained. 
PX and DS release profiles were determined in 200 mL of release 
medium, phosphate-buffered saline solution (PBS, pH 7.4) in the case of PX 
and physiological solution in the case of DS, continuously stirred at 100 rpm 
in a 37°C incubator to maintain adequate sink conditions. For each test, 100 
mg of microspheres containing the drug were suspended in 2 mL of release 
medium and charged into a dialysis sack. In the case of PX release, the 
addition of 0.5% Tween-80 into the phosphate-buffered solution was 
necessary to enhance PX solubility in the release medium. Indeed, PX 
solubility in pure water is 0.03 mg/mL at 37°C; whereas, in the used release 
medium is 1.00 mg/mL (Berkland et al., 2003). PX and DS release rates 
were both measured using an on-line UV-Vis probe at 276 nm.  
For each HA release test, since solubility of HA in water is about 0.01 
mg/mL, approximately 50 or 100 mg of microspheres containing HA 
(depending on the theoretical HA loading) were suspended in 2 mL of 
distilled water with 0.5% of Tween-80 and placed into a dialysis sack. This 
sack was then incubated in 200 mL of distilled water continuously stirred at 
100 rpm and 37°C to maintain adequate sink conditions. The concentration 
of the HA released in the external medium was continuously detected by an 
on-line UV-Vis spectrophotometer, measuring the absorbance at 254 nm.  
In vitro release kinetics of INS from microsphere formulations were 
evaluated by suspending accurately weighed 20 mg of dried microspheres in 
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2 mL of Phosphate-Buffered Saline (PBS, 100 mM, pH 7.4) or 2 mL of 
Dulbecco's Modified Eagle Medium (DMEM) used for cell culture, in a 
centrifuge tube. Then, the tubes were placed in an incubator-shaker at 37°C 
and stirred continuously at 50 rpm. At defined time intervals, the samples 
were centrifuged at 4000 rpm for 15 min and the supernatant was completely 
withdrawn and replaced with fresh media to maintain sink conditions. The 
amount of released protein was determined by measuring the protein 
concentration in the supernatant using HPLC method.  
 
IV.2.8 Microspheres degradation  
100 mg of PLGA microspheres were suspended in 20 mL of water, 
agitated at 50 rpm and 37°C. 10 mL of suspension were sampled every 7 
days, dried and mounted on an aluminum stub for the morphological 
analysis by FE-SEM. The suspension pH was measured by a pHmeter (mod. 











V.1 Volumetric properties of ethyl acetate+carbon dioxide binary 
mixtures at high pressures 
Information on the volumetric properties of fluids and fluid mixtures at 
high pressures is important for the design and operation of processes 
involving dense or supercritical fluids. Density and its dependence on 
pressure, temperature and fluid composition are particularly important 
because many properties of supercritical fluids, such as their solvating 
power, viscosity, diffusivity (which depend on several parameters such as 
temperature, pressure and composition) can be correlated and scale best with 
density.  
Several publications have already appeared on thermodynamics and 
phase behavior of ethyl acetate+CO2 mixtures. Critical loci have been 
reported (Ting et al., 1993; Chester and Haynes, 1997). Even though 
publications on vapor-liquid equilibrium for these mixtures have been 
published (Wagner and Pavlíček, 1994; da Silva et al., 2000; Byun et al., 
2006), their reliability has been questioned in a recent publication 
(Wyczesany, 2007). Limited density information has been published, but at 
pressures below 20 MPa and temperatures below 313 K (Aida et al., 2010; 
Smith et al., 1998). Even though density (Vargaftik, 1975; Gardas et al., 
2007) and volumetric property data are available for ethyl acetate (Gardas et 
al., 2007), there is no information on the higher pressure/temperature 
volumetric properties such as density, compressibility, expansivity or 
pressure coefficient for its mixtures with carbon dioxide.  
In this work, therefore, the density and related volumetric properties of 
ethyl acetate+CO2 mixtures containing 0, 27.7, 42.6, 52.9, 67.3 and 100 wt 
% CO2 have been determined over a wider range of temperatures up to 340 
K for mixtures and up to 380 K for pure components at pressures up to 32 
MPa. These measurements have been carried out in a variable-volume view-
cell employing a unique measurement technique. The methodology allows 
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real-time recording of the piston position which permits generation of 
essentially continuous density-pressure data (Falco and Kiran, 2012). 
 
V.1.1 System description 
Figure V.1 shows a schematic diagram of the experimental system used. 
It is based on a system that had been reported earlier (Zhuang and Kiran, 
1996), which now incorporates a modified computer interface and data 
acquisition software. It consists of a high-pressure variable-volume cell 
(VC/VVP) with an internal movable piston, a special linear variable 
differential transformer (LVDT) to monitor in-real time the position of the 
movable piston, a pressure generator (PGN), two sapphire windows (SW) 
for visual or optical observations, an optical sensor to monitor the 
transmitted light intensity from a laser source (L), and a data acquisition 
board (DAQ) for the real time computerized recording of the pressure, 
temperature, transmitted light intensity and position of the piston while 
pressure is changed. The cell body and the variable volume part of the cell 
are each heated with four cartridge heaters controlled with a Omega (Model-
CN76000) temperature controller. Temperature of the fluid inside the cell is 
monitored with a J-type thermocouple directly mounted on the cell. 
Temperature is maintained within ± 0.5 K of the set value. The cell pressure 
is measured with a flush-mount pressure transducer (Dynisco PT467E-15M) 
mounted on the recirculation loop near the inlet port of the cell. It permits 
monitoring the pressure with an accuracy of ± 0.06 MPa.  
The far end of the variable volume part (VVP) of the cell is extended with a 
stainless steel tube (30.5 cm long) which houses an extension rod. The 
extension rod is connected to the movable piston at one end, while the other 
end is connected to a long ferromagnetic core. A special, large diameter (5 
cm) and 30 cm long LVDT unit (Lucas-Schaevitz 2003 XS-A) positioned 
around the stainless steel tube (housing the extension rod) is used to monitor 
the position of the ferromagnetic core and with it the position of the piston. 
The signal from this long-stroke LVDT is directly recorded by the computer 
in real time and converted to actual position using a calibration curve. In the 
pressure generator (High Pressure Equipment Co., mod. 50-60-15), ethanol 
is used as the pressurizing fluid to bring about the changes in the position of 














































Figure V.1 Schematic diagram of the experimental system: SL, solvent line; 
PG, pressure gauge; PGN, pressure generator; LP_1 and LP_2, liquid 
pumps; LVDT, linear variable differential transformer; VC, view cell; VVP, 
variable-volume part of the view cell; SW, sapphire window; SP, sample 
port; PS, pressure sensor; L, laser; PRU, position readout unit; PI, pressure 
indicator; TI, temperature indicator; TC, thermocouple; DAQ, computerized 
control and data acquisition units; TLI, transmitted light intensity; TV, 
transfer vessel; B, balance; V_1...V_12, valves. 
 
The maximum internal volume of the cell is 19.27 cm
3
, corresponding to 
the all the way out position of the piston. The density of the fluid is then 
determined from the following equation: 
ρ = M / (19.27 -1.98 L)  (V.1) 
where ρ is the density (in g/cm
3
), M is the total mass (in grams) initially 
loaded to the cell and L is the piston position (expressed in mm). The factor 
1.98 incorporates the cross-sectional area of the piston and the conversion 







The experimental system used is located at Virginia Polytechnic Institute 
and State University (Virginia, USA), and a picture is shown in Figure V.2: 
 
 
Figure V.2 Experimental system used, located at Virginia Polytechnic 
Institute and State University (USA). 
 
V.1.2 Operational procedures 
Prior to loading the fluid of interest, the cell was cleaned and purged by 
flushing it through the solvent delivery line with CO2. This procedure was 
repeated 3-5 times to ensure that the cell was free of air or any residual 
solvent. Then, a known amount of the fluid to be tested was charged into the 
cell at room temperature using an HPLC pump (SSI, mod. 200) from a fluid 
transfer vessel that had been previously filled with the fluid. The transfer 
vessel for ethyl acetate was simply a glass bottle. The transfer vessel for CO2 
was a high pressure vessel. It was filled with carbon dioxide from a tank 
with an educator tube. The exact amount of each fluid charged during 
pumping was determined by direct reading of the weight change of the 
transfer vessels (containing ethyl acetate, or carbon dioxide) using a balance 
with 0.01 g accuracy (Mettler, mod. PM 6100). In a typical experiment, ethyl 
acetate was firstly charged, followed by CO2 charge. The range of ethyl 
acetate mass charged was from 14.0 g for pure ethyl acetate to 4.93 g for the 
mixture with 67.3 wt % carbon dioxide content.   
After the system was loaded, the cell was heated to the target temperature 
and held for about 1 h for equilibration before measurements were carried 
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out. After thermal equilibration was achieved, the piston was moved by 
applying pressure from the pressure generator. Pressure was continually 
changed slowly up to a desired high pressure (32 MPa in the present study) 
and then lowered back. After the pressure scan was completed, the system 
temperature was changed to a new value and the up-and-down pressure 
scans were carried out at each temperature.  
During each scan, pressure, temperature, piston position and transmitted 
light intensity are recorded in real time with the dedicated computer. Under a 
continuous and slow pressure change, the fluid experiences a smooth 
expansion or compression. The pressure changes being brought about very 
slowly, the temperature control unit of the system compensates for any 
thermal changes associated with expansion or compression of the fluid. The 
experiments are thus conducted under quasi equilibrium state conditions.  
Figure V.3(a-c) shows the real-time recording of pressure (a), piston 
position (b) and the internal volume (c) as a function of time during a 
pressure increase (compression) and pressure reduction (decompression) 
cycle for CO2 at 340 K. The internal volume was changed from 18.6 to 13.7 
cm
3
 over a 2100 s (35 min) time-interval by increasing the pressure from 16 
to 32 MPa, and then reducing it back by manipulation of the pressure 
generator by hand. This particular data set corresponds to about 7000 data 
points with data being recorded every 0.3 s during the scans. The resulting 
pressure-density curve from this experiment is shown in Figure V.3(d). The 
solid curve is a cubic polynomial fit to the data. The relatively high degree of 
reproducibility of the data in the up and down direction of the pressure 
change should be noted at this rate of pressure change employed. As shown 
in Figure V.3(a), relatively smooth pressure change is not too difficult to 
achieve by manipulating the pressure generator by hand if patience is 
exercised. The differences in the up and down pressure scans observed in 
Figure V.3(d) can be minimized further by reducing the rate of pressure 
increase or decrease. In this particular data set, the rate of pressure change 
employed was about 0.015 MPa/s. Of course, one can change the pressure to 
a new value, hold it there for a while to ensure full equilibration, and then 
move to a new equilibrium state and generate the pressure-position and thus 
pressure-density curves. However, the slow scanning procedure employed 
provides high degree of flexibility in the efficiency of generating data that 
are still reliable. Much smoother variations at desired rates are achievable by 


















































































Figure V.3(a-d) Real-time recording of pressure (a), piston position (b), cell 
volume (c) during a up-and-down pressure scan of CO2 at 340 K, and the 
resulting pressure-density plot along with a polynomial fit (d). 
 
Figure V.4(a-d) show the real-time recording of pressure, position, 
volume and density during compression and decompression cycles for the 
binary mixture containing 67.3% by mass CO2 at 313 K. The internal 
volume was changed from 18.7 to 16 cm
3
 over a 850 s (14 min) time-interval 
by increasing the pressure from 14 to 30 MPa and then reducing it back. This 
particular data set corresponds to about 2700 data points with readings 
having again been taken every about 0.3 s during the experiment. Here the 
rate of pressure change employed was faster, being about 0.085 MPa/s. At 
this higher rate of pressure change, which is nearly 6 times faster than the 
case shown in Figure V.3(a), the density values in Figure V.4(d) show a 
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small hysteresis in the pressure increase or decrease direction, reflecting the 
small frictional differences arising from the O-ring of the piston.   
Figure V.4(d) illustrates a unique feature of the present density 
determination procedure in that the demarcation pressure (or density) from 
the homogeneous one-phase to two-phase region (where the pressure 
remains unchanged -- strictly true for pure compounds-- while the density is 
altered) is distinctly displayed. In the absence of continuous recording of 
density (or volume) with continually changing pressure, the experimental 
identification of the exact point of this demarcation from one-phase to two-
phase region would not be easy, as numerous single point measurements 



















































































Figure V.4(a-d) Real-time recording of pressure (a), piston position (b), cell 
volume (c) during a up-and-down pressure scan of the binary fluid mixture 
(ethyl acetate+CO2) containing 67.3% by mass CO2 at 313 K, and the 
resulting pressure-density plot along with a polynomial fit (d). 
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The primary sources of error in the determination of density are linked to 
the uncertainties on the exact amount of fluid charged to the cell and the 
errors associated with the LVDT reading and its relation to the position of 
the piston. The balance was accurate to 0.01 g. The nonlinearity of the 
LVDT sensor was ± 0.30%. As will be discussed in the following sections, 
comparisons with NIST data base for CO2 shows that the overall combined 
average error is less than 1%. To compensate for any errors that may arise 
from the pressure change rate, the density data were correlated by using all 
the values generated in both the pressure increase and decrease direction. 
The near continuous density data permits fitting the data with smooth 
polynomial functions representing the average values, as shown in Figure 
V.3(d) and Figure V.4(d). Experiments that were conducted by changing the 
pressure in step-wise manner and equilibration in between indicate that the 
equilibrium values indeed lie in between the up-and-down pressure-scan 
values, however, in the vicinity of the entrance to the two-phase region, they 
are closer to the values obtained in the pressure reduction direction. 
 
V.1.3 Carbon dioxide 
V.1.3.1 Density 
Even though density of CO2 is well documented in the literature and there 
are extensive data bases, such as those available through NIST (National 
Institute of Standards and Technology (NIST) - 
http://webbook.nist.gov/chemistry/fluid), for internal consistency and use in 
the comparisons with mixtures with ethyl acetate explored in the present 
study, the density of CO2 at 295, 300, 320, 340 and 360 K over a pressure 
range from 5 to 32 MPa was measured. The results are shown in Figure V.5. 
The average rates of pressure increase and decrease employed were 0.027 
and 0.034 MPa/s, respectively. The average piston velocities during pressure 
increase and decrease stages were 0.028 mm/s and 0.024 mm/s, respectively. 































Figure V.5 Variation of density with pressure of CO2 at different 
temperatures. The filled symbols are the present experimental data at the 
indicated temperatures, the black solid curves are the polynomial fits to the 
data, and the open symbols are values from the NIST data base at the 
corresponding temperatures. 
 
At 295 K, CO2 is subcritical (Tc = 304.1 K) and the density-pressure 
curve in Figure V.5 shows distinctly the two phase (V-L) region where 
density (volume) can change at constant pressure, and a smooth curved 
region corresponding to the homogeneous dense fluid domain where density 
increases monotonically with pressure. As indicated earlier, the near 
continuous recording of the density facilitates differentiation of the V-L two 
phase region from the homogeneous one-phase region. At higher 
temperatures, where the fluid is supercritical, the variation of density with 
pressure is smooth as there is no phase transition.  
The density-pressure isotherms were fitted to quadratic equation of the 
form ρ = a + bP + cP
2
 in the homogeneous domains. These equations are 
given in Table V.1 and shown also in Figure V.5. The data has been 
compared with the values from the NIST data base at selected pressures. 
They are shown in Table V.2 and also in Figure V.5. The average error is 
less than 1%. Overall, the agreement is excellent considering the rapidity 
with which such data are generated. The error increases at the higher 
temperatures. This, as will be discussed later also, stems from small leaks 
that develop in the system at higher temperatures, which leads to slightly 




Table V.1 Density (g/cm
3
)-Pressure (MPa) and Density-Temperature (K) 






T      
(K) 
P range   
(MPa) 
CO2 
242 10140.210565.17066.0 PP    295K 10MPa<P<32MPa 
242 10393.210753.16452.0 PP    300K 11MPa<P<32MPa 
242 10651.310671.24117.0 PP    320K 15MPa<P<32MPa 
242 10604.610523.40421.0 PP    340K 16MPa<P<32MPa 









T range         
(K) 
CO2 
T3105152.83756.3   12 MPa 295 K<T<300 K 
T3106822.68738.2   16 MPa 295 K<T<340 K 
T3104952.55533.2   20 MPa 295 K<T<340 K 
T3106856.43388.2   24 MPa 295 K<T<360 K 
T3100849.41789.2   28 MPa 295 K<T<360 K 
T3104952.55533.2   32 MPa 295 K<T<360 K 
 
 




Figure V.6 shows the variation of density with temperature at selected 
pressures from 12 to 32 MPa. In this temperature interval, density shows 
linear decrease with temperature given by the equations in Table V.1. 
 
 T (K) 























10 0.8427 0.8417 0.8016 0.7966 0.4483 - 0.2586 - 0.2083 - 
15 0.8940 0.8932 0.8658 0.8543 0.7268 0.7302 0.5356 - 0.3871 - 
20 0.9287 0.9340 0.9056 0.9001 0.8023 0.7999 0.6797 0.6825 0.5515 - 
25 0.9557 0.9641 0.9354 0.9339 0.8487 0.8513 0.7527 0.7601 0.6517 0.6660 






























Figure V.6 Temperature dependence of density of CO2 at selected pressures. 
 
V.1.3.2 Isothermal compressibility, isobaric expansivity, and isochoric 
pressure coefficients 
Using the equations describing the variation of density with pressure and 
temperature given in Table V.1, isothermal compressibility kT, isobaric 
expansivity αP and isochoric thermal pressure coefficient γρ for carbon 










































































The results are shown in Figures V.7-9. Isothermal compressibility and 
isobaric expansivity values increase with temperature, but decrease with 
pressure. Both of these coefficients show a greater change with the 
temperature at the lower pressures. Compressibility values are in the range 
from 0.002 to 0.04 MPa
-1







. At a fixed pressure, the thermal pressure coefficient decreases 
with the increasing temperature. At a given temperature, it increases with 


























































































































Figure V.9 Thermal pressure coefficient γρ of CO2 at selected temperatures. 
 
Isothermal compressibility values for CO2 were reported earlier in the 
literature at 298, 323 and 348 K (Zhuang and Kiran, 1996). At 298 K, the 
literature values are in the range 0.06 to 0.005 MPa
-1
 in going from 5 to 20 
MPa; at 323 K, they are in the range 0.07 to 0.005 MPa
-1
 in going from 10 to 
30 MPa, and at 348 K in the range 0.08 to 0.01 MPa
-1
 in going from 15 to 30 
MPa. The present values are in a similar range. A recent article provides 
isothermal compressibility data for mixtures of carbon dioxide with dimethyl 
carbonate (Hou et al., 2010) in the temperature range from 308 to 337 K, but 
at a lower pressure range from 6 to 17 MPa. Even though kT values are not 
given for pure carbon dioxide at these conditions, for a mixture containing 
0.98 mole percent of CO2, the values are reported to be below 0.05 MPa
-1
 for 
pressures in the range 10-15 MPa. 
 
V.1.4 Ethyl acetate 
V.1.4.1 Density 
Figure V.10 shows the density data for ethyl acetate at 295, 320, 340, 360 
and 380 K. The pressures ranges investigated were up to 28 MPa at 295 K, 
320 K and 340 K; up to 20 MPa at 360 K, and up to 13 MPa for 380 K. The 
density values in the pressure increase and decrease directions were almost 
identical with some minor hysteresis observed at 320 and 340 K. In these 
experiments, the average rates of compression and decompressions were 
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0.140 MPa/s and 0.154 MPa/s, respectively. Piston velocities were about 
0.017 mm/s.   
 These temperatures are all below the critical temperature of ethyl acetate 
(Tc = 523.1 K). A density range from about 0.80 to 0.92 g/cm
3
 has been 
covered. Linear equations of the form ρ = a + bP were used to correlate the 
density at each temperature. These equations are given in Table V.3 and are 






























Figure V.10 Pressure dependence of density of EA at selected temperatures. 
The solid lines are the linear fits to the data. 
 
Figure V.11 shows the variation of density with temperature for ethyl 
acetate at selected pressures from 4 to 28 MPa. These again could be 
represented by linear equations which are shown in the figure and are given 

































Figure V.11 Variation of density of EA with temperature at selected 
pressures. 
 
Table V.3 Density (g/cm
3
)-Pressure (MPa) and Density-Temperature (K) 






  T           
(K) 




P310946.08960.0   295K 0.05MPa<P<28MPa 
P310081.18683.0   320K 0.05MPa<P<28MPa 
P310293.18448.0   340K 0.05MPa<P<28MPa 
P310522.18197.0   360K 0.05MPa<P<20MPa 







 P      
(MPa) 




T310114.1229.1   4 MPa 295 K<T<380 K 
T310072.1220.1   8 MPa 295 K<T<380 K 
T310030.1211.1   12 MPa 295 K<T<380 K 
T310029.1215.1   16 MPa 295 K<T<360 K 
T3109928.0208.1   20 MPa 295 K<T<360 K 
T3109528.0200.1   24 MPa 295 K<T<340 K 
 T
3109223.0194.1   28 MPa 295 K<T<340 K 
Chapter V 
66 
The density data for saturated ethyl acetate are available at atmospheric 
pressure over the temperature range from 273 to 523 K (Vargaftik, 1975). As 
shown in Figure V.12, the values obtained in the present study are in very 






















200 300 400 500 600
Temperature, K  
Figure V.12 Comparison of density data of EA (filled symbols) at 
atmospheric pressure at different temperatures with literature values (open 
symbols) from Vargaftik (1975). 
 
Density values for ethyl acetate at high pressures have also been 
previously reported. One data set is at 313 K in the pressures range from 0.1 
to 21 MPa (Smith et al., 1998). A more recent publication (Gardas et al., 
2007) provides density data over a wider range of temperatures (from 298 to 
393 K) at pressures up to 35 MPa. Table V.4 illustrates a comparison of the 
densities at 20 MPa reported by Gardas et al. (2007) with the values from the 
present study using the density-temperature correlations at this pressure 
given in Table V.3. They are in close agreement with deviations being in the 
range from 0.19 to 0.92%. The higher deviations at high temperatures, which 
were also observed in carbon dioxide density measurements, most likely 
arise from small leaks in the system over time as measurements are carried 








Table V.4 Comparison of EA density values at 20 MPa with literature 
(Gardas et al., 2007).  


















ρ (g/cm3) 0.8954 0.8971 0.8843 0.8871 0.8630 0.8673 0.8397 0.8474 
% 
difference 
 0.19  0.32  0.50  0.92 
 
 
V.1.4.2 Isothermal compressibility, isobaric expansivity, and isochoric 
pressure coefficients 
From the density vs pressure and temperature correlations, the parameters 
kT, αP, γρ for pure ethyl acetate have also been determined.  
Figure V.13 shows the pressure dependence of the isothermal 
compressibility at selected temperatures. The isothermal compressibility 
displays the expected decrease with pressure and increase with temperature. 




, which are 
much lower (by a factor of about 10-30) than the compressibility values for 















































Figure V.14 shows the variation of the isobaric expansivity with 
temperature at selected pressures. Isobaric expansivity increases with 
temperature and decreases with pressure. The rate of increase with 
temperature is noted to be slightly higher at lower pressures. The expansivity 




, which are less than the values for 






































Figure V.14 Isobaric expansivity αP of EA at selected pressures. 
 
The thermal pressure coefficient γρ for ethyl acetate is shown in Figure 
V.15. As expected, the thermal pressure coefficient decreases with 
increasing temperature. Along each isotherm, it decreases with pressure. 
Thermal pressure coefficients are in the range from 0.55 to 1.2 MPa/K, 















































Figure V.15 Thermal pressure coefficient γρ of EA at selected temperatures. 
 
There is one earlier study in the literature that has reported on the 
compressibility, expansivity and the thermal pressure coefficients for ethyl 
acetate (Gardas et al., 2007). The values and the trends are in very close 
agreement with the present observations. In the 10-30 MPa range, depending 










, and pressure coefficients are in the range 0.6-1.3 MPa/K. In the present 
study, the thermal pressure coefficients are decreasing with pressure, as 
shown in Figure V.15 at all temperatures investigated. However, in the 
literature, a similar decreasing trend is noted only at temperatures above 380 
K.  
It should be pointed out that a recent publication reports on these 
coefficients for other esters, such as ethyl propionate, ethyl butyrate and 
ethyl pentanoate, from 298 to 393 K and up to 35 MPa (Costa et al., 2009). 





, while for ethyl butyrate expansivity values are 






both of which are similar to 
the values for ethyl acetate. For ethyl propionate, thermal pressure 
coefficients that are reported are in the range 0.77-1.05 MPa/K, which are 
somewhat lower than that for ethyl acetate. However, for ethyl propionate 
pressure coefficients are reported to increase with pressure, which is a trend 
opposite to that observed with carbon dioxide or ethyl acetate. 
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V.1.5 Ethyl acetate+carbon dioxide mixtures 
V.1.5.1 Density 
The densities for ethyl acetate+CO2 mixtures have been determined for 
solutions containing 27.7, 42.6, 52.9 and 67.3% by mass CO2 at selected 
temperatures in the range 295-340 K at pressures up to 30 MPa. The results 
are shown in Figures V.16-19. Along each isotherm, the two-phase, vapor-
liquid region where large density changes occur with small variations in 
pressure, and the homogeneous liquid region where the density changes 
monotonously with pressure are easily noted. In these experiments, the 
average rates of pressure increase and decrease were 0.137 MPa/s and 0.134 
MPa/s, respectively. Piston velocities were around 0.03 mm/s during the 
pressure increase and around 0.02 mm/s during pressure decrease stages. 
The pressure dependence of the experimental densities in the one-phase 
region was correlated using quadratic equations of the form ρ = a + bP + cP
2
. 
The equations are given in Table V.5. They are also included in Figures 
V.16-19. These correlations provide the average values of the densities 
obtained during pressure scans in both the pressure-increase and decrease-
directions. The hysteresis is more apparent in these binary mixtures where 
the density values obtained tend to be higher (volumes that are recorded tend 






























Figure V.16 Pressure dependence of density of EA+CO2 mixture with 27.7 



























Figure V.17 Pressure dependence of density of EA+CO2 mixture with 42.6 





























Figure V.18 Pressure dependence of density of EA+CO2 mixture with 52.9 































Figure V.19 Pressure dependence of density of EA+CO2 mixture with 67.3 
wt % CO2 at 295, 300, 313, 320 and 340 K. 
 
Figures V.20-23 show comparative plots for the different mixtures at 295, 
300, 320 and 340 K. These figures include also the density data for pure CO2 
and ethyl acetate. As shown, ethyl acetate has a relatively low 
compressibility as displayed by the steep increase in pressure required to 
bring about changes in density. For example, in Figure V.20, at 295 K, the 
density of ethyl acetate changes only from about 0.90 to 0.93 g/cm
3
 when the 
pressure is changed from about 6 to 30 MPa, while in the same interval the 
density of carbon dioxide increases from 0.60 to 0.98 g/cm
3
. With increasing 
pressure, the density of carbon dioxide becomes greater than that of ethyl 
acetate at around 17 MPa.  
As shown in Figure V.20, the mixtures are all more compressible than 
pure ethyl acetate (densities of the binary mixture are higher than the density 
of pure ethyl acetate), and each mixture shows a density crossover (i.e., the 
density of the mixture becomes greater than that of pure ethyl acetate) at a 
characteristic pressure. At a given pressure, density goes through a 
maximum with increasing CO2 mass fraction in the mixture. For example, at 
15 MPa density increases with increasing CO2 content up to 52.9 mass %. 
The density of the mixture containing 67.3% CO2 is however lower than that 
of the mixture containing 52.9% CO2 at the same pressure condition. As will 
be discussed later, excess volume becomes less negative for mixtures with 
carbon dioxide content higher than about 50 wt %. As the CO2 content is 
increased, the slope of the mixture density vs pressure becomes less steep, as 
it should gradually fold over to attain the shape of the isotherm for pure CO2. 
Similar trends are observed at the other temperatures (Figures V.21-23), 
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which show the variation of density with pressure at 300, 320 and 340 K. 
The densities of the mixtures at these temperatures are mostly higher than 
the density of pure CO2. 
 
Table V.5 Density (g/cm
3













253 10297.110620.19087.0 PP    295K 5MPa<P<30MPa 
253 10523.110897.18857.0 PP    300K 5MPa<P<30MPa 
253 10468.110885.18816.0 PP    313K 5MPa<P<30MPa 
253 10562.110034.28695.0 PP    320K 5MPa<P<30MPa 
253 10876.110417.28374.0 PP    340K 5MPa<P<30MPa 
42.6 % 
CO2 
253 10517.110265.29169.0 PP    295K 4MPa<P<30MPa 
253 10081.210783.28838.0 PP    300K 5MPa<P<30MPa 
253 10909.110799.28772.0 PP    313K 5MPa<P<30MPa 
253 10920.210287.38594.0 PP    320K 5MPa<P<30MPa 
253 10902.410647.48039.0 PP    340K 8MPa<P<30MPa 
52.9 % 
CO2 
253 10423.210965.29153.0 PP    295K 5MPa<P<30MPa 
253 10266.310684.38759.0 PP    300K 13MPa<P<30MPa 
253 10825.210550.38714.0 PP    313K 13MPa<P<30MPa 
253 10533.110076.38614.0 PP    320K 19MPa<P<30MPa 
67.3 % 
CO2 
253 10577.410454.48869.0 PP    295K 5MPa<P<30MPa 
253 10309.710306.68232.0 PP    300K 6MPa<P<30MPa 
253 10901.710753.68089.0 PP    313K 7MPa<P<30MPa 
253 10468.810316.77825.0 PP    320K 8MPa<P<30MPa 






































Figure V.20 Pressure dependence of density of EA+CO2 mixtures at 295 K 
(compositions are in mass percent). At 15 MPa, order of curves from higher 

































Figure V.21 Pressure dependence of density of EA+CO2 mixtures at 300 K 
(compositions in mass percent). At 15 MPa, order of curves from higher to 





































Figure V.22 Pressure dependence of density of EA+CO2 mixtures at 320 K 
(compositions in mass percent).  At 20 MPa, order of curves from higher to 
































Figure V.23 Pressure dependence of density of EA+CO2 mixtures at 340 K 
(compositions in mass percent). At 25 MPa, order of curves from higher to 




There is only one prior publication that reports densities for ethyl 
acetate+CO2 mixtures containing 25, 42.9 and 66.6 wt % CO2 (Smith et al., 
1998). Data are however only at 313 K and at pressures below 20 MPa. Even 
though not identical with the compositions reported in the literature, for 
comparisons, density determinations were carried on the mixtures explored 
in the present study (which contain 27.7, 42.6 and 67.3 % CO2) at 313 K as 
well. As shown in Figure V.24, the results are in good relative agreement in 
































Figure V.24 Comparisons of density of EA+CO2 mixtures at 313 K with 
literature data from Smith et al., (1998) (open symbols). At 15 MPa, order of 
curves from higher to lower density: 42.6; 27.7; 67.3 % CO2. 
 
Figures V.25-28 show the variation of density of the mixtures with 
temperature at different pressures from 8 to 30 MPa.  The data were fitted to 


































Figure V.25 Temperature dependence of the density of EA+CO2 mixture 































Figure V.26 Temperature dependence of the density of EA+CO2 mixture 


































Figure V.27 Temperature dependence of the density of EA+CO2 mixture 






























Figure V.28 Temperature dependence of the density of EA+CO2 mixture 





Table V.6 Density (g/cm
3












T310303.1300.1   8 MPa 295K<T<340K 
T310249.1290.1   12 MPa 295K<T<340K 
T310199.1280.1   16 MPa 295K<T<340K 
T310152.1271.1   20 MPa 295K<T<340K 
T310109.1263.1   24 MPa 295K<T<340K 
T310069.1255.1   28 MPa 295K<T<340K 
T310051.1251.1   30 MPa 295K<T<340K 
42.6 % 
CO2 
T310922.1495.1   8 MPa 295K<T<340K 
T310783.1462.1   12 MPa 295K<T<340K 
T310668.1435.1   16 MPa 295K<T<340K 
T310575.1415.1   20 MPa 295K<T<340K 
T310505.1400.1   24 MPa 295K<T<340K 
T310457.1393.1   28 MPa 295K<T<340K 
T310442.1391.1   30 MPa 295K<T<340K 
52.9 % 
CO2 
T310663.1438.1   16 MPa 295K<T<313K 
T310582.1423.1   20 MPa 295K<T<320K 
T310516.1412.1   24 MPa 295K<T<320K 
T310438.1396.1   28 MPa 295K<T<320K 
T310395.1386.1   30 MPa 295K<T<320K 
67.3 % 
CO2 
T310782.2725.1   8 MPa 295K<T<320K 
T310503.2658.1   12 MPa 295K<T<320K 
T310510.2677.1   16 MPa 295K<T<340K 
T310263.2616.1   20 MPa 295K<T<340K 
T310082.2572.1   24 MPa 295K<T<340K 
T310967.1547.1   28 MPa 295K<T<340K 





V.1.5.2 Isothermal compressibility, isobaric expansivity, and isochoric 
pressure coefficients 
For each ethyl acetate+CO2  mixture, isothermal compressibility, isobaric 
expansivity and isochoric thermal pressure coefficients were determined 
from the density vs pressure data shown in Figures V.16-19 and the 
correlations given in Table V.5 and Table V.6. 
Figures V.29-31 show the results for the mixture containing 27.7% by 
mass CO2. The compressibility values for this mixture vary in the range from 




. They decrease with increasing pressure or 
decreasing temperatures. The isobaric expansivity increases with 





. The thermal pressure coefficient decreases with temperature 
and increases with pressure. The values are in the range of 0.6-1.25 MPa/K. 
Figure V.32(a-c) show the isothermal compressibility, Figure V.33(a-c) 
the isobaric expansivity and Figure V.34(a-c) the isochoric thermal pressure 
coefficient as a function of temperature and pressure for the other mixtures 
containing 42.6, 52.9 and 67.3% by mass of CO2, respectively.  
Figure V.35(a-c) shows these quantities at 20 MPa as a function of CO2 
content of the mixture. As illustrated, at a given temperature, compressibility 
and expansivity values increase with increasing carbon dioxide content in 
the mixture. This increase becomes more significant at CO2 levels above 50 











































Figure V.29 Pressure dependence of the isothermal compressibility of 









































Figure V.30 Temperature dependence of the isobaric expansivity of 














































Figure V.31 Pressure dependence of the thermal pressure coefficient of 



































































































































Figure V.32(a-c) Pressure dependence of the isothermal compressibility of 
























































































































Figure V.33(a-c) Temperature dependence of the isobaric expansivity of 










































































































































Figure V.34(a-c) Pressure dependence of the thermal pressure coefficient of 



























































































































Figure V.35(a-c) Compositional dependence of the (a) isothermal 
compressibility, (b) isobaric expansivity and (c) thermal pressure coefficient 
of pure CO2, pure ethyl acetate and EA+CO2 mixtures containing 27.7, 42.6, 
52.9, 67.3 wt % CO2 at selected temperatures. 
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V.1.6 Excess volume 
The excess volumes for the mixtures were determined from the 
experimental density values using the following relationship in which the 
















Here m  is the density of the mixture, and ix , iM , and i  are the mole 
fraction, the molar mass and the density of the component i, respectively. In 
these evaluations, density values were calculated from the correlation 
equations obtained in the present study for a given temperature and pressure. 
 In Figures V.36-38 excess volumes are shown respectively at 295, 320 
and 340 K for different pressures as a function of carbon dioxide mole 
fraction. As shown, the excess volumes are negative and become more 
negative with decreasing pressure and increasing temperature. The excess 
volume goes through its highest negative value for the mixture containing 
52.9 wt % (69.2 mole %) CO2. This composition appears to represent the 
mixture composition with the highest degree of packing. This is further 
reflected in the higher densities that are displayed with this mixture, which 
can be observed from comparisons of Figures V.16-19. The negative values 
of excess volume in mixtures is indicative of better packing, often arising in 
asymmetric systems that involve molecules of different sizes displaying 
differences in free volumes (Pensado et al., 2008). Negative excess volumes 
are common in mixtures of carbon dioxide with organic solvents and have 
been reported for mixtures of CO2 with pentaerythritol tetra-2-
ethylhexanoate (Pensado et al., 2008), toluene (Pöhler and Kiran, 1996) 
ethanol (Pöhler and Kiran, 1997a) and acetone (Pöhler and Kiran, 1997b). 
As would be anticipated, when pressure is increased, the magnitude of the 
negative excess volume should be reduced. This is clearly observed in 
Figures V.39-41, which show the excess volumes at 16, 20 and 28 MPa at 
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V.2 SEE-C operating parameters  
Operating pressure and temperature conditions were selected to enhance 
the extraction of the oily dispersed phase of the emulsion. Extraction 
pressure and temperature conditions of 80 bar and 38°C, respectively, were 
selected for processing emulsions, according to the following considerations: 
 T = 38°C is compatible with several drugs or peptides to be 
encapsulated and lower than the PLGA glass transition that occurs at 
about 40°C (De and Robinson, 2004); 
 solubility of EA in CO2: these process conditions assure the complete 
miscibility of EA in SC-CO2 (Smith et al., 1998); 
 solubility of H2O in CO2: at these operating conditions the solubility of 
the continuous phase of the emulsion in CO2 is very small, so it is very 
small and can be neglected (Sabirzyanov et al., 2002; King et al., 1992; 
Wiebe and Gaddy, 1940); 
 the difference in density between the emulsion and SC-CO2 is very 
large (~1 g/cm
3
 for the liquid phase against 0.310 g/cm
3
 for CO2). Since 
the countercurrent operation in the packed column is favoured by large 
density differences between the two phases involved in the process, for 
a fixed temperature the lower is the pressure the larger is the density 
difference, therefore, pressures higher than 100 bar were not considered. 
 
V.3 Flooding calculations 
In a countercurrent packed column, efficient mass transfer conditions are 
reached when the liquid flowing down over the packing begins to be held in 
the void spaces between the packing; this is called loading condition and the 
pressure drop in the column begins to increase. Further increases in gas or 
liquid velocity will produce further increases of the pressure drop until the 
liquid completely fills the void spaces in the packing, no more liquid can 
flow down through the column and it is forced to flow up, together with the 
gas stream. This condition is referred as flooding and the column is no more 
operative. Given a packed column, for a fixed gas rate, there is a definite 
liquid rate above which the column will flood; similarly, at any given liquid 
rate there is a definite gas rate above which the column gives flooding. The 
flooding point represents the upper limiting condition of pressure drop and 
liquid and/or gas flow rates for practical tower operation, therefore, it must 
be avoided. A typical operating range for the gas velocity through the 
columns is 50 to 75% of the flooding velocity. It is assumed that, by 
operating in this range, the gas velocity will also be below the loading point. 
The flooding condition depends on density difference between the two 
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phases involved, the characteristics of the packing material and the liquid 
and gas rates.  
Experiments on flooding conditions at different CO2 densities were 
performed on SEE-C apparatus, using water as the liquid phase and 
supercritical carbon dioxide as the dense gas phase. For each experiment, gas 
flow rate and CO2 density (i.e. pressure and temperature conditions) were 
fixed; whereas, the liquid velocity was increased by small increments to 
measure the increase of the pressure drop, until the flooding point was 
reached. Firstly, the limit in density difference between the liquid and gas 
phase that allows countercurrent operation was measured; the results are 
reported in Figure V.42 at fixed L/G ratios. For CO2 densities below ~0.6 
g/cm
3 
(below the dashed line), the gas to liquid (water) density difference 
allows the proper interaction of the two phases; for CO2 densities above ~0.6 
g/cm
3 
(above the dashed line), entrainment of the liquid phase increases 
rapidly until flooding occurs; small changes in the flow rates near the limit 
conditions lead to an unstable process. A similar value of the density 
difference was also found by Brunner and co-workers that, operating a 
continuous supercritical fractionation process of fish oil ethyl esters, found 
that the operating point at 0.603 g/cm
3
 was close to the flooding point (Riha 
and Brunner, 2000). Flooding velocities (Gf) as a function of the liquid/gas 
ratio for different densities are also illustrated in Figure V.43: at constant 
L/G ratio, the flooding velocity decreases with the increase of CO2 density.  





























Figure V.42 Effect of the gas density upon flooding for different L/G ratios 



















Figure V.43 Flooding velocities (Gf) as a function of the liquid/gas ratio 
(L/G) for different CO2 densities: (■) P = 100 bar, T = 57°C, ρ = 0.31 g/cm
3
 
and (▼) P = 100 bar, T = 44°C, ρ = 0.52 g/cm
3
. 
Flooding points can also be calculated using standard procedures based 
on the use of graphs of experimental data reported in the literature. 
 
-   “Generalized Pressure Drop Correlation” (GPDC) 
 
A common and relatively simple procedure for estimating flooding 
velocity is to use a generalized flooding and pressure drop correlation. One 
version of this relationship for a packed tower is in the Sherwood 
correlation, shown in Figure V.44 (Richardson et al., 2002). The 
“Generalized Pressure Drop Correlation” (GPDC) describes the balance 
between the up-flowing gas momentum force and the gravitational forces 
acting on the liquid droplets. It is a function of the physical properties of the 
gas and of the liquid stream; therefore, mass flow rates, gas and liquid 
densities, viscosity of the liquid, as well as a packing factor must be known. 





Figure V.44 “Generalized Pressure Drop Correlation” (GDPC) (L = liquid 
mass flow rate, Kg/s; G = gas mass flow rate, Kg/s; ρl = density of the 
absorbing liquid (Kg/m
3
); ρg = density of the gas stream (Kg/m
3
); G' = mass 
flow rate of gas per unit cross sectional area of column, Kg/m
2
·s; gc = 
gravitational constant, m/s
2
; F = packing factor, m
-1
; ϕ = ratio of specific 




- “Brunner correlation”, that is the GPDC correlation modified by 
Brunner for towers operating with supercritical CO2. 
 
The correlation proposed by Brunner (Brunner, 2009) allows to calculate 
flooding points for packed columns with structured packings (Figure V.45). 
Particularly, the gas capacity factor on the ordinate is a measure for the gas 
velocity necessary to suspend a liquid droplet, and the flow parameter on the 
abscissa rates the kinetic energy of the liquid phase to the kinetic energy of 
the gas phase. The “Brunner correlation” differs only marginally (i.e., only 
for the term used for the ordinate) from the correlation originally suggested 





Figure V.45 “Brunner correlation” (uG = superficial velocity of gas phase, 
m/s; uL = superficial velocity of liquid phase, m/s; ρG = density of the 
supercritical phase, Kg/m
3
; ρL = density of the liquid phase, Kg/m
3
; ε = 
fractional void volume of the packing; g = gravitational acceleration, m/s
2
; 
dH = hydraulic diameter, m). 
 
-   “Random packing correlation”(RPC) 
 
The “Random packing correlation” (Peters and Timmerhaus, 1968) 
depends on liquid and gas flow rates, surface area of packing per unit lower 
volume, fractional void volume of dry packing, liquid viscosity, local 
acceleration due to gravity, liquid and gas densities (Figure V.46). This 
correlation is based on the method proposed by Sherwood et al. in 1938, 
with the modification of experimental determination of appropriate packing 
factor (aP/ε
3
) values as given by Lobo et al. (1945). The correlation shows 
three separate curves: the intermediate curve can be used for random 
packings, the upper curve is used for stacked packings and the lower curve is 
useful for indicating an approximate lower limit when random packings are 
loaded. The flooding line for random packings is based on experimental data 
obtained with 15 different liquids, 3 gases and various random packings such 





Figure V.46 “Random packing correlation” (RPC) (L = liquid flow rates, 
lb/h·ft
2
; G = gas flow rate, lb/h·ft
2
; aP/ε = packing factor ft
-1
, µL = liquid 
viscosity, cP; ρG = density of the supercritical phase, lb/ft
3
; ρL = density of the 
liquid phase, lb/ft
3
; g = gravitational acceleration, ft/h
2
). 
CO2 flow rates at flooding conditions, calculated using the various 
correlations discussed above, are reported in Table V.7 and Table V.8 at 
different L/G ratios and at different densities, respectively. In the same 
tables, flooding values experimentally measured are also reported. Looking 
at the results reported in Table V.7, SC-CO2 flooding flow rate (Gf) 
decreases with the increase of L/G for all literature correlations and the same 
trend has been found for the experimental values produced in this work. But, 
the Gf values calculated from the literature are from about 2.5 to 4 times 
larger than experimental data; moreover, their variation with L/G is also less 
pronounced. Possible explanations for these differences are that literature 
correlations have been produced for processes using gases at ordinary 
pressure conditions, i.e. near the atmospheric pressure, where gas densities 
are very small compared to those of supercritical CO2. The only exception is 
the Brunner correlation, that has been developed for SC-CO2; however, in 
that case, structured packings have been used, that allow a larger void 
section through the column to which correspond larger possibilities for gas 
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to flow up with reduced interactions with the liquid. Very small random 
packings have been used, instead, in the SEE-C tower. Table V.8 shows also 
that looking at the literature correlations and at our experimental data, for 
CO2 densities largely smaller than 0.6 g/cm
3
 there is no influence of the gas 
density on flooding conditions. An exception is given by RPC correlation 
that indicates a larger Gf at larger pressures, that is the contrary of what one 
can expect for a dense gas. 
Using the results discussed until now, efficient separations in the column 
used, can be obtained with a flow rate of 1.4 kg/h of CO2 that corresponds to 
the 50% of the flooding experimental value, when operating at 80 bar, 38°C 
with an L/G ratio of 0.1. When, L/G is varied between 0.1 and 0.4, the 
corresponding limits for liquid flow are indicated in Table V.9. 
 
Table V.7 Evaluation of the Gf conditions varying the L/G ratio between 0.1 
and 0.4 at fixed T = 38°C and P = 80 bar (ρ = 0.31 g/cm
3
) using the 
correlations previously discussed. 
L/G 
G f  (Kg/h) 
GPDC Brunner RPC This work 
0.1 10.25 11.26 7.50 3.0 
0.2 8.68 9.38 6.64 1.4 
0.4 7.09 7.51 5.21 1.0 
 
Table V.8 Evaluation of the flooding conditions varying the density at fixed 
L/G = 0.1, using the correlations previously discussed. 
ρ 
(g/cm³) 
Gf  (Kg/h) 
GPDC Brunner RPC This work 
0.31 10.25 11.26 7.50 3.0 








Table V.9 Liquid and SC-CO2 flow rates used at different values of L/G. 
L/G 
SC-CO2 flow rate liquid flow rate 
(Kg/h) (Kg/h) 
0.1 1.4 0.14 
0.2 1.4 0.28 
0.4 1.4 0.56 
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PLGA microparticles can be administered by in-situ injection, achieving 
a precise and localized drug delivery which is more effective in many cases, 
such as for chemioterapy, hormone therapy, DNA/protein or vaccine 
delivery (Verrijk et al., 1992; Meinel et al. 2001; Walter et al., 2001; Luten 
et al., 2008). Moreover, PLGA microparticles with a specific size and 
distribution have also been proposed for the use in tissue engineering as 
building blocks of implantable 3D scaffolds because can offer several 
benefits, like the control over morphology and physicochemical 
characteristics (Mercier et al., 2005; Singh et al., 2010) and the versatility of 
the release kinetics of encapsulated specific growth factors for cellular 
function orienting and directing (Jaklenec et al., 2008). PLGA microparticles 
have also been suggested as biodegradable carrier for cell culture and/or cell 
administration in the so-called “injectable scaffolds” which may affect stem 
cells lineage restriction and, after polymer degradation, allow a complete 
integration of the grafted cells in the host tissue (Declercq et al., 2005; Kang 
et al., 2005; Hong et al., 2005). 
Starting from the optimized operating conditions, the SEE-C process has 
been applied to the production of PLGA microparticles with an engineered 
size and distribution, from single and double emulsions. Polymer 
microparticles have been characterized by scanning electron microscopy, 
size distribution, differential scanning calorimetry and X-Ray diffractometry. 
A study of the PLGA microdevices degradation has also been performed to 
monitor morphological differences in time of the devices produced. 
 
VI.1 Droplets and microparticles size and morphology 
The size of the particles is mainly related to the emulsion droplet size 
and, therefore, depends on the emulsion formulation. Particularly, the 
increase of the oily solution viscosity, due to a higher polymer concentration 
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in the solvent, can produce larger droplets when using the same dispersion 
shear force and surfactant concentration (Li et al., 2008). As a consequence, 
SEE-C experiments (at steady state conditions) have been performed by 
processing 100 g of single (o-w, 20:80 w/w) and/or double (w-o-w, 1:19:80 
w/w/w) emulsions in each run, varying the PLGA content in the oily phase 
from 5 to 10% w/w to obtain PLGA microparticles of increased mean size 
(MS). All the distribution data of the droplets and of the microparticles 
produced are summarized in Table VI.1 (Della Porta et al., 2011). 
 
Table VI.1 Laser scattering size distribution data of droplets (DSD) and of 
microparticles (PSD) produced at different PLGA concentrations in the oily 
phase using SEE-C of single (o-w) and double (w-o-w) emulsions. Legend: 
MS = mean size; SD = standard deviation; CV = coefficient of variation; SF 
= shrinking factor. 
 
Droplet Size Distributions 
(DSDs) 
Particles Size Distributions  
(PSDs) 
 
o-w w-o-w o-w w-o-w 
PLGA (% w/w) 5 7.5 10 10 5 7.5 10 10 
MS (μm) 2.4 2.6 4.1 4.1 1.0 1.8 3.3 3.5 
SD (μm) 1.0 1.2 2.1 2.1 0.4 0.8 1.6 1.8 
CV(SD/MS) (%) 42 46 51 51 40 44 48 51 
SF(MSS/MSE) -- -- -- -- 0.42 0.69 0.80 0.85 
D10 (μm) 1.1 1.1 1.5 1.5 0.4 0.7 1.1 1.2 
D50 (μm) 1.8 1.8 3.0 3.1 0.7 1.3 2.3 2.6 
D90 (μm) 2.8 2.7 4.9 5.1 1.2 2.1 3.8 4.6 
 
Optical microscope images of two different emulsions (single o-w 
emulsion produced at PLGA concentration of 5% w/w and double w-o-w 
emulsion with a PLGA concentration of 10% w/w in the oily phase) are 
reported in Figure VI.1(a-b). From the images it is clear that the emulsions 
were stable with non-coalescing droplets. 
 














Figure VI.1(a-b) Optical microscope images of two different emulsions: (a) 
single o-w and (b) double w-o-w emulsions. 
 
The produced PLGA microparticles were spherical and non coalescing, 
as illustrated in the FE-SEM images reported in Figure VI.2(a-c). These 
images are related to particles obtained from single emulsions prepared with 
PLGA concentrations in the oily phase of 5% w/w, 7.5% w/w and 10% w/w, 
respectively. It is clear the increase of the mean particle size from about 1 to 
3 µm when PLGA concentration in the oily phase was increased from 5 to 





PLGA 5% w/w 
 
Mean Size 2.4 m (SD 1.0 m) 
(b) 
Double  
PLGA 10% w/w 
 

















Figure VI.2(a-c) FE-SEM images of PLGA microparticles obtained using 
SEE-C by processing single emulsions containing PLGA in concentrations of 
(a) 5% w/w, (b) 7.5% w/w and (c) 10% w/w. Operating conditions: 80 bar 
and 38°C, L/G ratio 0.1. 
 
Looking at the distribution data reported in Table VI.1, it is evident that 
the mean size of the microspheres is always smaller and the distributions 
narrower than the droplet mean sizes from which they were generated (the 
gap between PSD and DSD at D50 values is 1.1 µm, 0.5 µm and 0.7 µm for 
the PLGA concentration of 5%, 7.5% and 10% w/w in the oily phase of 
single emulsions, respectively). 
The PSD of the particles obtained from single emulsions containing 5% 
and 7.5% w/w of PLGA in the oily phase are also reported in a cumulative 
representation in Figure VI.3. The DSDs of the two emulsions processed by 
SEE-C are reported in the same figure, for comparison purposes. DSDs of 
the two emulsions practically overlap, showing that the variation of PLGA 
concentration from 5 to 7.5% w/w in the oily phase produced very similar 
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droplet sizes. Mean droplet sizes of 2.4 µm (SD 1.0) and 2.6 µm (SD 1.2) 
were obtained with PLGA amounts of 5% and 7.5% w/w, respectively. 
However, the PSD of the microparticles originated from the droplets 
containing 5% w/w of PLGA is sharper than the PSD of the microparticles 
from droplets containing 7.5% w/w of PLGA. This fact is due to the droplet 
shrinking factor (defined as the ratio between the particles and droplets mean 
sizes, SF = MSS/MSE) that also plays a relevant role in determining the final 
size of the microparticles. The droplets containing a higher percentage of 
polymer have a lower possibility to shrink when the solvent is eliminated; 
therefore larger particles are produced (Rosca et al., 2004). The shrinking 
factor (SF) has been measured for all the different PLGA concentrations 
explored in the oily phase and the obtained values are reported in Table VI.1. 
Particularly, the produced particles are about 60% and 33% smaller, 
respectively, than the original droplets (Della Porta et al., 2011). 
 



























Diameter, m  
Figure VI.3 PSDs of PLGA particles produced from single (o-w) emulsions 
containing 5% and 7.5% w/w of PLGA in the oily phase. The DSDs of the 
two emulsions processed by SEE-C are also reported (dashed curves), for 
comparison. 
 
DSDs of the emulsion containing 10% w/w of PLGA in the oily phase 
and PSDs of the related microparticles have also been studied using single 
(o-w) and double (w-o-w) emulsions and the related size distribution curves 
are reported in Figure VI.4. PLGA concentration of 10% w/w in the oily 
phase produced droplets with almost the same distribution in the case of 
single and double emulsions. The PSD cumulative curve of the 
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microparticles generated from single emulsion showed a larger shift from the 
DSD related curve, indicating a larger droplet shrinking (the gap between 
PSD and DSD at D50 values is 0.74 µm); whereas, when a double emulsion 
was processed, the size distribution curve of the generated particles showed 
a smaller shift (gap between PSD and DSD at D50 values is 0.49 µm) (Della 
Porta et al., 2011). 
 



























Diameter, m  
Figure VI.4 PSDs of PLGA particles produced from single and double 
emulsions containing 10% w/w of PLGA in the oily phase. The DSDs of the 
two emulsions processed by SEE-C are also reported (dashed curves), for 
comparison.  
 
The coefficient of variation (CV), defined as the ratio between the 
standard deviation (SD) and the mean size (MS) of the same distribution, has 
been evaluated for both droplet and particle distributions and its values are 
reported in Table VI.1. It gives an indication of the sharpness of the 
distribution, since put the variability in relation to the magnitude of the 
measured diameters. The CV of the particle size distributions obtained by 
SEE-C are in the range of 40-50 and always lower or, at least, the same of 
the ones of the original emulsions, confirming the fine reproduction of the 
size distribution from droplets to particles of the supercritical continuous 
process. Increasing the PLGA concentration, CV values increase; therefore 
the polydispersity of the particles tends to increase with the particle mean 
size, as expected. The increase of the CV value is mainly related to the type 
of the emulsion produced. Obviously, if emulsion with monodispersed 
droplets are produced, monodispersed microspheres can be obtained.  
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A single o-w emulsion using a PLGA concentration of 20% w/w has also 
been prepared to obtain particles with larger size. In this case, the produced 
PLGA microparticles covered approximately a range between 1.4 and 88.2 
μm. As illustrated in the FE-SEM image reported in Figure VI.5, broken 
particles were obtained when their size was larger than about 50 µm. This 
fact demonstrates that particles larger than 50 µm probably cannot be 
processed by continuous operating mode in the packed tower, due to the 
droplets/particles interaction by contact with the packing elements. 
 
 
Figure VI.5 FE-SEM image of PLGA broken microparticles obtained 
processing an o-w emulsion (20:80) containing PLGA in concentration of 
20% w/w in the oily phase. Operating conditions: 80 bar and 38°C, L/G 
ratio 0.1. 
 
VI.2 Comparison between SEE-C and solvent evaporation (SE) 
Double emulsions are more difficult to be processed by conventional 
solvent evaporation, since the emulsion is less stable and the produced 
microspheres are expected to be porous due to the entrapped internal water 
phase. Coalescence phenomena are frequent, as well as, the formation of 
concave particles due to the loss of the water internal phase and the 
formation of collapsed empty particles (Rosca et al., 2004). 
A systematic comparison between the characteristics of the microspheres 
obtained by SEE-C process and by conventional solvent evaporation 
technique (SE) has been performed, starting from the same w-o-w emulsion 
(ratio 1:19:80) containing 10% w/w of PLGA in the oily phase and 
processed using the two different technologies/process layouts. The 
corresponding PSDs of the microspheres obtained by SEE-C and SE are 
reported in Figure VI.6. The DSD of the emulsions processed is also 
reported in the same figure, for comparison purposes. The experimental 
evidence is that microspheres obtained by SEE-C process showed a PSD 
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narrower than the one obtained by the conventional process and than the 
DSD of the starting emulsion. 
 





















Diameter, m  
Figure VI.6 Particle Size Distributions (PSDs) of microspheres produced by 
SEE-C and SE processes using a w-o-w emulsion containing a PLGA 
content in the oily phase of 10 % w/w. The Droplets Size Distribution (DSD) 
of the emulsion processed by the two technologies is also reported, for 
comparison. 
 
The observed behavior can be confirmed evaluating the shrinking factor 
(SF) between the droplets and the related microspheres. The SF values are 
reported in Table VI.2. In the case of the microspheres produced by SEE-C 
process it is interesting to observe that the SF value is 0.86, indicating that 
the particles are about 10% smaller than the original droplets; whereas, in the 
case of the SE process, the microsphere mean size is equal to the original 
mean droplet size and the SF value is 1.00. 
Mean sizes and distributions of the microspheres obtained by SEE-C and by 
conventional SE are also reported in Table VI.2, together with the DSD data 
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Table VI.2 Laser scattering size distribution data of droplets (DSD) and of 
microspheres (PSD) produced using SEE-C and SE processes from a w-o-w 
emulsion containing 10% w/w of PLGA. Legend: MS = mean size; SD = 









PLGA (% w/w)     10 
MS (μm) 4.1 3.5 4.1 
SD (μm) 2.1 1.8 2.1 
CV(SD/MS) (%) 51 51 51 
SF (MSS/MSE) --- 0.86 1.00 
D10 (μm) 1.5 1.2 1.4 
D50 (μm) 3.1 2.6 2.9 
D90 (μm) 5.1 4.6 4.8 
 
 
Both technologies produced spherical particles; however, concave 
particles were also produced by SE. An example of the different results 
obtained is illustrated in the FE-SEM images reported in Figure VI.7(a) and 
Figure VI.7(b), respectively for SEE-C and SE microparticles: 
 
(a) SEE-C microspheres from w-o-
w emulsion with 10% w/w PLGA  
(b) SE microspheres from w-o-w 
emulsion with 10% w/w PLGA  
  
Figure VI.7(a-b) FE-SEM images of PLGA microspheres produced by SEE-
C (left side) and by SE (right side) from a double emulsion containing a 




Ethyl acetate residues measured in the microspheres after the continuous 
process ranged between 100 and 300 ppm, that are values considerably 
lower than the ones measured during the SE operation. Indeed, particles 
produced by SE showed a mean solvent residue of 500 ppm. This result 
confirms that the continuous process produces a better contact between the 
two phases (emulsion/SC-CO2), enhancing mass transfer. The higher solvent 
residue obtained in the case of SE can be explained considering the 
mechanism of solvent elimination of the two processes. In the case of the 
evaporation technology, EA evaporates from the continuous (aqueous) phase 
of the emulsion, according to the vapor-liquid equilibrium conditions for the 
system EA-water at the selected operating pressure and temperature (Reichl 
et al., 1998). EA content in the aqueous system tends to reduce by 
evaporation and this reduction induces the diffusion of EA from the liquid 
droplets of the dispersed phase that balances this reduction, until the droplets 
are completely dried. Only at this point of the process, the content of EA in 
the continuous phase starts to reduce until it reaches the lower boundary of 
the liquid equilibrium curve. When this condition has been reached, no more 
vapor-liquid fractionation of the EA-water mixture is possible. Therefore, a 
lower solvent residue is very difficult to be obtained by this technology. On 
the contrary, in the case of SC-CO2 processing, due to the complete 
miscibility of EA in CO2 at the process conditions and the very small 
solubility of water in CO2, EA is almost completely extracted from water 
during the extraction process without any equilibrium limitation.  
The reduced solvent residue is another important advantage of supercritical 
emulsion processing with respect to conventional SE.  
The reasons of the success of the continuous process are in the very short 
processing time of the emulsion treated by SEE-C. Indeed, considering as a 
reference time, the residence time of the liquid phase that crosses the packed 
column, the continuous processing requires a residence time of the 
emulsion/suspension in the column of about 5 minutes; whereas, 4-6 hours 
are necessary to perform the conventional SE (often also at higher 
temperatures). The enhanced mass transfer characteristic of SC-CO2 
generates a faster extraction avoiding coalescence or aggregation phenomena 
typically occurring during the solvent evaporation process. 
 
VI.3 Microparticles solid state analyses 
Thermal analysis (DSC) has been performed on microparticles obtained 
by SEE-C and on raw PLGA, for comparison purpose. The obtained 
thermograms are reported in Figure VI.8. PLGA shows a glass transition 
between 39 and 45°C (onset 39.98°C; endset 45.32°C) and the 
decomposition that occurs at above 300°C. The produced microparticles 
show the same glass transition and degradation event of the unprocessed 
polymer (Della Porta et al., 2011). 
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T, °C  
Figure VI.8 DSC traces of unprocessed and PLGA microparticles produced 
by SEE-C.  
 
X-ray analysis has also been performed on the untreated polymer and on 
PLGA microparticles, to have information about the solid state of the 
produced materials. The X-ray patterns are reported in Figure VI.9; they 
indicate that both unprocessed polymer and microparticles are amorphous, 
confirming the fast polymer precipitation inside the droplets during the 
microparticle formation by SEE-C. 
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Figure VI.9 X-ray profiles of unprocessed and PLGA microparticles 
produced by SEE-C.  
VI.4 PLGA microparticles degradation: morphological study 
PLGA is well known for its bulk erosion properties (Von Burkersroda et 
al., 2002). In order to study the degradation of the microparticles produced 
by the supercritical process, two different batches of particles produced 
using single and double emulsions containing 10% w/w PLGA (with a fixed 
MS of 3 µm; SD 1.5 µm) have been suspended in distilled water at 37°C 
with an agitation of 50 rpm. The PLGA particles degradation started in the 
first 48 h, as indicated by the pH lowering of the suspension that decreased 
from 6.8 to 4.5. From each suspension, 10 µl were sampled every 7 days, 
dried and prepared for the morphological analysis by FE-SEM. The 
microparticles surface modification after 14, 28 and 35 days are reported in 
Figure VI.10(a-c, left side). A smooth surface is still present on the particles 
sampled after 14 days of degradation (Figure VI.10(a, left side)). The 
progressive erosion starts to be evident after 35 days, when the microdevices 
became nanoporous (Figure VI.10(c, left side)). The microparticles produced 
by double emulsion showed a complete erosion in 60 days. Their surface 
morphologies after 14, 28 and 35 days are also reported in Figure VI.10(a-c, 
right side). A smooth surface can be still observed after 14 days of residence 
in distilled water (Figure VI.10(a, right side)); whereas, the circular 
structures observed on the microparticles surface should due to the polymer 
precipitation on the internal water phase of the double emulsion. Nanoporous 
and near-collapsed particles were observed after 35 days, indicating the 
polymer bulk depolimerization (Figure VI.10(c, right side)). The overall 
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period between 50-60 days required for PLGA microparticles complete 
degradation in water, coupled with a maximum pH lowering of the 
suspension to a value of 4.5, is in agreement with the literature data (Okada 
and Toguchi, 1995), which suggest a degradation time of 60 days for similar 
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Figure VI.10(a-c) FE-SEM images (Mag = 50.00 KX) related to a 
morphological study of PLGA microparticles degradation in water after (a) 
14, (b) 28 and (c) 35 days, respectively. The particles have a diameter of 
almost 3 µm and were produced by SEE-C using a single (left side) and 
double w-o-w emulsions (right side). 
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NSAID/PLGA injectable 
microspheres: continuous versus 





Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most commonly 
prescribed medications in the world. Due to their short half-lives and a 
strong relationship between concentration and response, it is necessary to 
dose them at regular, frequent time intervals to maintain the drug 
concentration within the therapeutic range. However, almost all NSAIDs 
available in the market show severe side effects such as gastrointestinal (GI) 
mucose damage, irritation, and bleeding. High doses at frequent time 
intervals may also generate toxicity. As a consequence, a trend in NSAIDs 
formulation is the development of controlled release dosage form.  
In this chapter, the production of NSAID/PLGA microspheres with high 
drug encapsulation efficiency by using less toxic solvents, such as EA, and 
by applying SEE-C process is proposed. Among the non-steroidal anti-
inflammatory drugs (NSAIDs), Piroxicam (PX) and Diclophenac Sodium 
(DS) have been chosen as model compounds to be entrapped within 
microspheres, to obtain extended release devices. The microdevices 
produced by SEE-C have also been compared with the ones obtainable by 
SEE and conventional SE. A detailed characterization of the produced 
microspheres has been performed comparing morphologies, size 
distributions and physico-chemical properties of the different products 
obtained using the three different technologies/process layouts. Drug release 
profiles of microspheres have also been monitored to check the structure of 
the microspheres produced by SEE-C technology. 
VII.1 Microspheres produced by SEE-C: particle size control 
To obtain injectable PLGA microspheres charged with PX of DS, single 
and double emulsions were prepared, respectively, using EA as oily phase. A 
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single o-w emulsion (20:80 w/w) was used to encapsulate PX in PLGA, due 
to the good solubility of both PX and PLGA in EA. A double w-o-w 
emulsion (2:18:80 w/w/w) was used to encapsulate DS in PLGA, due to the 
good solubility of DS in water and its insolubility in EA. This type of 
emulsion decreases contact between the organic phase and the active 
substance and improves the encapsulation efficiency of water-soluble drugs. 
To produce particles with different mean sizes, the PLGA amount in the oily 
phase of the emulsions has been varied. Particularly, single emulsions with 
o-w ratio of 20:80 w/w have been formulated fixing the PX loading in EA at 
10% w/w and varying the PLGA concentration from 5% to 7.5% w/w; 
whereas, double emulsions with w-o-w ratio of 2:18:80 w/w/w have been 
prepared maintaining the DS concentration fixed at 10% w/w and varying 
the PLGA amount from 2.5% to 5% w/w. 
The DSDs obtained are shown in a cumulative representation in Figure 
VII.1(a) for the single emulsions and in Figure VII.1(c) for the double 
emulsions. As already reported, an increase of PLGA concentration induces 
an enlargement of the droplets and the formation of wider DSDs (Della Porta 
e al., 2010). Particularly, mean droplet sizes of 2.1 µm (SD 0.9) and 3.5 µm 
(SD 1.8) were obtained in the case of o-w emulsions with PLGA amounts of 
5% and 7.5% w/w, respectively. Mean droplet sizes of 1.1 μm (SD 0.5) and 
2.4 μm (SD 1.0) were obtained in the case of w-o-w emulsions for PLGA 
concentrations of 2.5% and 5% w/w, respectively. 
The corresponding PSDs are reported in Figure VII.1(b) for  
microspheres produced from the single emulsions, and in Figure VII.1(d), 
for microspheres obtained from the double emulsions. The increase of the 
emulsion droplets size with the PLGA concentration produces a significant 
increase in PSDs of the obtained microspheres. In the case of microspheres 
produced from single emulsions, the mean size varied from 1.4 μm (SD 0.6) 
to 3.1 μm (SD 1.6) when the PLGA concentration was varied from 5% to 
7.5% w/w, respectively; in the case of microspheres produced from double 
emulsions,  the mean size varied from 1.0 μm (SD 0.5) to 1.9 μm (SD 0.8) 
when the PLGA concentration was varied from 2.5%, to 5% w/w, 
respectively. 
Comparing the DSDs with the related PSDs, it is evident that the relative 
position of the two PSDs has been maintained: i.e., there is approximately 
the same gap between the two distribution curves; but, the PSDs are always 
narrower than the corresponding DSDs. As example, cumulative size 
distributions of the droplets and of the related microspheres obtained with a 
PLGA concentration of 5% w/w are plotted together in Figure VII.2(a-b) for 
a single and a double emulsion, respectively.  
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Figure VII.1(a-d) Cumulative size distribution curves describing the 
droplets in (a) single and (b) double emulsions obtained varying the PLGA 
concentration in the oily phase, and the related microspheres produced by 






















































Figure VII.2(a-b) Cumulative size distributions of the droplets and of the 
relative microspheres obtained from (a) single (o-w) emulsion containing 
5% w/w of PLGA and 10% w/w of PX, and (b) double (w-o-w) emulsion 
containing 5% w/w of PLGA and 10% w/w of DS. 
 
All the microspheres produced were spherical and not agglomerated. 
Examples of microspheres are shown in the FE-SEM images reported in 
Figure VII.3(a-b) and related to particles obtained from single and double 
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(a) SEE-C microspheres from o-w 
emulsion with 5% w/w PLGA and 
10% w/w PX 
(b) SEE-C microspheres from w-o-
w emulsion with 5% w/w PLGA 
and 10% w/w DS 
  
  
Figure VII.3(a-b) FE-SEM images of (a) PX/PLGA microspheres obtained 
by SEE-C from a single (o-w) emulsion and (b) DS/PLGA microspheres 
obtained from a double (w-o-w) emulsion, both containing PLGA in 
concentration of 5% w/w. Operating conditions: 80 bar and 38°C, L/G ratio 
0.1. 
 
VII.2 Comparison between SEE, SEE-C and SE  
VII.2.1 PSD and morphology  
A comparison between the products obtained by SEE, SEE-C and 
conventional solvent evaporation technique (SE) has been performed from 
single (o-w) and double (w-o-w) emulsions that were processed using the 
three different technologies/process layouts. Microspheres size and 
distribution are the first parameters considered for the comparison of the 
results obtained by SEE, SEE-C and SE. These parameters were measured 
by dynamic laser scattering. All the PSDs data of the PX/PLGA and 
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DS/PLGA microspheres recovered using the three process layouts are 
reported in Table VII.1 and Table VII.2, respectively. In the same tables, the 
DSDs of the treated emulsions are also reported, for comparison purposes. 
Table VII.1 o-w emulsion: laser scattering size distribution data of droplets 
(DSD) and of microspheres (PSD) containing different PLGA concentrations 
in the oily phase and produced using standard SEE layout, SEE-C, and SE 
process. Legend: MS = mean size; SD = standard deviation; CV = 






SEE SEE-C SE 
PLGA  
(% w/w) 
 5         7.5 5        7.5  5         7.5  5         7.5 
MS (μm) 2.1 3.5 1.9 3.1 1.4 3.1 2.8 4.0 
SD (μm) 0.9 1.8 0.8 1.5 0.6 1.6 1.3 1.9 
CV (SD/MS) (%) 43 51 42 48 43 52 46 48 
SF (MSS/MSE) --- --- 0.90 0.89 0.67 1.00 1.33 1.14 
D10 (μm) 1.0 1.2 0.9 1.3 0.4 0.7 0.9 1.3 
D50 (μm) 1.6 2.5 1.5 2.4 0.8 1.7 1.6 2.4 
D90 (μm) 2.4 4.3 2.3 4.0 1.5 3.4 2.4 4.1 
Table VII.2 w-o-w emulsion: laser scattering size distribution data of 
droplets (DSD) and of microspheres (PSD) containing different PLGA 
concentrations in the oily phase and produced using standard SEE layout, 
SEE-C, and SE process. Legend: MS = mean size; SD = standard deviation; 






SEE SEE-C SE 
PLGA  
(% w/w)  
 2.5       5    2.5          5    2.5         5    2.5         5 
MS (μm) 1.1 2.4 1.0 2.3 1.0 1.9 1.5 2.6 
SD (μm) 0.5 1.0 0.4 1.0 0.5 0.8 0.7 1.2 
CV(SD/MS) (%) 45 42 40 43 50 42 47 46 
SF (MSS/MSE) --- --- 0.91 0.96 0.91 0.79 1.36 1.08 
D10 (μm) 0.5 1.1 0.5 1.1 0.3 0.7 0.5 1.0 
D50 (μm) 0.8 1.8 0.8 1.7 0.5 1.3 0.7 1.7 
D90 (μm) 1.2 2.7 1.2 2.5 1.1 2.3 1.3 2.7 
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SEE-C allows the recovery of microspheres with MSs and SDs identical 
or slightly smaller than the ones produced by SEE and smaller than the ones 
produced by SE. Indeed, for example, starting from an o-w emulsion 
(containing 5% w/w PLGA) with a droplet mean size of 2.1 µm (SD 0.9), 
microspheres with mean sizes of 1.4 µm (SD 0.6), 1.9 µm (SD 0.8) and 2.8 
µm (SD 1.3) were obtained by SEE-C, SEE and SE, respectively; whereas, 
starting from a w-o-w emulsion (containing 5% w/w PLGA) with a droplet 
mean size of 2.4 µm (SD 1.0), microspheres with mean sizes of 2.3 µm (SD 
1.0), 1.9 µm (SD 0.8) and 2.6 µm (SD 1.2) were obtained by SEE-C, SEE 
and SE, respectively. As a consequence, the PDSs of microspheres produced 
by SEE-C are narrower than the ones produced by SEE and SE; the PSDs of 
microspheres produced by SEE and SE have, instead, practically the same 
D50 and similar D90, but SE produces a fraction of microspheres that is not 
present in the sample produced by SEE and, of course, in the original 
emulsion droplets. This behavior is better evidenced in Figure VII.4(a-b), 
where two examples of cumulative size distributions of microspheres 
obtained by SEE-C, SEE and SE from single and double emulsions 
containing 5% w/w of PLGA are reported, respectively. 
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Figure VII.4(a-b) Comparison between PDSs of (a) PX/PLGA and (b) 
DS/PLGA microspheres obtained by SEE-C, SEE and SE processes starting 
from the same single or double emulsion with a PLGA content in the oily 
phase of 5 % w/w. 
 
These results confirm that the PSD of the produced particles is mainly 
related to the emulsion droplet size; but, the solvent elimination process also 
plays a relevant role in determining the final size of the produced 
microspheres. Indeed, the faster precipitation route obtained in SEE-C 
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processing (only 5 min necessary to perform the SEE-C against 30 min for 
SEE and 4-6 h for the conventional SE) prevents droplets coalescence or 
aggregation phenomena occurring during SE. With respect to the SEE 
standard layout, the SEE-C offers other advantages such as, complete 
absence of aggregated particles that may occur during the depressurization 
step when impacting against to the wall of the reactor, and minimized lost of 
particles in the CO2 gas stream released during the final depressurization 
step. Indeed, SEE usually showed a recovery percentage (defined as: PLGA 
charged in emulsion/PLGA recovered after the processing x 100) variable 
from 40 to 60% and SE allowed the recovery of maximum 50% of the 
charged material; whereas, a recovering percentage of about 90% was 
measured in SEE-C. 
A systematic comparison between microspheres morphology obtained 
using SEE-C and SE processes has also been performed. Examples of the 
obtained results are reported in Figure VII.5(a-b), where FE-SEM images of 
DS/PLGA microspheres produced by SEE-C and SE from a double emulsion 
containing 2.5% w/w of PLGA and 10% w/w of DS are showed, 
respectively. The two technologies produced well-defined spherical 
particles; however, the FE-SEM images show that SE also produced large 
DS crystals, suggesting that part of the drug went out from the emulsion 
droplets during the SE. This would result in poor drug loading and initial 
rapid release of the drug (burst effect) (O‟Donnell and McGinity, 1997; 
Ghaderi et al., 2000; Della Porta et al., 2010). 
 
(a) SEE-C microspheres from w-o-
w emulsion with 2.5% w/w PLGA 
and 10% w/w DS 
(b) SE microspheres from w-o-w 
emulsion with 2.5% w/w PLGA 
and 10% w/w DS 
  
Figure VII.5(a-b) FE-SEM images of DS/PLGA microspheres produced by 
SEE-C (left side) and by SE (right side) from a double emulsion containing a 
PLGA amount of 2.5% w/w (DS is 10% w/w of PLGA). Operating 
conditions: 80 bar and 38°C, L/G ratio 0.1. 
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VII.2.2 Drug loading  
The theoretical and experimental drug loading, and the encapsulation 
efficiency of all discussed microspheres are summarized in Table VII.3. 
From the data reported, the encapsulation efficiency into PLGA 
microspheres produced by SEE-C and SEE technologies is higher than 95% 
in the case of PX and maximum 90% in the case of DS; whereas, 
microspheres produced by SE show lower encapsulation efficiencies of 
about 70% in the case of PX and only 30% in the case of DS (Della Porta et 
al., 2010). These measured values are in agreement with the results reported 
in literature in the case of SE; indeed, a mean of 60% of the drug can be 
conventionally encapsulated in microspheres produced starting from a single 
o-w emulsion; whereas, only about the 30% of the drug is charged in the 
microspheres in the case of a double w-o-w emulsion (Rosca et al., 2004; 
Herrmann and Bodmeier, 1998; Li et al., 2008). Indeed, according to Rosca 
et al. (2004), especially when a double emulsion is used, during the solvent 
elimination and the consequent droplet shrinkage, the polymer walls around 
the inner microdroplets may break forming holes inside and on the 
microsphere surface, through which the inner aqueous phase is partly 
expelled, affecting the loading efficiency. The above mechanism description 
also justifies the formation of porous microspheres, when a double emulsion 
is evaporated. During the supercritical extraction of emulsions, on the 
contrary, an excellent drug loading is observed, even in the case of double 
emulsions, due to the very fast solvent elimination and polymer 
precipitation; that is, microsphere wall breakage is reduced and the water 
soluble drug has a reduced time to migrate to the external continuous phase. 
Moreover, according to Herrmann and Bodmeier (1998), the drug 
encapsulation efficiency is strongly reduced in the SE methods especially 
when EA is used, as the dispersed phase, due to the higher solubility of ethyl 
acetate in water compared to that one of methylene chloride. Therefore, 
methylene chloride is still the most favorable solvent (even if more toxic 
than EA) when the SE technology is used. The SC-CO2 emulsion extraction 
can give, instead, more process alternatives since a high encapsulation 












Table VII.3 Theoretical and measured drug loading in the microspheres 
recovered using SEE-C, SEE and SE processes. 
             PX/PLGA                           DS/PLGA 
 
SEE-C   SEE    SE SEE-C   SEE    SE 
Theoretical drug 
loading (% w/w) 
10 
Experimental drug 
loading (% w/w) 








   8.8  
(±0.12) 
   3.3  
(±0.42) 
Encapsulation 
efficiency (% w/w) 














VII.2.3 Solid state characterization 
The particles solid state has been studied comparing the X-ray patterns of 
the untreated materials with those of the produced microspheres. The X-ray 
profiles of untreated PX and PLGA and of the microspheres produced by 
supercritical emulsion extraction (SEE or SEE-C) and by SE are reported in 
Figure VII.6. In the case of DS/PLGA microspheres, the X-ray patterns of 
the untreated materials and of the produced microspheres are reported in 
Figure VII.7. Untreated drugs (PX and DS) show a crystalline structure, 
whereas PLGA is substantially amorphous. PX/PLGA and DS/PLGA 
microspheres produced by SC-CO2 technology show an amorphous pattern, 
suggesting the formation of a polymer/drug solid solution; whereas, the 
microspheres produced by SE show a pattern with some small peaks due to 
the presence of drug crystals not encapsulated in the polymer microspheres. 
This result indicates that microspheres with a more accurate polymer/drug 
solid solution can be obtained by SC-CO2 processing. 
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Figure VII.6 Comparison of X-ray patterns of untreated PX and PLGA 
compared with PX/PLGA microspheres obtained by supercritical emulsion 
extraction (SEE or SEE-C) and SE technology. 
 













Figure VII.7 Comparison of X-ray patterns of untreated DS and PLGA 
compared with DS/PLGA microspheres obtained by supercritical emulsion 
extraction (SEE or SEE-C) and SE technology. 
 
VII.3 Microspheres produced by SEE-C: release study 
Drug release mechanisms from PLGA can be described in two steps: 
diffusion through the polymer and liberation from the matrix via bulk 
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erosion (Siepmann et al., 2001). In the recent literature, several studies have 
been focused on the interpretation of the predominant release mechanism 
related to the selected PLA/PGA copolymer ratio (Faisant et al., 2006; Klose 
et al., 2006). These two mechanisms can overlap or operate in sequence, 
depending on the polymer molecular weight and mainly on the polymer 
composition (PLA/PGA). According to Siepmann et al. (2001), drug release 
from PLGA can be initially diffusion-controlled and, after a certain period of 
time, overcompensated by the polymer bulk erosion. The length of the 
diffusion step is also influenced by the content of poly-lactic acid that will 
erode more slowly that the poly-glycolic acid.  
PLGA microspheres produced by SEE-C with a mean size of 3.1 µm (SD 
1.6) and with PX theoretical loading of 10% w/w have been tested for drug 
release studies in a release medium of phosphate buffered solution (PBS 0.2 
M, pH 7.4) with 0.5% Tween-80 at 37°C. The release profile data are 
reported in Figure VII.8(a), where it is evident that the diffusion-controlled 
drug release prevails in the first days, followed by a fast bulk erosion which 
characterizes the second part of the drug release. About the 50% of the drug 
seems available for diffusion; whereas, the remaining part seems to be 
blocked inside the polymer and cannot be reached by diffusion alone. A 
complete drug release was obtained in about 8 days. 
The release profile from PLGA microspheres produced by SEE-C with a 
mean size of 1.0 µm (SD 0.5) and with DS theoretical loading of 10% w/w is 
reported in Figure VII.8(b). In this case, a complete drug release is obtained 
in about 2 days and a moderate „„burst effect‟‟ can be observed (30% of the 
charged drug). The release curve show again the presence of two distinct 
zones: the first, in which diffusion is the controlled mechanism; the second, 
in which the DS release is related to the bulk erosion. The overall drug 
release times measured for DS are one fourth of those measured for PX. This 
behavior may be due to the fact that probably DS is not blocked into the 
polymer forming the microspheres, since the microspheres resulting from 
double emulsion have a completely different internal and surface structure 
with respect to those coming from single emulsion. Indeed, it is well know 
that microspheres produced starting from double emulsions can be porous 
due to the presence, during their formation, of a water internal phase that 
will induce the formation of partially empty structures with micropores 
distributed inside the microsphere (Li et al., 2008). In such porous PLGA 
structures, the diffusion of water from the external medium is expected to be 
facilitated and, consequently, the resulted diffusion times are shorter (Della 
Porta et al., 2010).  
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Figure VII.8(a-b) In vitro release profiles of (a) PX from PLGA 
microspheres with a mean diameter of 3.1 µm and PX theoretical loading of 
10% w/w, and of (b) DS from PLGA microspheres with a mean diameter of 
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A critical problem for implantable devices used for monitoring and 
treatment of patients is the inflammatory response of the body caused by the 
tissue injury, that results from implantation of the devices as well as their 
presence in the body (Onuki et al., 2008). The inflammatory response 
consists of several phases: acute inflammation, chronic inflammation and 
fibrotic encapsulation (Ratner and Bryant, 2004). The acute inflammatory 
response is of relatively short duration (24-48 h) and is mostly responsible 
for matrix formation and cleaning of the wound site (Anderson, 2001). 
Persistent inflammatory stimuli lead to a chronic inflammatory reaction 
(Johnston, 1988), that usually continues for 1-2 weeks, after that a fibrotic 
tissue is formed or normal tissue re-growth occurs. These tissue reactions 
affect the normal function of numerous implantable devices; therefore, to 
increase their longevity and functionality, inflammatory reactions have to be 
prevented or suppressed.  
It has been suggested (Hickey et al., 2002a, 2002b) that, to control 
inflammatory reactions produced by implanted devices, it should be possible 
to load these structures with glucocorticoid/polymer microspheres, 
engineered to release the anti-inflammatory principle during the first weeks 
after implantation. Glucocorticoids are usually used to prevent or suppress 
inflammation because they can inhibit the production of factors that are 
critical in generating the inflammatory response (Hardman et al., 1996); 
among these, Hydrocortisone Acetate (HA) is one of the most broadly used. 
However, HA can have serious systemic side effects; therefore, its controlled 
local release at the specific implantation site via microsphere-based 
formulations can be significant to avoid the adverse effects and suppress 
local inflammatory reactions. Moreover, this drug is poorly soluble and 
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unstable in aqueous media, and both solubility and stability of HA can be 
improved by forming drug/polymer microspheres. 
In this work, the applicability of the SEE-C process has been explored for 
the production of PLGA microspheres loaded with HA and for controlling 
their characteristics. The influence of kind and formulation of emulsion on 
the produced microspheres has been investigated in terms of morphology, 
particle size distribution, solid state properties and encapsulation efficiency. 
The produced microspheres have been also studied for in vitro HA release, 
to obtain further information about the particles structure and to verify their 
applicability to continuous localized delivery of HA at a specific implant 
site, to suppress the inflammatory response. 
VIII.1 Particle size and morphology 
VIII.1.1 HA/PLGA microspheres from w1-o-w2 emulsion (w1: EtOH) 
Different w1-o-w2 emulsions (1:19:80 w/w/w), with ethanol as solvent in 
the internal water phase, have been prepared varying the PLGA percentage 
from 5% to 10% w/w (at fixed drug concentration) or the HA percentage 
from 2.3% to 4.1% w/w (at fixed PLGA content). PSDs data of the 
microspheres recovered using the SEE-C process are reported in Table 
VIII.1; DSDs data of the emulsions treated are also reported in the same 
table. 
Table VIII.1 Laser scattering size distribution data of droplets (DSD) and 
of microspheres (PSD) produced from w1-o-w2 emulsions (1:19:80 w/w/w, 
w1: EtOH) at different HA contents or PLGA concentrations, using SEE-C 
process. Legend: MS = mean size; SD = standard deviation; CV = 
coefficient of variation. 
Emulsion kind w1-o-w2 emulsion (w1: EtOH) 
HA (% w/w) 2.3   4.1                        4.1 
PLGA (% w/w) 5 5   10 
Distribution data DSD PSD DSD PSD DSD PSD 
MS (µm) 1.8 0.8 1.2 1.0 3.2 2.3 
SD (µm) 0.8 0.4 0.5 0.4 1.5 1.1 
CV (%) 44 50 42 40 47 48 
D10 (µm) 0.9 0.4 0.5 0.4 1.5 0.9 
D50 (µm) 1.4 0.6 0.9 0.7 2.7 1.7 
D90 (µm) 2.0 1.0 1.3 1.1 4.2 2.8 
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An optical microscope image of the droplets and a FE-SEM image of the 
related particles containing 2.3% w/w of HA and 5% w/w of PLGA are 
reported in Figure VIII.1, showing the formation of very uniform droplets 
and particles. This result is confirmed by CV values reported in Table VIII.1, 
ranging between 40 and 50 for DSDs and PSDs; i.e., sharp particle size 












Figure VIII.1 Optical microscope image of the droplets and FE-SEM image 
of the microspheres produced by SEE-C process from a w1-o-w2 emulsion 
(w1: EtOH) containing 2.3% w/w of HA and 5% w/w of PLGA. 
The effect of the variation of the PLGA concentration in the oily phase 
from 5% to 10% w/w has been studied with respect to the microspheres size 
distribution, at fixed HA concentration. DSDs and PSDs obtained by laser 
scattering analysis are reported in a cumulative representation in Figure 
VIII.2. As expected, the increase in the oily phase viscosity produced a 
significant increase in the PSDs of the corresponding microspheres; the 
mean particles size varied from 1.0 μm (SD 0.4) to 2.3 μm (SD 1.1) when 
the PLGA concentration was varied from 5% to 10% w/w, respectively.  
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Figure VIII.2 Cumulative size distributions of the droplets and of the 
corresponding microspheres obtained by SEE-C process from w1-o-w2 
emulsions prepared using EtOH as solvent in the internal water phase and 
varying the PLGA content in the oily phase from 5% to 10% w/w. The drug 
loading was fixed at 4.1% w/w. 
 
VIII.1.2 HA/PLGA microspheres from w1-o-w2 emulsion (w1: 
DMSO) 
w1-o-w2 emulsions (1:19:80 w/w/w) have also been prepared dissolving 
HA in dimethyl sulfoxide, at different drug loadings of 4.5% and 9% w/w; 
whereas, the PLGA concentration was set at 10% w/w. Distribution data of 
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Table VIII.2 Laser scattering size distribution data of droplets (DSD) and 
of particles (PSD) produced from w1-o-w2 emulsions (1:19:80 w/w/w, w1: 
DMSO) at different HA concentrations of 4.5% and 9% w/w, using SEE-C 
process; PLGA concentration was fixed at 10% w/w. Legend: MS = mean 
size; SD = standard deviation; CV = coefficient of variation. 
Emulsion kind w1-o-w2 emulsion (w1: DMSO) 
PLGA (% w/w) 10 
HA (% w/w) 4.5 9 
Distribution data DSD PSD DSD PSD 
MS (µm) 3.4 2.7 3.4 3.1 
SD (µm) 1.5 1.3 1.7 1.5 
CV (%) 44 48 50 48 
D10 (µm) 1.6 0.8 1.5 1.2 
D50 (µm) 2.9 1.7 2.8 2.3 
D90 (µm) 4.3 3.2 4.4 4.0 
 
An optical microscope image of the droplets and a FE-SEM image of the 
corresponding particles containing 10% w/w of PLGA and 9% w/w of HA 
are reported in Figure VIII.3: the droplets and the microspheres produced 
were very uniform in size and non-coalescing. This result is confirmed by 
CV values reported in Table VIII.2, that range between 44 and 50 for DSDs 












Figure VIII.3 Optical microscope image of the droplets and FE-SEM image 
of the microspheres produced by SEE-C process from a w1-o-w2 emulsion 




VIII.1.3 HA/PLGA microspheres from s-o-w suspension emulsion 
s-o-w suspension emulsions have been prepared with different HA 
contents of 4.5% and 9% w/w, at a fixed PLGA concentration of 10% w/w. 
FE-SEM images of the microspheres obtained in this case showed the 
presence of large HA crystals, identified via shape. An example of the 
microspheres obtained is reported in Figure VIII.4 and is related to particles 
charged with 4.5% w/w of HA; HA isolate crystals are clearly identifiable. 
This result indicates that part of the drug was lost from the droplets during 




Figure VIII.4 FE-SEM image of HA/PLGA microspheres prepared by SEE-
C from a s-o-w suspension emulsion containing 4.5% w/w of HA and 10% 
w/w of PLGA. 
For this reason, the preparation of s-o-w suspension emulsions was 
modified; to obtain a better drug encapsulation, HA was micronized using 
SAA processing (Supercritical Assisted Atomization). SAA is a 
micronization process based on the solubilization of controlled quantities of 
SC-CO2 in a liquid solution (in which was previously dissolved the solute to 
be micronized), using a saturator that contains high surface packings and 
ensures long residence times. Therefore, a near-equilibrium solution is 
formed, that is subsequently atomized through a nozzle and microparticles 
are obtained after droplet evaporation with warm nitrogen. In this case, SC-
CO2 acts both as a co-solute being partially miscible with the solution to be 
treated, as well as a pneumatic agent to atomize the solution in fine droplets. 
The liquid solvent, meanwhile, acts as a carrier for the product to be treated 
(Della Porta et al., 2006). In the specific case, ethanol was tested as liquid 
solvent and the best results in terms of precipitated HA particles morphology 
and size were observed operating in the saturator at 90 bar and 80°C, in the 
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precipitator at 0.7 bar and 35°C, and with a G/L ratio of 1.8 and a nitrogen 
flow rate of 1000 nL/h. HA particles in the micrometric range (mean size of 
0.95 µm (SD 0.11)) were obtained using this process and were used as the 
solid phase in the experiments on s-o-w emulsions.  
Distribution data of the droplets and of the related microspheres produced 
using micronized and not-micronized HA are summarized in Table VIII.3: 
Table VIII.3 Laser scattering size distribution data of droplets (DSD) and 
of microspheres (PSD) produced from s-o-w suspension emulsions (20:80 
w/w) at different HA concentrations of 4.5% and 9% w/w; PLGA 
concentration was fixed at 10% w/w. Legend: MS = mean size; SD = 
standard deviation; CV = coefficient of variation. 
Emulsion 
kind 
s-o-w suspension emulsion 
with not µ-ized HA 
    s-o-w suspension emulsion 






4.5 9 4.5 9 
Distribution 
data 
DSD PSD DSD PSD DSD PSD DSD PSD 
MS (µm) 3.5 3.0 3.2 5.4 3.2 2.5 3.9 3.0 
SD (µm) 1.6 1.5 1.5 2.9 1.4 1.1 1.9 1.6 
CV (%) 46 50 47 54 44 44 49 53 
D10 (µm) 1.6 0.7 1.4 0.7 1.5 1.3  1.3 0.9 
D50 (µm) 2.9 1.5 2.5 1.5 2.5 2.2 2.6 2.1 
D90 (µm) 4.4 2.9 3.9 3.2 3.8 3.3 4.2 3.8 
 
Examples of the results obtained are reported in Figure VIII.5, where an 
optical microscope image of the droplets and a FE-SEM image of the related 
microspheres containing 4.5% w/w of SAA-micronized HA and 10% w/w of 
PLGA are shown. The produced droplets and microparticles were very 
uniform and not aggregated. Indeed, CV values reported in Table VIII.3 for 
both droplet and particle distributions range between 44 and 54, confirming 
















Figure VIII.5 Optical microscope image of the droplets and FE-SEM image 
of the microspheres produced by SEE-C process from a s-o-w suspension 
emulsion loaded with 4.5% w/w of micronized HA and 10% w/w of PLGA. 
 
VIII.2 Solid state characterization 
Thermal analysis (DSC) has been systematically performed on the 
produced microspheres and on raw PLGA and HA, for comparison. An 
example of the corresponding thermograms is reported in Figure VIII.6. 
PLGA (50:50) shows a glass transition that remains relatively constant 
(onset 39.98°C; endset 45.32°C) in the observed samples and a polymer 
decomposition that occurs above 300°C; raw HA shows an endothermic 
peak at about 220°C, due to its melting point. The HA/PLGA microspheres 
exhibit only the PLGA degradation event, confirming that the supercritical 
process does not modify the polymer structure; whereas, the characteristic 
peak of HA is no more visible in the produced microspheres. This fact 
suggests the formation of an amorphous HA intimate dispersion inside the 
polymer microspheres.  
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Figure VIII.6 Example of DSC traces of untreated PLGA, HA and SEE-C 
microspheres prepared from a s-o-w suspension emulsion containing HA 
loading of 9% w/w and PLGA content of 10 % w/w. 
 
VIII.3 Hydrocortisone Acetate encapsulation efficiency 
Systematic analysis has been performed on the produced microspheres to 
measure the effective HA encapsulation, related to the quantity of HA 
initially loaded, the kind of emulsion used and the mean size of the 
microspheres. HA content (effective and theoretical) and encapsulation 
efficiency details for the different emulsion kinds and formulations are 
















Table VIII.4 Theoretical and experimental HA loading in the microspheres 
























) 1 2.3 1.8 80 
1 4.1 2.3 55 














) 3 4.5 1.4 32 
















3 4.5 1.4 30 













 3 4.5 2.2 48 
3 9.0 6.8 76 
 
 
Data reported in Table VIII.4 show a wide variation of the encapsulation 
efficiency of HA into PLGA microspheres, ranging between 30 and 80%. 
Particularly, in the case of microspheres produced from w1-o-w2 emulsions 
with EtOH as solvent in the w1 phase, increasing the theoretical HA loading 
from 2.3 to 4.1% w/w (at fixed microspheres size) the encapsulation 
efficiency decreases from 80% to 55%. Increasing the size of the 
microspheres from 1 to 2 µm (at fixed drug loading), the encapsulation 
efficiency is almost the same.  
For microspheres produced from w1-o-w2 emulsions with DMSO as solvent 
in the w1 phase, encapsulation efficiency is poor and the increase of the 
theoretical HA loading from 4.5 to 9% w/w does not produce appreciable 
variations.  
In the case of microspheres produced from s-o-w suspension emulsions, an 
increase of the theoretical HA content from 4.5 to 9% w/w (at fixed drug 
loading) improves the encapsulation efficiency. It is evident that a s-o-w 
suspension emulsion using micronized HA allows better encapsulation 
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performances than a s-o-w suspension emulsion using not-micronized HA. 
The optimized s-o-w suspension emulsion can be also favorable to be used 
when compared with the w1-o-w2 emulsion because only the solvent of the 
oily phase is used, due to the absence of an internal water phase. 
Comparing the encapsulation efficiency values shown in Table VIII.4 
with those reported in literature for the entrapment of Hydrocortisone, the 
success of SEE-C processing is immediately evident; indeed, encapsulation 
efficiencies of maximum 22% were obtained entrapping Hydrocortisone in 
PLGA microspheres (with mean size of 3, 13 and 39 µm) produced using a 
modified SEDS process (Ghaderi et al., 2000). Gelatin nanoparticles 
encapsulating Hydrocortisone were also produced using a desolvation 
method. In this case, drug encapsulation efficiencies varying from 35 to 45% 
were observed (Vandervoort and Ludwig, 2004). Very low encapsulation 
efficiencies were also obtained encapsulating other glucocorticoids; i.e., 
PLGA microspheres loaded with Dexamethasone (with mean size of 11 µm) 
were prepared by o-w emulsion-solvent evaporation method using a mixture 
of dichlorometane and methanol in the oily phase, and the encapsulation 
percentage was  4% (Hickey et al., 2002a).  
 
VIII.4 In vitro Hydrocortisone Acetate release 
Drug release studies have been performed on the produced microspheres  
to try to evidence the influence of particle sizes, drug loadings and structural 
differences between microspheres on the controlled release of HA.  
First, PLGA microspheres (produced from w1-o-w2 emulsions, w1: 
DMSO) with a mean size of 3 µm and charged with different effective HA 
loadings of 1.4% and 3.3% w/w have been studied. The release profiles 
obtained are reported in Figure VIII.7 and show that, when the HA content 
in the matrix is increased, a slower drug release is initially obtained. A 
complete drug release was obtained in almost 11 days for both charges. This 
behavior can seem surprising and is particularly relevant in the first part of 
the drug release curve, where the diffusion is the prevalent release 
mechanism. Indeed, one expects that a higher loading will correspond to a 
faster drug release, since the diffusion rate is ordinarily controlled by the 
difference of concentration between the inside of the polymer microspheres 
and the external medium. However, the release behavior at different drug 
loadings observed in this study can be explained considering the low 
solubility of HA in the release medium (water). Indeed, as suggested by Lee 
(1980), two moving fronts can be established in PLGA particles (diffusion 
followed by bulk erosion) and they are synchronized (the second motion of 
the front is influenced by the first one). When the concentration of the drug 
in the polymer is much higher than its solubility in water, the diffusion front 
is slow and can move towards the internal of the particles only when the 
concentration in the solid phase decreases to values lower than the 
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equilibrium value; as a consequence, the higher is the drug concentration in 
the polymer, the slower is the movement of the diffusion front (Chakraborty 
et al., 2009). 































time, days  
Figure VIII.7 Comparison between the release profiles of HA from PLGA 
microspheres (produced from w1-o-w2 emulsions, w1: DMSO) with the same 
mean diameter (3 µm) and charged with different effective HA loadings of 
1.4% and 3.3% w/w. 
HA release profiles from PLGA microspheres (produced from w1-o-w2 
emulsions, w1: EtOH) with different mean sizes of 1 µm and 2 µm but 
containing the same effective HA loading of 2.1% w/w are reported in 
Figure VIII.8. As expected, the drug release curves show a dependence of 
the release profiles on the mean particle diameter: the smaller is the mean 
size the faster is the drug release, since the diffusion path is shorter. The total 
drug release from the microspheres was obtained in about 6 days. However, 
the complete release is not sensibly dependent on the particle diameter and 
the overall duration of the release kinetics is relatively similar. 
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Figure VIII.8 Comparison between the release profiles of HA from PLGA 
microspheres (produced from w1-o-w2 emulsion with w1: EtOH) with 
different mean sizes of 1 µm and 2 µm and charged with the same effective 
HA loading of 2.1% w/w. 
A comparison between HA release profiles from PLGA microspheres 
with the same mean size of 3 µm but produced from s-o-w suspension 
emulsions using micronized and not-micronized HA has also been 
performed. As illustrated in Table VIII.4, at fixed microspheres size, a s-o-w 
suspension emulsion prepared with micronized HA allows a higher drug 
loading than that prepared using not-micronized HA. Particularly, the 
percentage of HA encapsulated was 1.4% w/w when using a s-o-w 
suspension emulsion with not-micronized HA and 2.2% w/w when using a s-
o-w suspension emulsion with micronized HA. As a consequence, increasing 
the HA loading the HA release rate of microspheres decreases, as illustrated 
in Figure VIII.9:  
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Figure VIII.9 Comparison between the release profiles of HA from PLGA 
microspheres with the same mean sizes of 3 µm and produced from s-o-w 
suspension emulsions using micronized and not micronized HA. 
 
The overall drug release times measured for microspheres produced from 
w1-o-w2 emulsions are smaller than those measured for microspheres 
produced from s-o-w suspension emulsions using micronized HA. This 
behavior may be due to the fact that in the case of w1-o-w2 emulsion the 
resulting microspheres have a different internal structure. 
Therefore, s-o-w suspension emulsions give better encapsulation efficiencies 
(see Table VIII.4) and also longer HA release times (around two weeks) in 
comparison with the other kinds of emulsion tested, covering the time 
required to control chronic inflammation step after devices implantation.  
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Preparation and 
characterization of Insulin-





Efficient delivery of peptides or proteins to target cells or organs has 
received considerable attention in medicine. In the last years, biodegradable 
microspheres have been extensively investigated as controlled release 
dosage forms for proteins and peptides to prolong their therapeutic effect. 
Most traditional devices are realized suspending the bioactive agents in a 
polymeric monolith and surgically implanting them into the body or 
encapsulating the bioactive agents in polymeric microspheres and injecting 
them subcutaneously (Gombotz and Pettit, 1995). The intrinsic physico-
chemical properties of proteins severely obstacle the development of new 
protein-based therapeutics (Talmadse et al., 1993). One major reason is the 
inherent instability of proteins when they are exposed to the conditions 
normally encountered during microparticle fabrication using conventional 
emulsion/solvent removal techniques. Indeed, the three dimensional 
structure of proteins, which is crucial for biological activity, can be damaged 
by heat and mechanical stresses, determining aggregation and formation of 
insoluble precipitates (Oliva et al., 1996; Shnek et al., 1998). 
To overcome the solvent evaporation limitations, the SEE-C technology 
has been applied to the production of controlled-size protein-loaded 
biopolymer microspheres to be used for locally injectable sustained release 
formulations, starting from a double emulsion system. Insulin has been 
chosen as model protein to be encapsulated within PLGA microspheres, for 
its wide use in the treatment of diabetes mellitus (Kang and Singh, 2005; 
Yeh et al., 2004; Bao et al., 2006). A detailed characterization of the 
produced microspheres in terms of morphology, size distribution, 
encapsulation efficiency and release profile is proposed. 
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IX.1 Size tailoring and morphology 
The decrease of the stirring rate or the increase of the polymer 
concentration in the oily phase during the emulsion preparation can produce 
larger droplets (Kluge et al., 2009a; Della Porta et al., 2010). The influence 
of the emulsion stirring rate has been measured on droplets/microspheres 
size and size distribution decreasing the stirring rate from 2800 to 1000 rpm 
during the formation of the secondary emulsion, to explore the possibility of 
microspheres size tailoring. A constant PLGA concentration of 10% w/w in 
the organic phase was used for all these experiments.  
Examples of the w1-o-w2 emulsions (1:19:80 w/w/w) produced at 
different stirring rates are shown in the optical microscope images reported 
in Figure IX.1(a-c, left side). All the emulsions were formed by stable, non-
coalescing droplets. After SC-CO2 solvent extraction in the continuous 
tower, microspheres were produced that maintained the spherical shape of 
the starting emulsion and formed no aggregates, as shown in the 
corresponding FE-SEM images reported in Figure IX.1(a-c, right side). 
DSDs of the emulsions and PSDs of the related microspheres, obtained 
by laser scattering analysis, are reported in Figure IX.2(a-c). The 
experimental evidence is that the microspheres are smaller and the 
distributions are narrower than the droplet mean sizes and distributions from 


















































Figure IX.1(a-c) Optical microscope images of the droplets and FE-SEM 
images of the microspheres produced from w1-o-w2 emulsions prepared at 









































































































Figure IX.2(a-c). Size distribution curves of the droplets and of the relative 
microspheres obtained from w1-o-w2 emulsions prepared at different stirring 
rates and treated by SEE-C. 
Preparation and characterization of Insulin-loaded PLGA microdevices 
 145 
The PSDs curves are comparatively reported in Figure IX.3 and confirm 
the general evidences obtained in Figure IX.1(a-c) and Figure IX.2(a-c). 
However, a further information can be qualitatively deduced from this figure 
and quantitatively measured by the data summarized in Table IX.1: the mode 
of the three distributions are very similar; whereas, the PSD strongly 
enlarges when the emulsion stirring rate is reduced. Mean droplet sizes from 
3.2 µm (SD ±1.2) to 16.9 µm (SD ±7.7) were obtained for emulsion stirring 
rates of 2800 and 1000 rpm, respectively. Correspondingly, microspheres 
with mean diameters varying from 1.8 µm (SD ±0.9) to 4.8 µm (SD ±2.8) 
were obtained. This result is in good agreement with those observed by other 
authors (Kluge et al., 2009a) and may be explained as follows: there is a 
minimum droplet size distribution that can be stabilized by the surfactant 
molecules and it is reasonable that at higher energy inputs, this lower bound 
is gradually approached.  
 









 2800 rpm: MD=1.8m
 1400 rpm: MD=2.8m









Particle diameter, m  
Figure IX.3 PSDs of Insulin-loaded PLGA microspheres produced from SC-
CO2 extraction of  w1-o-w2 emulsions, decreasing the stirring rate from 2800 










Table IX.1 Laser scattering size distribution data of droplets (DSD) and of 
microspheres (PSD) produced using SEE-C from w1-o-w2 emulsions 
prepared at different stirring rates. Legend: MS = mean size; SD = standard 
deviation; SF = shrinking factor. 
PLGA (% w/w)    10 
INS (% w/w) 0.5 0.5        0.5 
Emulsion stirring 
rate (rpm) 
2800  1400       1000 
Distribution data  DSD  PSD DSD PSD DSD PSD 
MS (μm) 3.2 1.8 5.6 3.2 16.9 4.8 
SD (μm) ±1.2 ±0.9  ±2.3 ±2.2  ±7.7 ±2.8 
D10 (μm) 1.6 0.9  1.5 1.1 4.4 0.9 
D50 (μm) 3.2 1.8 4.8 2.9  15.7 3.4 
D90 (μm) 5.4 3.1 11.1 6.5  29.7 9.9 
 
IX.2 Insulin encapsulation efficiency 
Encapsulation efficiency of proteins within polymeric microspheres is a 
complex phenomenon controlled by several factors. There are usually three 
main factors which are considered to affect the drug encapsulation efficiency 
during emulsification and solidification of double emulsions: 
- (1) coalescence between inner water phase and outer water phase, 
leading to the leakage of the drug into the outer water phase. Therefore, the 
more is stable the inner water phase, the higher is drug encapsulation 
efficiency. For example, Insulin molecules are highly loaded in PLGA 
microspheres when a hydrophilic component is added to the primary 
solution. In the specific emulsions prepared, glycerol has been added to the 
inner water phase to increase the inner phase viscosity and reduce the Insulin 
diffusion to the outer water phase, as suggested by some authors 
(Yamaguchi et al., 2002).  
- (2) coalescence and break-up of double emulsions, also leading to the 
leakage of drug;  
- (3) diffusion of drug from inner to outer water phase through oil phase, 
during the processes of droplets formation and solvent removal (Liu et al., 
2006; Bittner et al., 1998). 
The influence of the microsphere size on the encapsulation efficiency has 
been investigated: when Insulin was entrapped in larger microspheres, 
higher encapsulation efficiencies were obtained (Table IX.2). This result is 
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also confirmed by traditional process literature data, where it is reported that 
when Insulin was entrapped in large microparticles, larger entrapment 
efficiencies were obtained (Uchida et al., 1997b; Shao and Bailey, 2000). 
However, SEE-C is more efficient than solvent evaporation, since the 
encapsulation efficiencies obtained (up to about 70%, see Table IX.2) are 
higher than those observed in previous traditional studies, mainly obtained 
from emulsions formulated using dichloromethane as the oily phase solvent, 
more toxic than ethyl acetate (Kawashima et al., 1999; De Rosa et al., 2000).  
The effect of the protein loading on the encapsulation efficiency was also 
investigated and reported in Table IX.2: at a fixed particle mean size of 3 
µm, increasing the Insulin loading from 0.5% to 1% w/w there is no effect 
on the encapsulation efficiency that is similar (60%), as illustrated. 
 
Table IX.2 Theoretical and measured Insulin loading in the microspheres 
recovered using SEE-C technology.  
Microspheres 





loading, % w/w 
Encapsulation 
efficiency, %  
2 0.5 0.35 63 (±2.9) 
3 0.5 0.30 60 (±1.5) 
3 1.0 0.58 58 (±3.4) 
5 0.5 0.36 71 (±2.5) 
 
 
IX.3 In vitro Insulin release study  
Insulin-loaded microspheres with different sizes (2 and 3 m) and protein 
loadings (0.3 and 0.6% w/w) have been tested to monitor the Insulin release 
profiles at 37°C, in two different release mediums: PBS and DMEM. The 
effect of different microsphere sizes (at fixed Insulin loading of 0.3% w/w) 
on the release profiles is shown in Figure IX.4(a) for microsphere suspended 
in PBS medium, and in Figure IX.4(b) for microspheres suspended in 
DMEM medium. The experimental data showed that the smaller is the 
microspheres size, the faster is the Insulin release from the microspheres. All 
the microspheres showed a fast release of a fixed amount of the charged 
Insulin in the first 2 hours. Indeed, both microdevices of 2 and 3 m in size, 
when suspended in PBS, released about 55% of the encapsulated Insulin in 
the first 2 hours; whereas, the same microdevices suspended in DMEM 
showed a release of Insulin ranging between 10 and 40% in the first 2 hours. 
Microspheres with a mean size of 2 µm showed always a release of a higher 
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Insulin amount in the first 2 hours with respect to the ones with a mean size 
of 3 µm, in the two tested media. A possible explanation is that microspheres 
smaller in size have larger surface area and exhibit increased buffer 
penetration and a higher initial protein release. High initial release typically 
seen for proteins in PLGA microspheres is often ascribed to the rapid 
diffusion of protein molecules located at or close to the surface of the 
microsphere matrices (Zolnik et al., 2006). Furthermore, since Insulin is a 
small protein, molecules can diffuse fast as soon as the pores are formed due 
to water penetration after incubation (Yamaguchi et al., 2002).  
The complete Insulin release was obtained after about 30 days in PBS and in 
21 days in DMEM. When the DMEM medium was used, a more adequate 
profile in terms of sustained release was observed. The shape of the two 
Insulin release profiles obtained from microspheres of 2 and 3 µm also 
suggests the predominance of diffusion-controlled mechanism in the first 
part of the drug release curve, followed by a polymer bulk erosion 
mechanism when the two release curves of microspheres with different size 
start to overlap.  
The effect of different Insulin loadings of 0.3 and 0.6% w/w has also 
been monitored on release profiles of microspheres with the same mean size 
(3 m); the results obtained are shown in Figure IX.5(a) and in Figure 
IX.5(b) for microspheres suspended in PBS and DMEM, respectively. The 
higher Insulin loading of 0.6% w/w generated a faster release from 
microspheres and a higher amount of Insulin was released in the first 2 hours 
in both media. The difference in release rate is due to the fact that at higher 
Insulin loading there is a larger Insulin concentration gradient between the 
inside of the polymer microspheres and the external medium. Since the 
gradient is the driving force for Insulin diffusion, 0.6% w/w loading leads to 
a higher initial Insulin released and a more rapid release rate. Moreover, at a 
higher loading, there is more Insulin distributed near the surface area of 
microspheres. This also leads to a greater initial release. As Insulin is 
released, it leaves more pores and interconnecting channels for the release of 
the remaining protein. However, Insulin has to travel a longer path under a 
lower concentration gradient. Therefore, the release rate of Insulin from the 
microspheres decreases at the later stage, as shown in Figure IX.5(a) and in 
Figure IX.5(b) (Liu et al., 2006). From the comparison of the curves 
obtained in the two different release media, release profiles in DMEM show 
again reduced amounts of Insulin released in the first 2 hours and more 
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Figure IX.4(a-b) Comparison between the release profiles of Insulin from 
microspheres suspended in (a) PBS and (b) DMEM, with different mean 
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Figure IX.5(a-b) Comparison between the release profiles of Insulin from 
microspheres suspended in (a) PBS and (b) DMEM, with different loadings 
and the same mean size of 3 µm.  
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The aim of this thesis was the optimization and characterization of the 
SEE-C process to investigate its capabilities and performances in the 
production of microparticles with engineered size and distribution. The 
innovative process arrangement is obtained by using a high pressure packed 
column operating in countercurrent, in which mass transfer between the 
liquid and the gaseous phase is improved by the internal packing elements. 
This work was developed in two main parts: a process optimization 
followed by the production of different AP/PLGA systems for controlled 
drug delivery. The process optimization included a fluidodynamic study of 
the packed tower, together with the analysis of the process operating 
parameters. Moreover, a thermodynamic study of the selected system (ethyl 
acetate+CO2) was carried out. In the second part of the work, firstly drug-
free PLGA microparticles were successfully produced by SEE-C process. 
Then, different active principles were tested for their encapsulation within 
PLGA microspheres: anti-inflammatory drugs (such as Piroxicam and 
Diclofenac Sodium), corticosteroids (such as Hydrocortisone acetate) and 
proteins (such as Insulin) were chosen as model compounds. Due to the very 
high solubility of the organic solvents commonly adopted in the formation of 
emulsions, the SEE-C technology can be readily extended to the preparation 
of microspheres from many emulsions. 
The results obtained in this thesis confirm that the SEE-C technology 
offers a new strategy to produce tailored composite microspheres for 
controlled drug delivery formulations. Taking the advantage of the large 
contact area between SC-CO2 and emulsion in the packed tower, SEE-C 
allows the production of PLGA microspheres with different size in a robust 
and reproducible mode in only few minutes. Well shaped and not collapsed 
spherical microspheres were obtained. The faster solvent extraction rate did 
not influence the particles morphological structure but had a significant 
effect on the size distribution of the precipitated particles, which were 
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always smaller (or at least reproduce exactly) than the size of the original 
droplets, avoiding the aggregation phenomena that occur during 
conventional processes. 
Narrow particle size distributions resulted, showing a dependence on 
emulsion formulation parameters such as the polymer concentration and the 
stirring rate: increasing the polymer concentration or decreasing the 
emulsion stirring rate, larger particles can be obtained. Furthermore, 
systematic analyses confirmed that the active principles were entrapped and 
homogeneously dispersed, in an amorphous solid state, into the PLGA 
matrix.  
In vitro drug release analyses showed a controlled release of the active 
principle from microspheres produced by SEE-C process. A characteristic 
drug release profile of controlled release formulations was observed, in 
which both diffusion and degradation mechanisms have a significant 
contribution. In addition, emulsion kind, microspheres size and drug 
concentration were clearly controlling parameters for drug release. 
A comparison between the characteristics of the microspheres obtained 
by SEE-C and those produced by SEE and conventional SE was also 
proposed starting from several fixed emulsions. It was evident that SEE-C 
extraction is a faster process that allows a better control of the PSDs for all 
the systems studied. 
Greater product uniformity, higher throughput with small plant volumes 
and elimination of the batch-to-batch repeatability problems are important 
advantages of the SEE-C technology respect to the batches processes. 
Improved recovery efficiencies, shorter processing times, less residual 
solvents and good drug encapsulations are other advantages of the SEE-C 
operation. 
Future developments of these studies lie in the production of 
Pharmacologically Active Microcarriers (PAMs) that can be used in the 
regenerative medicine field to overcome problems of cell survival, lack of 
cell differentiation and integration in the host tissue. PAMs are 
biocompatible and biodegradable microparticles coated with adhesion 
molecules,  that may serve as a support for cell culture and may be used as 
cell carriers presenting a controlled delivery of target growth factor. In this 
configuration, they can thus support the survival and differentiation of the 
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